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Abstract 
Prion diseases in mice are characterised by prolonged, clinically silent incubation periods 
that are distinct in duration and reproducible. Incubation times are influenced by a number 
of factors with the major genetic determinant being variation within the prion protein 
gene, Prnp, however, different lines of inbred mice with identical Prnp genotypes show 
differences in incubation time indicative of a multi-genic effect. A heterogeneous stock 
of mice was used for fine mapping studies from which emerged several candidate genes 
including Hectd2, an E3 ubiquitin ligase. A human association study found that this 
genetic modifier is associated with an increased risk to vCJD and kuru.  
To characterise Hectd2, a yeast two hybrid screen was performed to search for novel 
interactors, yielding twenty binding partners. Selected candidates were verified by co-
immunoprecipitation in mammalian cells. These included Sh3glb1, which has been linked 
to autophagy in a Parkinson’s disease model as well as Stambp, which encodes a 
deubiquitination protein in the CNS, and Stmn2, a gene previously associated with 
susceptibility to vCJD in a genome wide association study. Pacsin2 and Sept7, also 
emerged as Hectd2 interactors. These proteins operate in the cytoskeletal network, serving 
a regulatory role for maintaining neuronal integrity, a pathway not previously recognised 
in prion pathology. By application of a cell based model of prion propagation, the Scrapie 
Cell Assay, it has been possible to establish the effect of knocking down candidate genes 
on cell susceptibility thus providing a direct link with prion pathology. In addition, Hectd2 
knockout and transgenic overexpressing mouse models were challenged with three strains 
of mouse adapted prions to search for an association with incubation time. In conclusion, 
this has been the first attempt at interactome mapping of a candidate gene associated with 
incubation time in mouse and susceptibility to human diseases. We have identified novel 
gene candidates that are implicated in prion pathology, thus providing an insight into the 
possible pathways that modulate prion disease. 
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1 Introduction  
1.1 The Prion Phenomenon 
1.1.1 Human prion diseases 
Prion diseases, or transmissible spongiform encephalopathies, are a group of fatal 
neurodegenerative conditions that are transmissible to both humans and animals. These 
include Creutzfeldt Jacob Disease (CJD), Fatal Familial Insomnia (FFI), Gerstmann 
Straussler Scheinker syndrome (GSS), variant CJD and kuru in humans. Animal prion 
diseases include Bovine Spongiform Encephalopathy (BSE), Scrapie, Chronic Wasting 
Disease (CWD) and Transmissible Mink Encephalopathy, which affect cattle, sheep/goat, 
mule deer/elk and mink, respectively1-4. The histopathological hallmarks by which the 
disease can be distinguished include spongiform vacuolation of the brain, neuronal loss 
and astrocytosis, which may be accompanied by brain deposition of an atypical version 
of the prion protein, PrPSc 2, 3, 5. The prion protein or PrPC is expressed normally in cells 
but may undergo post-translational conversion into an aberrant, pathogenic isoform, PrPSc 
6. This conformation of the prion protein has been found to constitute the principal if not 
sole component of the infectious agent7.  Although rare, affecting only one in a million 
per year worldwide3, intense research has been focused on this field due to the unique 
biology of the prion agent thought to cause disease. A notable feature that characterises 
these encephalopathies is their prolonged clinically silent period, or incubation time, 
which marks the interval between infection and onset of clinical symptoms3, 8.  
Distinct from any other disorder, prion diseases present as one of three different forms, 
sporadic, inherited or acquired9-11. Sporadic occurrences of the disease constitute ~85% 
of all cases, where most patients are aged between 45-75. This classical form of CJD 
manifests as a rapidly progressive dementia, characterised by a diffuse pattern of PrPSc 
deposition11, 12. Symptoms characterising the onset of disease include myoclonus, 
cerebellar ataxia, cortical blindness, depression, insomnia and fatigue.  It is speculated 
that the disease is triggered spontaneously in the brain although its aetiology remains 
unknown9, 11.  
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Inherited prion diseases account for ~15% of cases and have been causally linked to 
autosomal dominant mutations within the prion protein gene, PRNP13, 14. Although the 
molecular basis of how these mutations cause disease is unknown, it is thought that they 
increase the conversion of PrPC to PrPSc 15.  Alternative membrane topology of PrP has 
also been postulated as a possible mechanism by which neurotoxicity may be caused16. 
The A117V and G114V mutations associated with familial CJD may generate Ctm-PrP 
which spans the membrane once with its C terminus facing the cytosol16, 17. This 
membrane topology of PrP is enhanced following PrPSc accumulation, giving rise to the 
notion that Ctm-PrP may represent a neurotoxic species that causes pathogenicity17, 18.  
Over 30 pathogenic mutations have been defined, (Figure 1.1), where the E200K mutation 
is the most common cause of inherited prion disease19. Knowledge of these mutations 
makes it possible to perform pre-symptomatic diagnosis through PRNP analysis3. The 
inherited conditions include familial CJD (fCJD), Gerstmann-Straussler Scheinker 
syndrome (GSS) and fatal familial insomnia (FFI), which show variable clinical and 
neuropathological presentation depending on the mutation3. fCJD patients are affected by 
a rapidly progressive dementia including myoclonus; GSS manifests as a chronic 
cerebellar ataxia with patients suffering later onset of progressive dementia and FFI 
features include progressive insomnia, dementia, hallucinations, malfunction of the 
autonomous nervous system and is commonly linked to a missense mutation within PRNP 
at codon 17820. 
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Figure 1.1 Pathogenic mutations and polymorphic variations within the prion protein gene. Amino 
acid changes representing pathogenic mutations are shown above in the schematic whereas polymorphisms 
that influence the susceptibility to disease are shown below. Adapted from Mead et al., 2006. 
Acquired prion diseases are caused by exposure to infectious prion agents and include 
iatrogenic CJD (iCJD), kuru and vCJD. Iatrogenic CJD arose by accidental transmission 
of CJD prions through surgical procedures with contaminated instruments and 
transplantation material21. The most common cases of iCJD were due to treatment with 
cadaveric pituitary growth hormone and implantation of dura mater grafts from infected 
humans whilst the less common iCJD occurrences were due to transmission of iCJD via 
corneal transplantation and implantation of contaminated EEG electrode22, 23. Kuru and 
vCJD are also acquired forms of the disease. Kuru was the first human epidemic of prion 
disease, which occurred through a dietary medium in the Fore linguistic group as part of 
a ritual cannibalistic mortuary feast in the Eastern Highlands of Papua New Guinea24. 
Progressive cerebellar ataxia was the main clinical manifestation, in addition to 
psychiatric and behavioural changes with incubation periods in some individuals 
exceeding 50 years25.  
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The arrival of vCJD was identified as a result of BSE exposure to humans10, 26. Clinical 
features of the disease include psychiatric and behavioural changes as well as cerebellar 
ataxia, affecting patients that are mostly young3, 27, 28 The median age of onset is 26 years 
in sharp contrast to the late onset of sporadic CJD, where the median age at death is 68 
years29. The transmission of BSE from contaminated cattle to humans by widespread 
dietary consumption raised serious public health concerns at the time, due to its 
transmissibility across species1, 3, 29.  
1.1.2 Aberrant conversion of PrPC to PrPSc 
The prion phenomenon revolves around the hypothesis that aberrant conformational 
conversion of normal cellular PrPC to PrPSc is the chief cause underlying all prion 
conditions6, 30-33. In 1967 Griffith first suggested that the infectious agent was solely 
protein, which was later supported by Prusiner’s work in 1982, where the infectious 
fraction was enriched from brain homogenates in which the major element was a protease 
resistant glycoprotein6, 34. The protein was termed a prion, which he described as “small 
proteinaceous infectious particle which is resistant to inactivation by most procedures that 
modify nucleic acids”6. The basis of this hypothesis states that prion propagation is the 
result of PrPSc replication by it serving as a template to encourage the conformational 
conversion of wild type PrPC to the disease causing PrPSc. Both PrPC and PrPSc forms have 
the same primary sequence but differ in their tertiary conformation5. This has been lent 
support by PrP knockout mouse models in which  challenge of PrP0/0 mice with mouse 
scrapie prions resulted in healthy mice that survived without pathology for their natural 
life span comparable to controls that died under 6 months35. Pathogenic PrPSc was absent 
in brains of these mice following inoculation, indicating that PrP is necessary for prion 
propagation and that pathology is not the result of loss of PrP function but rather a toxic 
gain of function from PrPSc 35-37. Furthermore, Mallucci and co-workers found that 
conditional PrP knockout mice were resistant to prion disease; their work showed that 
neuronal knockout of PrP is protective and that non-neuronal PrPSc is not pathogenic38 . 
Thus mice devoid of the prion protein fail to propagate infectivity in the absence of PrPC 
and thus show resistance to prion infection, indicating that PrPC is essential for PrPSc 
replication35. In addition, mice hemizygous for one PrPC allele present an enhanced 
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resistance to prion replication compared to mice with two copies of Prnp, shown by a 
prolonged incubation period35. However, when PrP transgenes were engineered into 
PrP0/0 mice, subsequent inoculation with prions led to prion propagation and pathology39. 
Furthermore, neural grafting of PrPC-overexpressing tissues into mouse brains devoid of 
PrP, showed PrPSc propagation and infectivity accompanied by pathology characteristic 
of scrapie in the graft following challenge with scrapie prions. However, host PrPC-
deficient tissue showed no histopathological changes although an accumulation of PrPSc, 
derived from the grafts, was observed40, 41. 
Models that describe the mechanism through which replication may occur, in line with 
the protein only hypothesis, have been proposed as template-directed refolding and the 
seeded nucleation hypothesis2, 42. The template-directed refolding mechanism suggests 
that PrPSc interaction with PrPC, promotes conversion of wild type molecules to PrPSc to 
form aggregated amyloid. Dissociation of PrPSc-PrPSc complexes generate the free 
pathogenic prion to act on further PrPC molecules. The seeded nucleation theory 
postulates that PrPC exists in dynamic equilibrium with PrPSc, whereby an infectious seed 
is formed slowly from PrPSc molecules and when this is formed, a fast recruitment of 
monomeric PrPSc molecules to the seed generates amyloid aggregates. These aggregates 
can fragment, thereby liberating seeded nuclei to which further PrPSc monomers may be 
added to, thus propagating infectivity2, 42.  
Both of these models suggest that self-replication of prions gives rise to neurotoxicity, 
however, a further model postulates an alternative mechanism; an intermediate, PrPL for 
lethal, is generated as either a side product or an intermediate in the process of PrPSc 
replication31. Whether PrPL is produced as a template intermediate leading to the toxic 
pathway or as a side product from PrPSc acting as a surface template, thereby propagating 
the toxic pathway, it may be that neurotoxicity is the result of accumulation of PrPL that 
exceeds a threshold that cannot be tolerated, marking the end of the incubation period, 
rather than PrPSc as the toxic agent31. This theory has been lent support by a recent study 
by Sandberg et al., where they uncoupled neurotoxicity from infectivity by showing that 
prion replication occurs exponentially until saturation is achieved43. The authors suggest 
that the neurotoxic species is then catalysed from PrPSc or within that route, which in turn 
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activates the toxic pathway43. Although these models differ in their kinetics and the 
species that causes toxicity, they are unified in that prion propagation remains the essence 
of pathogenesis.  
 
1.1.3 Characterisation of the prion protein 
The prion protein was first identified as the protein product of a cellular gene in 1985 by 
Oesch et al., after which it was mapped to human chromosome 20 and mouse 
chromosome 244, 45. The PRNP gene that encodes the prion protein is ubiquitously 
expressed although an abundance of the protein is present in neurons and glial cells, 
suggesting an essential function that is of particular relevance in the CNS3. Structurally, 
PrPC has an N-terminal flexible region containing 5 octarepeats and a C-terminal globular 
domain, representing the structured region46. PrPC is composed of 40% α-helical structure 
and virtually no β-sheet (3%), whereas the disease-associated form, PrPSc has a 30% 
makeup of α-helix and a high β-sheet content (43%)33. This β-sheet conformation is thus 
a central feature in the conversion of normal PrPC to the pathogenic PrPSc isoform. β-
sheets have a high propensity to aggregate, which is supported by the presence of amyloid 
plaques of PrPSc aggregates in some prion diseases3. Three alpha helices and two beta 
sheets comprise the C-terminal domain, (Figure 1.2), and a conserved disulfide bond with 
cysteine residues at codon 179 and 214 forms a bridge between alpha helix 2 and 347. A 
hydrophobic domain features at residues 91-120 and an N terminal octapeptide repeat 
from residues 60-916. 
PrPC is highly conserved across species and in humans it forms a 253 residue protein48 . 
The protein is targeted to the secretory pathway by a 22 residue signal peptide located at 
the N-terminus, and it is N-glycosylated at Asn180 and Asn196 (Figure 1.2)48. PrPC is a 
membrane bound protein that is attached to the outer cell surface or lipid rafts on plasma 
membranes by a GPI anchor, attachment of which is mediated by a 23 residue signal 
sequence48. PrPC undergoes biosynthesis at the ER and is trafficked to the cell surface 
through the Golgi, after which recycling may occur via endocytic mechanisms by 
internalization of PrP into clathrin coated pits48. Such endocytic internalisation of PrPC is 
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of biological interest as the endosomal pathway has been associated with being a site of 
PrPSc conversion48. 
Figure 1.2 Prion protein structure. The secondary structure is comprised of an N-terminal flexible region 
housing 5 octarepeats and the C-terminal domain forms a globular structured region comprised of three 
alpha helices (αA, αB, αC) and two beta strands, β1 and β2. The glycans represent N-glycosylation at residues 
Asn180 and Asn196, whilst the disulfide bridge is formed between residues 179 and 214. The GPI moiety 
is attached at the C-terminus for anchoring to the membrane. Adapted from Didonna et al., 2013. 
Despite its wide expression profile, the precise physiological function of the prion protein 
remains elusive. A powerful strategy to unravel its role is to knockout the mouse 
orthologue of the gene in order to assess its effects in a physiological setting. Several 
knockout mouse models of PrP exist; PrP0/0 and PrP-/- both describe mice ablated for the 
prion protein gene37, 49. These knockout mice show modified circadian patterns and 
rhythm, which results in altered sleep regulation. The authors suggest that the prion 
protein may serve a function that is relevant to fatal familial insomnia, in which there is 
profound sleep disturbance50, 51. 
Further work has involved targeting PrP gene ablation to neuronal cells of adult mice, 
which has shown that it does not result in neurodegeneration52. However, 
neurophysiology was altered in these mice, for which the authors suggest a role for the 
prion protein in neuronal excitability regulation52. Depleting neuronal PrP in mice 
following disease initiation resulted in reversal of early spongiform change and 
preservation of neurons, although PrPSc accumulated in glia. The authors found that PrP-
depleted neurons confer resistance to infection from surrounding cells38. Furthermore, 
Collinge et al., showed that PrP is associated with a role in synaptic function53. The 
authors analysed brain hippocampal slices of PrP null mice and showed that synaptic 
inhibition was impaired giving rise to speculation that the epileptic-like phenotype seen 
in CJD patients may be due to dysfunctional synaptic inhibition53.  
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A cytoprotective activity has been attributed to PrPC, which has been demonstrated by 
Bax induction of the apoptotic pathway in a cellular system. When the pro-apoptotic 
protein, Bax, was overexpressed in human fetal neurons, the majority of the neurons 
underwent apoptosis, whilst co-expression of PrP and Bax showed that the level of 
apoptotic cells had decreased to ~10%54, 55. However, the precise function of PrP still 
remains elusive as this cytoprotective activity seemed to only apply to Bax-mediated 
apoptosis55. 
PrPC has also been implicated as a protective agent against oxidative stress. Brown et al., 
showed that neurons from Prnp0/0 mice develop abnormalities in their response to 
oxidative stress, resulting in cells that are highly susceptible to stress inducing agents 
relative to wild type neurons55, 56. The authors describe a decline in the Cu2+/Zn2+-
dependent SOD-1 activity, suggesting that loss of PrP is linked to the decline observed in 
SOD1 activity56 . This is supported by research where increased levels of oxidative stress 
markers were found in the brains of PrP0/0 mice57. Some mechanisms of SOD1 activity 
have been postulated to include a role for PrPC in directly detoxifying reactive oxygen 
species or indirectly by upregulating proteins that act to detoxify these agents. These data 
are in line with the process of neurodegeneration to which increased oxidative stress and 
neuronal excitability may contribute, placing PrPC in a neuroprotective role against toxic 
stressors52. However, reports that PrP possesses copper-dependent SOD activity58 were 
followed up by Jackson et al., who identified that the prion protein does not have SOD-1 
activity59. 
PrPC has been functionally associated with signal transduction in various pathways by 
virtue of its localisation on cell surfaces and lipid rafts48, 60. Evidence for PrPC-dependent 
signaling was provided by Mouillet-Richard et al., who showed that PrPC is coupled to 
cytosolic tyrosine kinase Fyn in a caveolin-1 dependent manner, activation of which is 
facilitated by recruitment of NCAM to lipid rafts by PrPC 61, 62, 63. Such signal transduction 
has been further substantiated by recent work in which Strittmater et al., found that the 
deleterious neuronal impairment observed in Alzheimer’s brains was linked to amyloid-
beta interaction with post-synaptic PrP, which in effect leads to the activation of Fyn to 
phosphorylate NMDA receptors followed by their subsequent loss64, 65. However, an 
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effect on incubation time or PrP accumulation is not observed in mice deficient in NCAM 
or Fyn suggesting that these pathways may not underlie prion pathology. 
PrPC has also been implicated in the PI3K/AKT pathway, which regulates a number of 
fundamental processes such as cell growth, migration, survival, metabolism and cancer 
progression48. An emerging role in neuroprotection has also been reported by a number 
of groups, including work by Roffe et al., who showed that PrPC interaction with stress-
inducible protein 1 modulates correct neuronal function through the PI3K/Akt/mTOR and 
ERK1/2 pathways66. PrPSc neurotoxicity has been investigated using PrP106-126 as a model, 
as this peptide possesses physicochemical and pathological properties like PrPSc with 
respect to its partial protease resistance, amyloid forming potential and neurotoxic 
activity67. The PI3K/Akt pathway has been shown to be disrupted following exposure to 
PrP106-126 peptide in a neuronal cell line and its neuroprotective involvement has also been 
observed following oxidative stress68, 69. 
 
1.1.4 Prion strains 
Distinct heterogeneity of PrPSc has been observed whereby different prion strains can be 
derived from pathogenic isolates70. These strains can be passaged into inbred mice and 
differ by  their distinct patterns of neuropathology and incubation periods11, 70-72. Strains 
are thus infectious isolates that have heritable properties manifesting as distinct disease 
phenotypes70. These may be propagated in a defined inbred mouse line to produce strain-
specific phenotypes29-31. Although this appears to oppose the protein only hypothesis in 
that a single protein cannot possibly be the cause of effect of different phenotypes, the 
diversity of strains have been described as conformational variations of PrPSc 2. 
Conformational variants have the capacity to propagate via conversion of host PrP into 
one that resembles the variant2, 31, 73. The specificity of strains was lent credibility by work 
where distinct transmissible mink encephalopathy (TME) prion strains, denoted hyper 
(HY) and drowsy (DY), which originated from the same PrP sequence, were serially 
propagated in Syrian hamsters74. TME caused by HY propagation presents with 
hyperexcitability, ataxia and tremors whilst DY manifests as progressive lethargy75, 76. 
The paradigm of prion strains was further described by the Telling group where they 
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transmitted isolates from the brains of patients with FFI, sporadic and inherited prion 
disease to transgenic mice expressing humanised PrP77. Challenge with these isolates 
resulted in the propagation of PrPSc that retained the biochemical properties of the original 
inocula. They suggested that strains are enciphered in the conformation of PrPSc, which 
serves as a template for the direction of nascent PrPSc molecules77. A number of groups 
have proposed that prions are an ensemble of PrPSc molecules that consist of major and 
minor species which are selectively maintained in a host dependent manner30, 31, 78. The 
minor subcomponent thus may show dominance in a new host or tissue, preferentially 
propagating due to factors that are permissive and favour that species, a phenomenon 
known as strain shifting or mutation that potentially produces a new phenotype, 
uncharacteristic of the original strain78. This was demonstrated by findings that the sheep 
scrapie 22A prion strain was stable on serial mouse passage under standard conditions, 
however upon passage into mice with a different genotype, gradual changes in the 
incubation periods were observed79, 80. Following further subsequent passages, 
stabilisation occurred in the form of a new strain, 22F80.   
Prion strains thus showed heritability in their physicochemical properties as observed by 
distinct prion accumulation in affected brains and different susceptibilities to proteinase 
K digestion in addition to their different cleavage products upon digestion75, 76. Four major 
types of human PrPSc have been defined, according to Hill et al., although classification 
using an universal nomenclature is yet to be established9. These relate to the fragment size 
and glycoform ratio following protease digestion corresponding to un-, mono or di-
glycosylated PrPSc. Types 1-3 correlate with classical CJD (sporadic or iatrogenic) whilst 
vCJD is associated with PrPSc forms of type 4 (Figure 1.3). Polymorphism at codon 129, 
encoding either methionine or valine, is known to have a strong modifying effect to 
disease susceptibility81 (discussed in detail in Section 1.1.6) and thus the strain types 
shown in Figure 1.3 also indicate the codon 129 genotype for a given strain. Types 1 and 
4 have only been associated with homozygosity at codon 129 of PRNP, type 3 being 
observed with a valine at one allele and type 2 has been observed for all genotypes of 
PRNP at this polymorphic residue9, 71, 82.  Kuru prions were found to have a PrPSc type 
that was in line with types 2 and 3, with valine or methionine homozygosity at codon 
12983. Although polymorphisms at codon 129 facilitate homotypic interactions, 
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differences in primary structure alone cannot account for the existence of strains as they 
can be propagated in mice with identical PrP primary coding sequence30, 31. Furthermore, 
strains may be isolated from mice following passage in a different species, wherein they 
retain their biochemical properties. The basis of strain diversity requires that a given 
isolate imprints its properties on a host PrP. It is thought that these strains account for the 
clinical and neuropathological heterogeneity seen in patients31, 71, 72, 77. Strains thus serve 
an important role in determining the ease with which an isolate can propagate in a new 
species, or the transmission barrier. 
 
 
Figure 1.3 Distinct pattern of bands showing types of prion strains for classical CJD, a novel type 
describing vCJD and kuru. Analysis of proteinase K digested sCJD, iCJD, vCJD and BSE infected brain 
extracts on an immunoblot show a characteristic type of banding representing diglycosylated, 
monoglycosylated and unglycosylated forms of PrPSc. Types 1-3 rare seen in sporadic or iatrogenic CJD 
brains whilst type 4 is observed in vCJD and both types 2 and 3 in kuru. Analysed using monoclonal 
antibody 3F4.  Adapted from Wadsworth et al., 2011; Wadsworth et al., 2008. 
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1.1.5 Transmission barrier 
Prions are transmissible between species but the efficiency with which they can propagate 
from one species to another is limited by a transmission barrier84. Within the same species, 
propagation may be highly efficient but across species a large barrier may be observed 
which translates as a prolonged incubation period30. Transmission reflects a stochastic 
process whereby only a few animals may propagate prions showing prolonged and 
variable incubation periods whereas subsequent transmissions into the same species 
permit adaptation and thus present incubation times that are characteristic of that 
species30. These barriers can be quantified by measuring the difference between first and 
subsequent passage where a drop in incubation time occurs30. The difference in 
transmission efficiency between the first passage of a prion into a particular species and 
the subsequent passages is thought to lie within differences in primary structure of the 
host and donor prion protein and the permissible conformational variants available, the 
prion strain type and the co-factors within the environment in which propagation occurs 
28, 73, 85. The work by Prusiner et al. found that when transgenic mice expressing the 
hamster prion protein were inoculated with hamster prions, synthesis of hamster prions 
were identified rather than mouse prions whilst transgenic mice for the mouse prion 
protein produced mouse prions and not hamster prions73. This work contributed to current 
thinking in that homotypic PrP interactions permit efficient prion propagation and 
contribute a role in the efficiency of transmission2, 73. Transmission barriers were analysed 
when hamster scrapie Sc237 prions were inoculated into mice, which did not show any 
clinical sign 735 days post-inoculation, however following transmission of this prion into 
mice transgenic for hamster prion protein, short incubation periods were observed73, 86. 
Sequence differences between hamster and mouse PrP show that they differ at 16 residues, 
indicating that non-homologous PrP interactions translate as prolonged incubation times 
6, 13. 
Thus transmission barriers reflect the degree of overlap between host and donor PrP, 
which is shown by the ease with which a strain may propagate in a species or the ability 
of a given strain to propagate prions in a new host from a limited set of conformations 
that can be assumed by PrPSc 30. However, the measure of transmission barriers by 
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determination of clinical end point may be misleading as it has been shown that prions 
are able to replicate although as a subclinical form of infection as the barrier to disease 
may be large85, 87. Hill et al., found that hamster prions that were historically thought to 
be non-pathogenic in mice, were able to replicate in mice, despite the barrier in causing 
clinical disease85. Failure to generate the neurodegenerative syndrome in subclinical 
animals may be associated with prion kinetics in terms of inefficient propagation, 
providing further support to this notion30. This results in a lack of the toxic species being 
able to surpass the threshold for neurotoxicity43. This was further supported by Beringue 
et al., who showed that prions infect the lymphoreticular system at a subclinical level88. 
They found that following CWD prion infection in mice expressing ovine PrP the 
transmission barrier to lymphoid tissue was more permissive than in brain88. These 
authors challenged mice expressing human PrP with BSE prions for which they found 
prion infection in the spleen but less than 10% of animals were found to have presence of 
prions in the brain following prolonged incubation periods88 . Together, these findings 
relate the risk of zoonotic potential of prions despite the large barrier to clinical disease30, 
88. 
 
1.1.6 Genetic susceptibility to prion diseases 
 
Polymorphic variation within the PRNP gene has a major influence in determining 
susceptibility to disease for both animals and humans. These polymorphisms are known 
to have a modifying effect, in particular, codon 129 of the prion protein, which serves as 
a major risk factor for disease susceptibility. At this location, a methionine or valine 
residue may alternate which is observed at a frequency of 38% for methionine 
homozygotes, 11% for valine homozygosity and heterozygotes at 51% in the UK 
population19. Homozygosity has been associated with an increased risk to acquired and 
sporadic cases of CJD. The majority of sporadic cases show methionine homozygosity at 
codon 129, and all cases of vCJD have methionine homozygosity at this PRNP locus81, 89, 
90. A crystal structure of human prion protein has shown that interactions with 
neighbouring prion proteins are mediated by homotypic contacts between residues that 
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surround codon 129; this shows the importance of this region in determining disease 
susceptibility91. 
Heterozygosity has however, been shown to confer partial resistance. Patients with 
iatrogenic CJD and codon 129 heterozygosity have a later age of disease onset92. 
Heterozygosity in familial CJD is also linked to a later age of onset, however, codon 129V 
in patients with the D178N mutation can predispose individuals to CJD93. Longer 
incubation times may reflect mechanisms of prion biology due to non-homologous 
interaction between prion proteins. As a result, the efficiency with which transmission can 
occur may decrease as the infective seed, PrPSc, struggles to propagate due to the 
restrictive conformation posed by the strain31. These findings concur with analyses of 
elderly survivors of kuru that had multiple exposures but were healthy and were 
heterozygous at codon 129. Heterozygotes were over 30 years of age at onset, whereas 
homozygotes of either allele were ~19 years of age at onset94. The survival advantage 
conferred by heterozygosity has thus driven a strong balancing selection pressure for 
codon 129 heterozygosity in the Fore region24. 
A protective polymorphism that showed a pronounced effect on kuru susceptibility was 
identified in the Fore region of Papua New Guinea as G127V, where heterozygosity 
confers kuru resistance95. This polymorphic variant was not found in patients with kuru 
and occurs at a frequency of 8% in the south Fore region although geographical 
distribution studies have found that this polymorphism is not seen elsewhere95.  
In the Japanese population, the E219K polymorphism has been identified with a 6% 
frequency as susceptibility factor for sporadic CJD19. Codon 129 is not polymorphic in 
the Japanese population, however heterozygosity at codon 219 appears to confer 
resistance to sporadic CJD.  
Although polymorphic variation within the PRNP gene is the major genetic determinant, 
there are other genes that may modulate disease susceptibility. To identify genes 
modulating genetic susceptibility to prion diseases, genome wide association studies 
(GWAS) and mouse models have proven to be key genetic tools to capture genetic 
variation between sample cases and normal controls.  
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1.2 Genetic modifiers of prion disease incubation time in mice 
 
1.2.1 Incubation time 
Prion diseases feature a prolonged, clinically silent incubation period. In animal 
transmission studies, this period is defined as the time between inoculation with prions 
and the onset of clinical symptoms. The mouse is ideal for modelling prion disease as it 
closely recapitulates the key features, including incubation time, a trait chosen for further 
investigation by many research groups96-100. 
In experimental transmission studies, under standard conditions, infection of inbred lines 
of mice with the same prion strain demonstrated large differences in incubation times that 
are well defined and reproducible101-104. The findings from these studies identified these 
striking variations, ranging in incubation times from 108 ± 1 days for mice with a 
NZW/OlaHsd background to 313 ± 3 days for Ju/FaCT mice. Incubation times are 
categorised as short and long incubation periods, where the former is assigned to those 
that present incubations ~100-200 days long and the latter for those that exceed 255 
days102. 
It has been shown that mice hemizygous for Prnp, Prnp0/+, showed an incubation time 
that was 125 days longer than that of wild-type mice, Prnp+/+ 35. This reflects an enhanced 
resistance to scrapie infection, providing evidence of an inverse relationship between 
incubation time and the level of PrPC 35. This was further supported by transgenic mice 
studies where overexpression of PrPC maintains this inverse relationship, which has 
resulted in incubation times as short as 62 ± 4 days35, 73, 105, 106. Prion strain also plays a 
role in influencing incubation time28, 71, 75. Following transmission of mouse adapted BSE 
and scrapie strains into C57BL mouse strains, mean incubation times of 207 ± 3 and 164 
± 4 days were observed respectively, showing the effect exerted by prion strains28. 
Differences in incubation time can also be attributed to the presence of a species barrier28, 
107, 108. This is demonstrated clearly by the incubation times that are obtained upon primary 
passage in VM mice inoculated with BSE and scrapie, which show incubation times of 
471 ± 8 and 769 ± 16 days but following subsequent mouse-mouse passage, 116 ± 3 and 
308 ± 15 days, respectively28. The route through which a prion strain is inoculated 
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presents variations in incubation times. It was shown that intracerebral transmission of 
Chandler/RML scrapie in C57BL mice had a mean incubation of 138 ± 3 days whilst 
intraperitoneal inoculation had a prolonged period of 184 ± 5 days, explained by the 
provision of  faster access to the CNS, permitting rapid prion propagation and thus shorter 
incubation times109. The inoculum dose is also important in determining these incubation 
times as dose response curves have shown an inverse relationship between the inoculum 
titre and incubation time110.  
Research by Dickinson and MacKay, found that control of incubation time could also be 
determined by host genotype. The authors described an exceptionally long incubation 
time of 280 days in the VM/Dk mouse strain relative to the shorter incubation times 
between 140 and 180 days of eight other strains upon infection with the ME7 scrapie 
strain under standard conditions97. Further observations of characteristic incubation 
periods of different mouse strains following infection with a defined prion strain were 
reported98, 102, 111, 112, highlighting a genetic influence of mouse background on incubation 
time. Attempts to delineate these genes involved mouse crosses between the RIII and 
VM/Dk mouse strains representing short and long incubation times respectively. As a 
result of this work, a discovery of the incubation time regulator, sinc, was made, which 
had short and long incubation time alleles, s7 and p7111. Similar segregation in incubation 
time was observed in crossing a sinc s7 mouse strain, NZW/LacJ, with a sinc p7 strain, 
I/LnJ, producing an incubation time that was intermediate of these two extremes101. 
Backcrossing of these F1 generation to NZW/LacJ resulted in progeny that segregated 
into two groups with defined incubation periods, leading to the identification of a single 
locus Prni, considered to be the same locus as Sinc.  This locus was found to modulate 
incubation time with its short and long alleles, N and I and was closely linked to Prnp101, 
102. These alleles were then re-designated as Prnpa and Prnpb respectively, following the 
discovery that Prnp was expressed as two variants in mice98. These variants arise from 
polymorphisms at codon 108 and 189, where a dimorphism encoding leucine and 
threonine at position 108 and 189, respectively, gives Prnpa whereas phenylalanine and 
valine at these codons express as Prnpb. These alleles segregate with incubation time, 
indicative of Prnp dimorphic control of incubation time. This was proven by a gene 
targeting strategy whereby Prnpa mice were engineered to express the Prnpb variant 
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endogenously113. The authors generated a 129/Ola mouse line that expressed PrPB in 
place of its wild-type PrPA. Upon infection with mouse adapted BSE, 301V, wild-type 
129/Ola PrP A/A mice that carry the Prnpa allele show an incubation of 244 ± 2 days in 
contrast to the 133 ± 0.2 days shown by gene targeted a[108F189V]/a[108F189V] 129/Ola mice 
that express variant PrPB. This is comparable to wild type VM/Dk PrP B/B mice that have 
the Prnpb allele, expressing PrPB, which have an incubation of 119 ± 2.1 days following 
challenge with 301V. This was the first demonstration in mouse that confirmed the 
congruency of Prnp and Sinc/Prni, thereby confirming the role of Prnp variation in the 
control of incubation time113. The difference in incubation times between the gene 
targeted Prnpa[108F189V] mice and wild-type Prnpb mice can be explained by their different 
genetic background suggesting that other genetic loci may also modify incubation time. 
The dimorphisms related here were further analysed separately through gene targeting 
Prnpa mice114. This work identified that both of these polymorphisms control incubation 
time and that each of these play a different role. The authors suggest that codon 189 
reflects initial binding of the donor PrP with host PrP whilst codon 108 may control the 
efficiency with which PrPC is converted to pathogenic PrPSc 114. 
Interestingly, a novel allele, Prnpc, was later discovered in MAI/Pas mice, which 
presented an incubation time greater than that shown by Prnpb alleles. This expanded the 
categorisation from Prnpa or Prnpb mice as this new variant carried an allele that encodes 
phenylalanine and threonine at positions 108 and 189 respectively104. Further work in 
generating a Prnpc congenic line that expresses this allele on a Prnpa C57BL/6JOlaHsd 
background found that upon challenge with Chandler/RML, an incubation time of 255±12 
days was seen relative to 360±11 days of wild type MAI/Pas mice. This suggests that 
Prnpc is associated with a long incubation time and is also indicative of a PrP independent 
control of incubation time, pointing at other genetic loci that may modulate this effect104. 
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1.2.2 Incubation time quantitative trait loci  
The range of incubation times produced for a given Prnp allele with a particular prion 
inoculum under standard experimental conditions suggests that other genes may also have 
a modifying effect. This is apparent in Prnpa mice challenged with Chandler/RML scrapie, 
which produce incubation periods ranging from 108±1 days to 221±5 days100, 101, 104, 113. As 
incubation time is measured in days it can be used as a quantitative trait for the identification 
of loci that are linked to this phenotype. The common method by which these quantitative 
trait loci (QTL) may be identified is through the crossing of two mouse strains bearing the 
same Prnp allele but with distinct incubation times; these may either be intercrossed or 
backcrossed. In this way, 21 loci were collectively identified across 8 chromosomes through 
intracerebral inoculations of four combinations of crossing with Chandler/RML scrapie, 
mouse adapted BSE, BSE and ME7 scrapie; CAST X NZW F2 intercross100, 115, CAST x SJL 
F2 intercross99, C57 X RIII backcross and an intercross116, 117.  
These crosses have the benefit of using large progeny numbers with only two different alleles 
that segregate, making analyses less complicated. However, they carry the limitation that two 
parental mice strains will not bear all the possibilities of alleles that influence incubation time. 
In order to maximize the number of QTL detected, experimental parameters may be modified 
such as route of inoculation or varying the prion strain used. The resulting incubation periods 
may be influenced by QTLs that might have gone undetected in the absence of prion strain 
variation or a particular route of prion infection8. 
The detectable loci that modulate incubation times span regions that encompass several genes 
covering many megabases, therefore the effect observed cannot be attributed to a single gene. 
Most of these genes remain undetected because the regions are so large, thus alternative 
strategies have been employed to fine map and identify candidate genes. One such method is 
through the use of heterogeneous stocks of mice such as the Northport heterogeneous stock118. 
Heterogeneous stocks of mice model an outbred population but have the advantage of 
starting with a defined number of parental alleles, which provide a high level of 
recombination119. These mice have been used to identify candidate genes, described below 
in Section 1.2.3, through size reduction of a QTL.  
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1.2.3 Candidate genes 
 
Much research has been dedicated to identifying some of these genes that modify 
incubation time through mouse genetics complemented by human genome wide 
association studies (GWAS) or through an individual candidate gene approach based on 
genes in pathways implicated in prion disease. By using the Northport heterogeneous 
stock of mice, Lloyd et al., carried out high resolution fine mapping of Mmu19 from which 
emerged several genes. Of these, Hectd2 was the most significantly associated with prion 
disease incubation time120. Hectd2 expression in prion-infected brains, from mice at the 
end stage of disease, was compared to controls and it was found that expression was five 
times greater in C57BL/6 mice relative to normal, uninfected mice. The authors also 
performed a human association study, where samples from patients with vCJD (n = 117), 
and sporadic CJD (n = 452) were analysed in parallel to a UK control population (n = 
601). An intronic SNP, rs12249854, was linked to an increased risk to vCJD (p = 0.0049) 
and sporadic CJD (p = 0.012) although this risk allele was not found to modify human 
disease phenotypes. However, recent work by Jeong and others have found that this 
polymorphism is not associated with sporadic CJD121.  Further analyses of HECTD2 
found that in the UK population there exists three HECTD2 haplotypes, termed 1-3. One 
of these, haplotype 2, tagged by rs12249854A, was linked to an increased risk to vCJD, 
possessing a statistical significance of p = 0.006. Samples from kuru patients were 
analysed in comparison to elderly female survivors from Papua New Guinea that have 
had multiple exposures to this prion strain. The Papua New Guinea population possessed 
four haplotypes, termed 1, 2, 4 and 5, where one of these population specific haplotypes, 
4, is associated with kuru. This haplotype showed a strong association with kuru (p = 
9x10-4). The expression of HECTD2 was also analysed in human lymphocytes, where 
heterozygotes for the genotype tagged by rs12249854, were shown to express 2.3 times 
greater than homozygotes, thereby suggesting that increased HECTD2 is associated with 
vCJD susceptibility. These data taken together, present Hectd2 as a strong candidate 
modifier for prion disease incubation time120. However, no functional analyses to link this 
gene to prion pathology have been found.  
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Lloyd et al., performed a microarray gene expression analysis on brains of wild type adult 
mice that manifest different incubation times122. Five genes were identified as having 
differential expression that correlates with incubation time, namely, Hspa13, Fkbp9, 
Cbx1, Gpr19 and AK013823. The authors further investigated Hspa13, encoding the 
protein Hspa13 (Stch), by generating an Hspa13 overexpressing transgenic mouse line, 
Tg222. By challenging Tg222 mice with three different prion strains, the authors were 
able to determine that the overexpression of Hspa13 leads to a pronounced reduction in 
incubation time. Precisely, 16, 15 and 7 % decreases in incubation time relative to wild 
type mice were observed following inoculation with Chandler/RML, ME7 or MRC2 
prions and this was not associated with an upregulation of PrPC. These results were 
substantiated using a cell based model of prion disease, wherein siRNA knockdown of 
Hspa13 in chronically infected N2a cells was performed to test for correlation of Hspa13 
expression to prion propagation. A curing effect was observed in Hspa13 knockdown N2a 
cells relative to the non-targeting control122. Hspa13 is a member of the Hsp70 family of 
molecular chaperones, thus implicating it in the correct folding of proteins123. 
Furthermore its functional activity has been extended to cell survival by regulation of 
tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)-dependent 
apoptosis124. TRAIL is a cytokine that has been reported in brains of Alzheimer’s patients 
in mediating amyloid-beta induced apoptosis125.  
 
Cpne8 is a further candidate quantitative trait gene successfully identified using the 
Northport heterogeneous stock of mice from Mmu15126.  Comprehensive sequencing of 
the region linked to incubation time found Cpne8 as a promising candidate (p = 0.0002). 
The authors found that this copine family member had an upregulated mRNA expression 
at the terminal stage of prion disease. Copine proteins are calcium dependent phospholipid 
binding proteins that have been implicated in membrane trafficking; this role may tie in 
with the regulated trafficking of PrP, suggesting that Cpne8 may serve to modulate this126. 
The largest screen performed to date based on an individual candidate approach was by 
Tamguney et al., who screened 20 genes implicated in prion pathogenesis, by testing 
knockout or overexpressing transgenic mouse models for each. The authors found that 
only three of the candidates showed an effect, SOD1, App and Il1r1127. Overexpression 
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of human SOD1 increased incubation time by 19% whilst knockout models of Il1r1 and 
App increased survival by 13 and 16%127. Superoxide dismutase, SOD1, is a ubiquitously 
expressed metalloenzyme that catalyses superoxide free radicals to hydrogen peroxide to 
prevent oxidative stress128. Mutations in this gene have been causally linked to a subset 
of familial Amyotrophic Lateral Sclerosis (ALS) cases128. It has also been implicated in 
Alzheimer’s disease wherein SOD1 knockout mice enhance amyloid-β oligomerisation 
and memory loss, supported by studies in which cerebral endothelial dysfunction that 
results from APP overexpression is rescued by SOD1129, 130. The cellular oxidative stress 
response is thus involved in the pathology of a number of neurodegenerative diseases131, 
132. Amyloid-β (A4) precursor protein, App, was tested due to the similarities between 
prion and Alzheimer’s diseases in terms of neuropathological hallmarks and also due to 
its co-localisation with PrPC in mouse127. The post-translational product of App, amyloid-
β (40-42 residues) has been reported to interact with PrP, which mediates amyloid-β 
induced synaptic plasticity impairment that may be prevented by targeting PrP64, 133. 
Interleukin-1 receptor, type 1 gene, Il1r1, was also tested to follow up studies that detected 
increased levels of its ligands, IL-1α and IL-1β in prion-infected mice and CJD patients134. 
The authors reported a delay in accumulation of PrPSc in Il1r1-/- mice and prolonged 
incubation time suggesting that suppression of the anti-inflammatory response perhaps by 
delayed astrocytic gliosis increases survival127, 135. 
Lloyd et al., extended these analyses by using the Northport heterogeneous stock of mice 
to determine whether natural variation in Sod1, App and Il1r1 was associated with 
incubation time through an association study136. Although they did not find any 
association with App, a Sod1 SNP from intron 3 and a non-synonymous Il1r1 SNP from 
exon 3 were linked to incubation time (p <0.0001, p = 0.02, respectively). The authors 
challenged Sod1-/- mice with RML and ME7, representing mouse adapted scrapie strains 
and MRC2, a mouse adapted BSE strain. Sod1-/- mice all showed reductions in incubation 
time irrespective of strain used, where RML, ME7 and MRC2 isolates led to decreases of 
20, 13 and 24% respectively, relative to wild type. These data support the association of 
Sod1 with prion disease incubation time136. 
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Knockout mouse models for a number of pro- and anti- inflammatory cytokines were 
tested in a bid to determine the role of such cytokines in prion pathology137. Interleukin 
10, Il-10, was found to be linked to incubation time following challenge with RML or 
ME7 mouse-adapted scrapie strains137. Il-10-/- mice showed shortened incubation times 
relative to wild type and an earlier expression of tumour necrosis factor-alpha, TNF-alpha. 
The authors suggest that this early expression of TNF-alpha sensitises mice to prion 
pathogenesis, thus placing Il-10 as a candidate gene that may be important for longer 
survival137. 
Genome wide association studies have also been used to detect alleles that are associated 
with human prion disease. In a human genome wide association study by Mead et al., 
STMN2 and RARB were identified as genetic risk factors for vCJD138. A SNP, rs1460163, 
upstream of STMN2, which maps to chromosome 8, was associated with vCJD (p = 
5.6x10-5) which was also associated with resistance to kuru (p = 2.5x10-4)138. They also 
found that Stmn2 expression was downregulated 30-fold in a cellular model of mouse 
prion disease138. This is supported by previous work by Greenwood et al., who 
investigated the expression profiles of prion infected neuronal cells and found a 
downregulation of Stmn2 expression139. Stmn2 was further investigated by Lloyd et al., 
who used a stock of ~1000 Northport heterogeneous stock of mice that were inoculated 
with Chandler/RML prions after which the incubation times were observed122. They found 
a small effect (p = 0.04) that associates the gene to incubation time. However, these 
authors found that Stmn2 expression in prion-infected brains, from mice at the end stage 
of disease, was upregulated relative to controls. They suggest that this may be due to the 
variation in prion propagation that exists in an in vitro situation compared to the in vivo 
environment at the end stage of disease and the pathological differences that lie in these 
two circumstances122. 
The product of Stmn2, SCG10, is a neuronally expressed protein with a high level of 
expression in the growth cones140, 141. SCG10 is highly expressed in the developing 
nervous system and the adult brain sustains it in regions of synaptic plasticity142-144. Stmn2 
is a key regulator of microtubule stability, which in turn modulates neurite outgrowth and 
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its subsequent elongation and branching145, 146. Overexpression of SCG10 has been shown 
to improve neurite outgrowth, substantiating its role in microtubule assembly146. 
Mead et al., found that the rs6794719 SNP, upstream of RARB and maps to chromosome 
3, was found to associate with vCJD (p = 1.96 x 10-7), in addition to iatrogenic CJD 
patients (p = 0.03)138. This work was followed up by Lloyd et al., who showed a highly 
significant association of Rarb with prion disease incubation time in mice147. However, 
the authors also found that this SNP maps within 0.5Mb of the THRB gene locus. In mice 
the Rarb-Thrb locus was linked to incubation time but the observed effect could not be 
directed towards a single gene as it is the effect of the region that is detectable147. Although 
Rarb expression in hypothalamic neuronal cells showed no difference upon prion 
infection, its level in prion-infected brains, at the end stage of disease, was upregulated in 
comparison to controls138, 147. 
RARB encodes the protein retinoic acid receptor beta and is a member of the retinoic 
acid/thyroid hormone receptor family148. It has also been demonstrated that retinoic acid 
regulates the expression of the prion protein through its downregulation. The authors 
suggest that a therapeutic approach to slowing down prion pathogenesis may benefit from 
investigating retinoids to prolong incubation time149.  
Mead et al., performed a further genome wide association study across vCJD, sporadic 
CJD, iatrogenic CJD, inherited prion diseases and kuru in UK and German patients150. 
Although their findings supported current knowledge that Prnp is the major genetic 
determinant for all human prion disease cases, certain SNPs were however associated with 
particular prion diseases. SNPs at the ZBTB38 locus were linked to CJD in the UK but not 
sporadic CJD in German cases or Kuru. A SNP in the CHN2 gene was also found to be 
associated with vCJD but not in sporadic UK or German cases or kuru. Zbtb38 is involved 
in the regulation of apoptosis in murine cells. Zbtb38 is a zinc finger protein that is highly 
expressed in the brain and can bind methylated DNA, implicating it in transcriptional 
repression151. 
 
In an European GWAS study of vCJD cases, an intronic SNP in MTMR7, rs4921542, was 
associated with risk to vCJD, (p = 1.6 x 108)152. The protein product of MTMR7, 
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(myotubularin related protein 7 gene) is a CNS-specific phosphatase that targets 
phosphatidylinositol 3-phosphate and inositol 1,3-bisphosphate, suggestive of a role for 
the phosphatidylinositol pathway in susceptibility to vCJD152. MTMR7 interacts with 
MTMR9, a protein that is implicated in autophagy153, 154.  The authors also found a SNP, 
rs7565981, in the intergenic region of NPAS2, (neuronal PAS (per-ARNT-sim) domain-
containing protein 2). NPAS2 is a transcription factor that is expressed in the brain and 
peripheral tissues155. NPAS2 serves a role in regulating circadian behaviour and mice 
deficient in NPAS2 show impaired contextual memory156, 157. 
 
1.3 HECTD2 is a prion disease modifier linked to incubation time 
1.3.1 E3 ubiquitin ligases 
Hectd2 is the first candidate gene that has been linked to prion disease incubation time in 
mice that also influences susceptibility to the human diseases, vCJD and kuru, making it 
a very promising candidate120. Limited information is available for Hectd2 and thus the 
characterisation of this gene is important in understanding the molecular basis of 
incubation times and risk to disease. 
By homology, Hectd2 is an E3 ligase, representing one of a cascade of ubiquitously 
expressed enzymes that modify proteins at the post-transcriptional level by 
ubiquitination158. Ubiquitination is a highly ordered process that regulates a myriad of 
cellular processes including and not exhaustive of protein quality control by proteasomal 
or autophagic pathways, cell cycle, transcription, DNA repair, apoptosis,  endocytosis and 
trafficking of transmembrane proteins by serving as a recognition element for downstream 
effectors to direct its fate159-166. The multi-step ATP-dependent reaction involves the 
sequential transfer of 76 amino acid ubiquitin from E1 ubiquitin activating enzyme, where 
it forms a high energy thiol ester bond, to an ubiquitin conjugating enzyme, E2, via 
another thiol ester link. The ubiquitin moiety is then transferred to a high energy thiol 
intermediate on an E3 ligase that catalyses the covalent attachment of the ubiquitin moiety 
to an NH2-group of a bound substrate
160, 167, 168. This ubiquitination is governed by an 
evolutionary conserved catalytic cysteine residue harboured within the ~350 residue C-
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terminal HECT domain that forms the thioester intermediate with ubiquitin prior to 
transfer to a given substrate160, 169.  
The human genome has been estimated to encode 2 potential E1s, ~30 E2s and over 600 
E3 ligases162. This large number of E3s accounts for the specificity of the ubiquitination 
system to regulate a myriad of cellular processes. There are two main types of E3s, the 
HECTs (Homologous to E6-AP Carboxyl Terminus), of which there are 28 and RING 
(Really Interesting New Gene) ligases which comprise ~95% of E3 ligases162. These differ 
in their mechanism of ubiquitin conjugation to their substrates, where HECT E3s use the 
approach described above by catalysing direct substrate ubiquitination, depicted in Figure 
1.4. In contrast, RING E3 ligases, lack the catalytic site and thus serve as scaffolds by 
which E2 enzymes are brought into close proximity to the target substrate (Figure 1.4)162, 
170, 171.  
 
Figure 1.4 Mechanism of substrate ubiquitin conjugation by the two main types of ligases, HECT and 
RING E3s. Ubiquitination is initiated in an ATP-dependent process by E1 activating and E2 conjugating 
enzymes. HECT ligases can catalyse ubiquitin transfer to the substrate directly whilst RING ligases serve 
as a scaffold for conjugation of the ubiquitin moiety onto a substrate by E2. Adapted from Rotin et al, 2009. 
Although poorly characterised, conservation of the catalytic cysteine site indicates that 
HECT E3 ligases convey the ubiquitination activity172. The HECT domain is bi-lobal and 
comprises an N-terminal lobe to which E2 interacts with, and a C-terminal lobe housing 
the catalytic cysteine that forms the thioester bond with ubiquitin, which are connected by 
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a flexible hinge region that facilitates ubiquitin transfer through conformational 
changes173, 174. The N-terminal extension of HECT E3s is thought to be the substrate 
determinant that dictates the specificity of the ubiquitination system and is variable in 
length and sequence thus accommodating the diversity of substrates it binds162, 172. This 
variability in the putative substrate binding region defines the grouping of human E3s into 
three subfamilies, the HERCS, NEDD4s and other HECTS, based on the domains that 
they carry in addition to HECT (Figure 1.5). The HERCs, totalling six, possess a regulator 
of chromosome condensation 1(RCCL)-like domain, (RLD), and the nine NEDD4 group 
members harbour an N-terminal C2 domain that binds phospholipids and two to four WW 
domains that contain two conserved tryptophan residues that impart a role in protein-
protein interactions162, 172. Other HECTs represent the final subfamily, which lack an 
archetypal domain architecture, where characterisation of some members of this group 
has identified a myriad of known domains within the N-terminal region and a number 
without any known domains162. Hectd2, falls into the latter category, where its N-terminal 
extension presents a region to which structural information is yet to be determined162, and 
thus extrapolation of potential binding substrates has not yet been possible owing to the 
absence of known protein-protein interaction domains. 
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Figure 1.5 Family of HECT E3 ligases.  a) The HECT E3 ligases can be divided into the three subfamilies 
based on the domains that they carry in addition to HECT depicted schematically as the ‘HERCs’, 
‘NEDD4s’ and ‘other HECTs’. Hectd2 is a member of ‘other HECTS’, for which structural information is 
yet unknown. b) Hectd2 conservation across species. Adapted from Rotin et al., 2009 
 
The ubiquitination signal that marks a substrate is dependent upon the downstream 
processes stipulated by the cell162, 175. Ubiquitination may thus serve as a signaling device 
for degradative processes such as those mediated by the proteasome or autophagy 
(described in detail in Sections 1.3.4 and 1.3.5) as well as non-degradative processes164-
166, 176-178. Consequently, signals are differentiated according to need by mono- or multi- 
ubiquitination at a single lysine residue of the target substrate or polyubiquitinated in 
which sequential transfer of ubiquitin generates chains at these sites161, 162. Ubiquitin has 
seven lysine residues at positions K6, K11, K27, K29, K33, K48 and K63 through which 
E3-mediated ubiquitination may occur with linkage through K48 and K63 being the most 
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common161. It has been long hypothesised that ubiquitination through K48 of the 
preceding ubiquitin moiety targets substrates for proteasomal degradation while non-K48 
linkages direct non-proteolytic fates179. K63-mediated ubiquitination has been reported to 
target substrates for autophagic degradation in addition to other cellular processes such as 
vesicular sorting and endocytosis, while K11 linkage to substrates implicates them in the 
endoplasmic reticulum associated degradation, ERAD, pathway165, 180. However, these 
canonical signals have been challenged as it has emerged that ubiquitination through all 
residues may target substrates for proteasomal degradation, and further to this, non-lysine 
ubiquitination of substrates may also occur thus adding complexity to the system161. Thus 
the multiplicity of the different structures of ubiquitination allows fine tuning of the 
signaling between a substrate and its effector, allowing the regulation of the numerous 
processes that it governs, with proteasomal degradation serving a predominant channel 
for protein fates.   
 
The literature outlined in the following sections highlights the roles of two of the key 
pathways through which ubiquitination may act as a signaling device in prion disease, the 
ubiquitin proteasome system (UPS) and autophagy. These cellular mechanisms have 
shown prominence as emerging themes in neurodegenerative diseases, from which a 
greater understanding of pathogenesis may be derived, in addition to serving as a possible 
therapeutic avenue. 
 
1.3.2 Ubiquitin proteasome system-mediated clearance in prion pathology  
The major protein turnover system at the cell's disposal for homeostasis maintenance and 
regulation of a diversity of cellular processes and localisation is the ubiquitin proteasome 
pathway181, 182. In coordination with the ubiquitin conjugating machinery, this multi-
functioning cytosolic complex serves as a quality control mechanism in the degradation 
of unwanted, misfolded or missense proteins, or for the regulation of short lived proteins 
182, 183. This may be of particular importance when proteins are toxic or have a propensity 
to aggregate182. The degradative capacity of the UPS is governed by its proteolytic core, 
which harbours caspase-like, trypsin-like and chymotrypsin-like enzymatic activities182. 
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With the UPS being implicated in a myriad of cellular processes, dysfunction of 
components of its machinery have been linked to disease pathogeneses and in particular, 
prion diseases182, 184. The first evidence of a connection between prions and the UPS was 
demonstrated by the identification of the GSS-linked prion protein mutant, Y145Stop and 
wild type prion protein that were degraded by the proteasomal pathway via endoplasmic 
reticulum-associated degradation (ERAD)185; ERAD is a process whereby misfolded 
proteins within the endoplasmic reticulum (ER) are subjected to degradation by the 
proteasome186. Incorrectly folded proteins in the ER are retrotranslocated into the cytosol, 
for proteasomal-mediated degradation186, 187. It was also found that by blocking the 
proteasome with inhibitors, an accumulation of the mutant protein could be observed – 
suggestive of an important role for the proteasome 188, 189. A further GSS associated prion 
mutant Q217R, following binding to the chaperone protein BiP, was also targeted for 
proteasomal degradation190. 
Later studies confirmed that wild type PrP also undergoes ERAD, by means of retrograde 
transport into the cytosol and subsequent ubiquitination188, 189. It was shown that UPS 
impairment can thus encourage the conformational conversion of wild type PrPC to a 
PrPSc-like form since a defective degradative ability may increase the propensity for the 
aberrant conformer to initiate the conversion process191, 192. These authors found that 
inhibiting the proteasome leads to the accumulation of cytosolic prion aggregates that 
reflect the pathogenic properties of prions such as self-replication in addition to partial 
protease resistance. Elimination of the proteasome inhibitors does not demonstrate a 
reversal of the process since conversion of just one wild type molecule results in a seed 
for self-perpetuation, leaving the UPS with little power to overcome it191, 192. 
Ongoing research in this field suggests a strong relationship between UPS malfunction 
and prion pathogenesis. Kang et al., , reported that following challenge with the ME7 
prion strain in mouse brains, ubiquitin protein conjugates accumulated in parallel to the 
protease resistant species, coinciding with the first clinical signs and decreased proteasomal 
activity184. Subsequent analyses determined that these PrPSc species were ubiquitinated at 
the terminal stage of the disease184. It was observed that the chymotrypsin like and 
caspase-like peptidase activities of the proteasome were diminished in these scrapie 
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infected brains184. Such evidence firmly implicates UPS impairment in prion aetiology 
and may suggest that the proteasome is inhibited by PrPSc protein aggregates, which 
would be consistent with data published by Bence et al., who showed that two different 
aggregated proteins could inhibit proteasomal function193.  
Later work by Kristiansen et al., verified these data, by showing that mild infection of two 
neuronal cell lines that sustain prion infectivity showed a reduction of the caspase-like 
and chymotrypsin catalytic functions of the proteasome194. This was substantiated by the 
finding that RML infected mouse brain also displayed the same decline in the proteasomal 
catalytic activities. The authors also found that by expressing a fluorescent GFP-tagged 
proteasome reporter substrate in live cells, the proteasome function could be quantified195. 
Upon prion infection, the levels of the fluorescent reporter were significantly increased 
but a reversal of the effect was seen on curing of the prion-infected cells, suggesting prion-
related UPS dysfunction. The mechanism by which prions are thought to cause 
proteasome dysfunction remains elusive although it is speculated that PrPSc species act 
directly by inhibiting gate opening of the 20S chamber, in turn leading to neuronal 
death194, 196. 
These experiments were extended to determine a possible mechanism through which 
inhibition of the proteasome is achieved. This has been described by Deriziotis et al., 
where they postulate that misfolded PrP inhibits the proteasome through an antagonistic 
mechanism, whereby it binds to the outer lateral surface of the  proteasome, stabilising 
the closed- gated conformation182, 194, 197.  Although pathologically, the nature of the 
misfolded PrP species conformation that results in inhibition of substrate entry remains 
unclear, it has been reported that proteasomal activity is decreased upon exposure to beta-
sheet rich PrP oligomers194, however, the degree to which this affects the 
neurodegenerative process is yet to be elucidated.  
Together these data point towards a role for the UPS in prion disease, and the key role 
that this system plays in proteostasis makes such a mechanism of neurodegeneration 
plausible, placing the proteasome or its cognate ubiquitinating machinery as possible 
therapeutic targets. It is thus clear that a strong relationship between the UPS and prion-
mediated toxicity exists although the specific mechanisms underlying pathology remain 
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unknown. Whether prions themselves are a direct cause of UPS impairment or a 
secondary effect of deteriorating function is yet to be determined. 
 
1.3.4 Autophagy mediated clearance in prion pathology 
 
Autophagy is another major intracellular quality control pathway that functions in parallel 
to the UPS as a bulk degradative mechanism to which components bound for destruction 
may be targeted183, 198. Homeostasis is achieved through this highly conserved system via 
degradation of cytosolic proteins, organelles and pathogens by lysosomal digestion183, 198. 
While basal autophagy occurs to target dysfunctional cellular components for degradation 
in the absence of stimuli, the process can be selective by induction through a number of 
conditions such as starvation, oxidative stress or toxic insult198. Autophagy can be defined 
by the mechanism through which targeted cargo is digested by lysozymes, described as 
macroautophagy, microautophagy and chaperone-mediate autophagy198. 
Macroautophagy is the most common form and is otherwise referred to as autophagy. 
Unwanted cargo is sequestered within a double membraned vesicle, termed an 
autophagosome or autophagic vacuole that undergoes maturation by recruitment of 
specific proteins prior to fusing with endosomes to form amphisomes. The 
autophagosomes are then transported to fuse with lysosomes for hydrolase-mediated 
degradation198. Microautophagy, involves the internalisation of cytosolic material directly 
into the lysosome via invagination of its membrane198. Chaperone mediated autophagy 
facilitates the targeting of cytosolic proteins bearing the KFERQ motif to the lysosome 
by Hsc70198. Although these defined mechanisms of autophagy are important in the 
regulation of degradation, protein synthesis and recycling of resources, macroautophagy 
has been the most intensively studied owing to its link to neurodegeneration and some 
forms of cancer198, 199. 
Autophagy was first implicated in prion disease following the observation of 
autophagosomes in the neurons of scrapie infected mice200. Increased presence of these 
autophagosomes is indicative of defective autophagy200. Furthermore, the accumulation 
of autophagosomes was also described in scrapie-infected hamster brains, which 
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correlated with incubation time, suggestive of defective autophagic mechanisms in prion 
disease201. These autophagic vacuoles were localised in neuronal perikarya and processes, 
gradually accumulating across entire neurites201. Autophagy has been linked to neuritic 
dystrophy and this may be extended to the neurite pathology observed in prion diseases, 
which may subsequently affect neuronal function202-204.  
A protective effect of autophagy in PrP clearance has been substantiated by studies in 
which the induction of autophagy using small molecules enhanced the degradation of 
PrPSc in chronically infected neuronal cells205-209. Inhibition of autophagy counteracted 
PrPSc clearance indicative of an autophagy-mediated mechanism of degradation205, 209. 
Furthermore, prion-infected mice treated with an inducer of autophagy, rapamycin, 
showed longer incubation times relative to mock-treated control mice, suggesting 
autophagic mechanisms can prolong lifespan208, 209. It has been reported that mice lacking 
genes essential for autophagy develop neuronal ubiquitin aggregates and selective 
degeneration of cerebral and cerebellar cortical neurons, in turn leading to 
neurodegeneration210, 211. This is lent support by studies in which induction of autophagy 
has been reported to ameliorate protein aggregation that may lead to disease 
progression206, 212-214.  
Autophagy has also been implicated in mitochondrial homeostasis as demonstrated by a 
neuronal cell model in which Sirt1 activates autophagy to protect against PrP-induced 
mitochondrial dysfunction206, 215. The authors found that the PrP106-126 peptide causes a 
decrease in the mitochondrial membrane potential and that Sirt1 overexpression can 
attenuate Bax translocation to mitochondria and cytochrome c release into the cytosol, 
signals that initiate apoptosis206, 215.  
A key feature identified by many proteasomal inhibition studies is the formation of 
aggresomes - cytosolic structures that accumulate PrPSc species and proteasomal 
components216. It is thought that formation of aggresomes reflects a cytoprotective 
response to misfolded and aggregated protein201, 217, 218. Aggresomes have thus been 
proposed as a cellular response to misfolded proteins that are then targeted to the 
autophagic-lysosomal pathway for degradation218. These findings have been corroborated 
by studies in neuroblastoma cells, where prion protein mutants linked to familial forms of 
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the disease were found to convert into a PrPSc-like form and accumulated in aggresomes 
following impairment of the UPS219. In addition prion-infected neuronal CAD cells show 
aggresomal sequestration of PrPSc following proteasome inhibition220. Substrates may be 
targeted to aggresomes by ubiquitination, linking the UPS machinery to autophagic 
mechanisms, however evidence also suggests misfolded proteins may be sequestered by 
ubiquitin-independent signalling221, 222. This accumulation in aggresomes may serve as a 
cytoprotective role in response to toxic insult that cannot be degraded by the proteasome 
perhaps due to prion infection or age related decline216. Convergence with the autophagic-
lysosomal pathway thus may ameliorate or may mediate neurotoxicity, as this is yet to be 
determined223. 
It is yet unclear as to how UPS and autophagy are orchestrated in the cell for specific 
degradation of aberrant or unwanted material but substrates that are aggregated and thus 
exceed the capacity of the proteasome may necessitate activation of the autophagic 
pathway to facilitate clearance182, 223. However, the evidence points towards a 
neuroprotective role for both of these systems although the interplay between the two in 
disease conditions may underlie the neuropathology observed in neurodegeneration and 
thus the molecular players involved are key to defining the precise mechanism. 
 
1.3.5 E3 ubiquitin ligases in neurodegenerative diseases 
 
The only E3 ligase that has been functionally associated with pathology reminiscent of 
prion disease is the RING E3 Mahogunin, Mgrn, albeit with conflicting results. 
Chakrabarti et al., found that Ctm-PrP or cytosolic PrP interacts with Mgrn, resulting in 
its sequestration and thus functional depletion224. Loss of this ubiquitin ligase results in 
spongiform neurodegeneration and a mahoganoid coat colour phenotype in mice 
suggesting that disruption of Mgrn may contribute to spongiform pathology225. This 
interaction between cytosolically exposed prion proteins and Mgrn, lead to sequestration 
of the ligase, thus depletion of functional Mgrn and aberrant endo-lysosomal trafficking 
that was rescued by its overexpression224-226.  However, recent work has found that loss 
of Mgrn, or its overexpression in mice challenged with RML prions does not influence 
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the onset or pathology of disease226. The experiments performed by Chakrabarti et al., 
used transgenic mice and cultured cells expressing cytosolically exposed PrP,  and as PrP 
is not normally cytosolic, this might provide an explanation as to why Mgrn-deficient or 
overexpressing mice challenged with RML show no observable effects. 
Miyazaki et al., identified a HECT E3 ligase, NEDL1, that selectively targeted mutant 
SOD1 but not wild type, for ubiquitination to signal proteasomal–mediated 
degradation227. Mutant SOD1 being its substrate implicates this E3 ligase in the 
pathogenesis of ALS as mutations within SOD1 are reported to account for 20% of 
familial ALS cases128, 228. This progressive paralytic disease is characterised by 
degeneration of motor neurons in the brain stem, cerebral cortex and spinal cord although 
the mechanism by which this selective neuronal death occurs is yet to be elucidated. 
NEDL1 is neuronally expressed and has been detected in the Lewy-body like hyaline 
inclusions that are apparent in the remaining motor neurons of familial ALS patients and 
transgenic mice expressing mutant SOD1227. Furthermore, transgenic mice 
overexpressing human NEDL1 were found to be associated with muscle atrophy and 
motor neuron degeneration and microglial activation229. NEDL1 has been shown to 
ubiquitinate DVL1, which also interacts with mutant SOD1, suggesting an interplay 
between these proteins that may underlie the selective neuronal degeneration227. The 
ability of NEDL1 to distinguish between mutant and wild type forms of SOD1 thus 
substantiates its position as a quality control E3 ligase, suggestive of a role in 
neuroprotection. 
The RING-finger type E3, Dorfin, has also been identified in Lewy-body like hyaline 
inclusions in the spinal cord of ALS patients and in mice transgenic for mutant SOD1230, 
231. Dorfin ubiquitinates mutant SOD1 associated with familial ALS and enhances its 
proteasomal degradation and reduces mutant SOD1 inclusions, in turn protecting neural 
cells from mutant-SOD1 mediated neurotoxicity231. These data were lent support by a 
mutant SOD1 transgenic mouse model of familial ALS in which overexpression of Dorfin 
ameliorated motor neuron degeneration and the disease phenotype whilst increasing the 
clearance of mutant SOD1 in the spinal cord232, lending E3s as a possible mechanism 
through which pathogenesis may be mediated. Interestingly, Dorfin is also localised in 
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the Lewy body neuronal inclusions that characterise patients of Parkinson’s disease232, 233. 
This movement disorder is characterised by selective degeneration of dopaminergic 
neurons of the substantia nigra accompanied by Lewy bodies or Lewy neurites that are 
composed of aggregated proteins234. Parkinson’s disease and ALS thus may share a 
common biochemical pathway via Dorfin that generates the ubiquitinated inclusions and 
whether this ligase is involved in the degeneration of the specific populations of neurons 
observed in these diseases is yet to be determined. 
Another substrate of Dorfin is Synphilin-1, which forms a major component of Lewy 
Bodies and has been shown to interact with alpha-synuclein, a protein in which mutations 
cause autosomal dominant form of PD that also aggregates in these inclusions233, 235. This 
demonstrates that the interactome of a given ligase may have profound effects regardless 
of whether that particular ligase itself is directly causative in pathogenesis. The ring 
finger, cytosolic E3 ligase, Parkin is an example of a ligase that is directly linked to disease 
as mutations within the gene cause autosomal recessive Parkinson’s Disease236. 
Physiologically, Parkin has been attributed a role in mitochondrial homeostasis in concert 
with PINK1, a kinase that recruits Parkin to dysfunctional or depolarised mitochondria to 
mediate their selective degradation by autophagy237. Impairment of this process, 
otherwise known as mitophagy, has been reported to recapitulate a number of hallmark 
traits such as the neuronal accumulation of proteinaceous aggregates and defective motor 
coordination and tremor210, 237. Parkin ubiquitinates FAF1 directly and the relevance of 
this effector protein was investigated using a mouse model in which FAF1 levels were 
diminished238. These mutant mice were treated with MPTP, which recapitulates the 
dopaminergic neuronal loss observed in Parkinson’s disease. This model showed that 
MPTP-induced dopaminergic neuronal loss was attenuated relative to wild type mice and 
that deficiency of FAF1 averted Parkinson’s disease events such as ROS generation, 
caspase activation and cell death238. These data provide evidence that relates the 
importance of downstream targets of E3 ligases and the effects they may culminate in 
disease. 
Recent work has shown that Parkin also plays a role in Alzheimer’s disease, where it was 
found that it co-localises with intraneuronal amyloid-β(1-42) in the cortex and 
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hippocampus of patients with the disease239. The authors investigated the role of Parkin 
in autophagy by using transgenic mice expressing amyloid-β in the presence and absence 
of Parkin. Defective autophagy was observed by means of autophagosome accumulation 
following expression of amyloid-β that resulted in hyperphosphorylated tau. Clearance of 
amyloid-β and hyperphosphorylated tau through the lysosomal pathway was promoted by 
Parkin via autophagy-mediated degradation239.  
The F-box family of proteins form the substrate recognition component of a multisubunit 
family of E3 ligases known as the SCF (Skp1, Cullins, F-box proteins) ligases. FBXW7, 
a member of the F-box family has been implicated in Alzheimer’s disease.  FBXW7 has 
been found to interact with the protein product of Presenilin 1, a gene in which mutations 
have been associated with autosomal dominant Alzheimer’s disease240, 241. This 
interaction has been reported to facilitate ubiquitination of Presenilin 1 resulting in 
modified amyloid-beta peptide generation240. Furthermore, FBXO7, a different member 
of the F-box family has been associated with PARK15 parkinsonism242, 243. FBXO7 is 
involved in ubiquitin-dependent proteasomal degradation as well as non-proteasomal 
functions, although the molecular mechanisms by which mutations in this gene cause its 
associated parkinsonian syndrome is yet to determined243, 244. Furthermore, SKP1A, a 
component of SCF ligase complexes was found to be downregulated in the substantia 
nigra of sporadic parkinsonian patients245, 246. The authors suggest that this could stipulate 
defective or altered function in the repertoire of its substrate proteins. 
CHIP (Co-chaperone carboxyl terminus of Hsp70-interacting protein) is a bi-functional 
E3 ligase and co-chaperone that ubiquitinates a number of substrates implicated in 
neurodegenerative diseases247, 248. In Alzheimer’s disease, phosphorylated tau, a 
pathological hallmark, has been reported to be ubiquitinated by CHIP for targeted 
degradation249. Furthermore CHIP also ubiquitinates misfolded proteins in Huntington’s 
and hereditary ataxias working in concert with molecular chaperones, thus promoting cell 
survival248, 250, 251. Although these examples provide evidence of directly selective 
degradation by ubiquitination of misfolded proteins, CHIP has also been reported to 
enhance proteasome-mediated degradation of mutant SOD1 via ubiquitination of the 
chaperone Hsp70247. Interestingly, CHIP has been implicated in Parkinson’s disease 
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where it orchestrates α-synuclein degradation through either proteasomal or autophagy-
lysosomal mediated targeting. The authors found that overexpression of this ligase 
promotes degradation of α-synuclein and alleviates aggregation252, further substantiating 
a positive regulatory role for E3 ligases. 
 
Together these data provide evidence that E3 ligases serve to orchestrate proper cellular 
function by calling the fate of their substrates and may thus be viewed as neuroprotective 
components in the pathogenesis of disease. However, it is feasible that in disease 
conditions altered cellular metabolism of its substrates or the ligase itself, modifies the 
cellular response to toxic insult, mediating neurotoxicity. The interactome of a given E3 
ligase may be involved in the activation of pathways that may underlie pathogenesis. The 
connection between neurodegenerative diseases and E3 ligases is thus apparent, although 
the mechanisms by which neurodegenerative processes transpire are enigmatic. The 
discovery that Hectd2 is linked to prion disease incubation time corroborates the emerging 
importance of E3 ligases in the nervous system and calls for further investigation into its 
functional activity in order to elucidate the downstream processes that it governs.  
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1.4 Project Outline 
The discovery of Hectd2 as a potential modifier of prion disease incubation time and its 
association with the human prion diseases, vCJD and kuru shows its promise as an 
excellent candidate gene for modulating prion susceptibility. The aims of this project were 
to characterise Hectd2 in order to elucidate its functional role in pathogenesis. The 
objective was to identify proteins that interact with Hectd2 so that its functional 
pathway(s) could be determined. The downstream effectors of these pathways are 
anticipated to underlie the mechanisms by which incubation time and disease 
susceptibility may be modulated. To address this, yeast two-hybrid screening was used to 
map the interactome of Hectd2 from a library of universal mouse proteins covering mouse 
genes that are expressed in all tissues. Interactions identified from the screen were verified 
independently in yeast and subsequently by co-immunoprecipitation in mammalian cells. 
Hectd2 and each of the candidate interactors were tested for a modulatory role in the 
susceptibility of cells to prion propagation and clearance of prions by using a cell-based 
model of prion disease. This model, the Scrapie Cell Assay (SCA)253, allows one to 
measure the number of cells infected with PrPSc over time where candidate gene 
expression is manipulated. Modifications stipulated by a candidate gene in the SCA can 
allow us to delineate the pathways that are implicated in prion pathology by virtue of the 
molecular networks that they are placed in. 
Genes and pathways identified in mice are anticipated to serve a similar role in human 
prion diseases. To test the effect of Hectd2 on incubation time, Hectd2 knockout and 
overexpressing transgenic mouse models were generated. These models were challenged 
with three strains of mouse adapted prions to search for an association with incubation 
time. Together, it is hoped that this functional characterisation of Hectd2 will shed light 
on the molecular basis of incubation time and the mechanisms by which disease 
susceptibility may be modified. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and reagents 
Ethanol (Absolute)  Fisher Scientific 
Ampicillin Sigma Aldrich 
Aureobasidin A Clontech Takara Bio Europe 
BglII NEB 
Better Buffer Microzone 
β – glycerophosphate Sigma Aldrich 
BglII NEB 
Big Dye Applied Biosystems 
Bromophenol blue Sigma 
dNTPs Promega 
UltraPure Agarose Life Technologies Ltd 
Ethidium Bromide Sigma Aldrich 
EGTA Sigma Aldrich 
Glass beads Sigma 
Glycerol Sigma Aldrich 
HindIII NEB 
HEPES Sigma Aldrich 
Hyperladder I Bioline 
Hyperladder IV Bioline 
Kanamycin Sigma Aldrich 
Luria Base Agar, Miller Sigma Aldrich 
Luria Broth Sigma Aldrich 
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MegaMix Blue Microzone 
MicroCLEAN Microzone 
MgCl2 Sigma Aldrich 
Oligonucleotides Sigma Aldrich/Eurofins 
Pfu Promega 
Phenylmethylsulfonide Sigma 
PstI NEB 
Puromycin Sigma 
Phosphate Buffered Saline 10X VWR 
NaCl Sigma Aldrich 
NcoI NEB 
N,N-Dimethylformamide Sigma Aldrich 
Dimethylsulfoxide Sigma Aldrich 
Phenylmathanesulfonyl Oxide Sigma Aldrich 
SalI NEB 
SeeBlue Plus II Life Technologies Ltd 
YPDA Broth and Agar Clontech Takara Bio Europe 
SD/-Trp Broth and Agar Clontech Takara Bio Europe 
SD/-Trp Broth and Agar Clontech Takara Bio Europe 
SD/-Leu Broth and Agar Clontech Takara Bio Europe 
SD/-Trp/-Leu Broth and Agar Clontech Takara Bio Europe 
SD/-Trp/-Leu/-Ade/-His Broth and Agar  Clontech Takara Bio Europe 
SfiI NEB 
Shrimp Alkaline Phosphatase Roche 
Shrimp Alkaline Phosphatase Buffer 10X  Roche 
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TaqMan® Gene Expression Assay 20X  Life Technologies Ltd 
TaqMan® Gene Expression Master mix 2X  Life Technologies Ltd 
TaqMan® Mouse GAPDH Assay 20X  Life Technologies Ltd 
T4 DNA Ligase NEB 
T4 DNA Ligase Buffer 10X NEB 
TRIS/Glycine/SDS 10X VWR 
TRIS/Glycine 10X VWR 
Triton-x 100 Sigma Aldrich 
TBE 10X VWR 
X-α-Gal Clontech Takara Bio Europe 
 
2.1.2 Commercial kits 
Matchmaker Gold Yeast-Two-Hybrid System  Clontech Takara Bio Europe 
Matchmaker Yeast Transformation System  Clontech Takara Bio Europe 
Matchmaker Insert Check PCR Mix 2  Clontech Takara Bio Europe 
Matchmaker Easy Yeast Plasmid Isolation kit  Clontech Takara Bio Europe 
MinElute Gel Extraction Kit QIAGEN 
QIAprep Spin Miniprep Kit QIAGEN 
Endotoxin Free Plasmid Maxi Kit QIAGEN 
ZeroBlunt TOPO PCR Cloning Kit Life Technologies Ltd 
Taqman® Gene Expression Cells to CT™               Life Technologies Ltd 
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2.1.3 Equipment 
BioRad Thermal Cycler PTC-225 Applied Biosystems 
LI-COR Odyssey Imaging System Biosciences  
Molecular Imager Gel Doc XR System                  BioRad  
3730XL DNA Analyzer Applied Biosystems 
ABI Prism 7700 Sequence Detection System  Applied Biosystems 
XCell SureLock® Mini-Cell system Life Technologies Ltd 
XCell SureLock® Blot Module Life Technologies Ltd 
Eppendorf Microcentrifuge 5424 R Eppendorf 
Allegra™ 25R Centrifuge Beckman Coulter 
Heracell 150i CO2 incubator (cell culture) Thermo Scientific 
Innova® 42 incubator (bacteria/yeast culture) Eppendorf 
V-639 Spectrophotometer Jasco Inc. 
Beckman Coulter Z1 Particle Counter Beckman Coulter 
Zeiss KS ELISPOT system Carl Zeiss 
 
2.1.4 Software  
SeqMan Pro version 7.2.1 DNA Star Lasergene 
Odyssey 2.1 Infrared Imaging System  LI-COR Biosciences  
Primer 3 Version 0.4.0 Rozen and Skaletsky 2000 
GraphPad Prism 6 GraphPad Software, USA 
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2.1.5 Websites 
http://www.ncbi.nlm.nih.gov/ NCBI 
http://blast.ncbi.nlm.nih.gov/Blast.cgi BLAST 
http://expasy.org/cgi-bin/dna_aa Expasy Proteomics Server 
http://frodo.wi.mit.edu/primer3/ Primer 3 
docs.appliedbiosystems.com/pebiodocs/04331468.pdf     3730XL DNA Analyser User Guide 
http://www.dharmacon.com/designcenter/                 siRNA Design Center 
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2.2 Methods 
2.2.1 Cloning 
2.2.1.1 Oligonucleotide primer design 
Primers were designed either manually for cloning specific DNA inserts (Table 2.2.1), for 
amplifying a cloned insert (Table 2.2.2) or by utilising the Primer 3 version 0.4.0 software 
for sequencing primers254. The following parameters were considered in the primer 
design: a primer length of 18-30 nucleotides to ensure specificity; a melting temperature 
in the region 55-78°C with primer pairs having a difference of less than 5°C, calculated 
using the following formula: 2[no. of A/T nucleotides] + 4[no. of G/C nucleotides]; a GC 
content of 40-60%; avoidance of primer dimers between primer pairs and avoidance of 
secondary structure within the primer for maximum availability for PCR amplification; 
avoidance of stretches of the same nucleotide to prevent mispriming. Primers for cloning 
of Hectd2/fragments and candidate genes into pGBKT7, pCMV-MYC/pCMV-HA or 
pCRII-Blunt-TOPO expression vectors are listed below (Table 2.2.1). These were sourced 
from Sigma Aldrich or Eurofins in a freeze-dried form, resuspended to a final 
concentration of 100µM in 10mM TE, pH 8.0. A working stock concentration of 10µM 
was made by diluting in 10mM TE, pH 8.0 for storage at -20°C. 
 
Table 2.2.1. Primers for cloning into pGBKT7, pCMV-MYC or pCMV-HA 
Primer Sequence Vector 
Hect414NcoI-F* 5’ ggCCATGGagatgagtgaggcggctcgggatctc 
pGBKT7 
Hect414Pst-R 3’ cgCTGCAGttaaaataacatattcatatcaggtct 
Hect330Pst-R 3’ cgCTGCAGttaagggtgaaccaaattgttggcagt 
Hect180Pst-R 3’ cgCTGCAGttagtcctcaatagtattaaatgaggc 
Hect414-F 5’ atGTCGACcatgagtgaggcggctcgggatctc 
pCMV-MYC 
Hect414-R 3’ atGTCGACttaaaataacatattcatatcaggtct 
Hectd2-F 5’ atGTCGACcatgagtgaggcggctcgggatctc 
Hectd2-R 3’ atGTCGACttattcaagtccaaaaccttctgaatt 
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tcSh3glb1-F 
tcSh3glb1-R 
Sh3glb1-F 
Sh3glb1-R 
Stmn2-F 
Stmn2-R 
tcPacsin2-F 
tcPacsin2-R 
Pacsin2-F 
Pacsin2-R 
tcStambp-F 
tcStambp-R 
Stambp-F 
Stambp-R 
tcSept7-F 
tcSept7-R 
Sept7-F 
Sept7-R 
5’atGGCCATGGAGGCCgaagaaaagcttggccaggcag 
3’atGGCCTCCATGGCCttacttgcccttttgatttcctctc 
5’atGGCCATGGAGGCCatgaacatcatggatttcaacgtga 
3’atGGCCTCCATGGCCttaattgagaagttctaagtaggtaat 
5’atGGCCATGGAGGCCatggctaaaacagcaatggccta 
3’atGGCCTCCATGGCCtcagccagacagttcaacctgc 
5’atGGCCATGGAGGCCaagaactggcagaaggaagcctt 
3’atGGCCTCCATGGCCttactcaaactgtggccagttcat 
5’atGGCCATGGAGGCCatgtctgtcacctacgatgactc 
3’atGGCCTCCATGGCCtcactggatagcctcgacatagt 
5’atGGCCATGGAGGCCtatgagcagtataaagagcgaaag 
3’atGGCCTCCATGGCCttatcgaaggtctgtgatcgtca 
5’atGGCCATGGAGGCCatgtctgaccatggggatgtga 
3’atGGCCTCCATGGCCttatcgaaggtctgtgatcgtca 
5’atGGCCATGGAGGCCaacaacaagaacaaagggcagct 
3’atGGCCTCCATGGCCttaaaagatcttgcctttcttctt 
5’atGGCCATGGAGGCCatgtcggtcagtgcgagatcc 
3’atGGCCTCCATGGCCttaaaagatcttgcctttcttctt 
pCMV-HA 
NcoI, PstI, SalI or SfiI restriction site sequence | base pair insertions to maintain frame | linker region| 
inserted stop codon. Primers were designed to clone Hectd2 sequences or candidate gene sequences into 
their appropriate vector as detailed in the table. The suffixes F and R succeeding primer names denote 
forward or reverse primers for amplification of the 5’ or 3’ ends, respectively. *Hect414NcoI-F was used 
to prime the 5’ end of Hect414, Hect330 and Hect180 sequences. 
 
2.2.1.2 PCR amplification of inserts for cloning 
PCR amplification of DNA was carried out in a 96-well PCR plate (Thermo Scientific) 
using a DNA plasmid template concentration of 20 ng in a total reaction volume of 25 µl. 
A mix of 0.5 µl of proof reading, Pfu DNA Polymerase, (3 U/µl; Promega), 2.5 µl of  Pfu 
DNA Polymerase Buffer (10X; Promega), 1 µl of 10 µM forward primer, 1 µl of 10 µM 
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reverse primer, 0.5 µl of dNTPs (200 µM; Promega) was added to the DNA and 
constituted to 25 µl with ddH2O. A non-template control reaction using H2O in place of 
DNA was carried out in parallel and the plate sealed using a Thermocycler PCR lid (ABI) 
prior to mixing of the reactions by flicking the wells. Following a pulse-spin at 4000 x g, 
the plate was transferred to the Biorad PCR ThermoCycler version PTC-225. Typically, 
the cycling conditions were as follows: 95°C, 2 minutes for initial denaturation, 95°C, 1 
minute for template denaturation, 55°C-65°C gradient cycling for 30 seconds to determine 
the optimal primer annealing temperature and 73°C, 3 minutes for extension. These steps 
were repeated for an additional 39 cycles followed by a final extension step at 73°C, 5 
minutes to conclude the PCR reaction. However extension times were determined 
empirically based on amplicon size, where 1.0 kb/per minute is extended. The PCR 
products were visualised by agarose gel electrophoresis as described in Section 2.2.4.2. 
 
2.2.1.3 Small-scale purification of plasmid DNA 
To isolate plasmids from bacterial culture the QIAGEN QIAPrep Spin Miniprep kit was 
used. Plasmid isolation was carried out according to manufacturer’s instructions. 
Plasmid DNA was extracted from yeast cells using the Clontech Easy Yeast Plasmid 
Isolation Kit. Plasmid isolation was carried out according to manufacturer’s instructions. 
 
2.2.1.4 Large-scale purification of plasmid DNA 
To prepare high quality and yield of plasmids, the Endotoxin-Free QIAGEN Plasmid 
Maxi kit was used. Plasmid isolation was carried out according to the manufacturer’s 
instructions. 
 
2.2.1.5 Vector preparation 
Vectors were linearised for cloning by digestion of 20 µg of vector DNA in a 150 µl 
volume according to Section 2.2.4.3. Digests were cleaned of buffers and enzymes by 
addition of one volume of MicroCLEAN (Microzone) to one volume of digested DNA 
58 
 
and mixed by brief vortexing. The sample was incubated for 5 minutes at room 
temperature for binding of DNA to the purifying reagent prior to a spin at 14, 000 x g for 
7 minutes. Removal of the supernatant was followed by a further spin at 14, 000 x g for 1 
minute to discard residual supernatant. This step was repeated for a final spin after which 
the cleaned DNA was resuspended in 200 µl of ddH2O. 
Phosphates were removed from the ends of 80 µl of linearised vector (approximately 1 
µg)  by addition of 10 µl of Shrimp Alkaline Phosphatase (500 U/µl; Roche) diluted in 10 
µl of Shrimp Alkaline Phosphatase Buffer (10X; Roche). The reaction was incubated for 
15 minutes at 37°C followed by 15 minutes at 65°C to inactivate the phosphatase. The 
DNA was cleaned with microCLEAN as described above and resuspended in 100 µl of 
ddH2O. 
 
2.2.1.6 Ligation 
For the blunt end ligation of PCR products into pCRII-Blunt-TOPO vector, the Zero 
Blunt® TOPO® PCR Cloning kit was used according to the manufacturer’s instructions. 4 
µl of PCR product, of an approximate concentration of 100 ng, was mixed with 1 µl of 
Salt Solution and 1 µl of pCRII-Blunt-TOPO vector. The reaction was incubated at room 
temperature for 30 minutes prior to transformation into E. coli as described in Section 
2.2.3.1. 
For ligation via overhanging ends, restriction digestion according to Section 2.2.4.3 was 
performed to generate insert and vector with the complementary overhanging ends. Inserts 
and vectors were prepared according to Sections 2.2.1.5 and 2.2.4.3. An insert:vector 
molar ratio of 6:1 was mixed with 1 µl of T4 DNA Ligase Reaction Buffer (10X; NEB) 
and 1 µl of T4 DNA Ligase (400,000 cohesive end units/ml; NEB). The ligation was 
incubated at 16°C for 24 hours prior to transformation into E. coli as described in Section 
2.2.3.1. 
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2.2.1.7 shRNA design and construct generation 
shRNAs were designed using the siDesign Center algorithm on Dharmacon RNAi 
Technologies, (http://www.dharmacon.com/designcenter/designcenterpage.aspx), which 
employs an algorithm to identify functional siRNAs255. Four 19-mer shRNAs generated 
by the algorithm were selected based on the following parameters; A/U at position 1, no 
more than  2 T bases at the 3’ end, avoiding stretches of 3 A/U and runs of 4 of any base 
and at least one shRNA in the untranslated region, all with a GC content ranging from 30-
64%.  5’ BglII/3’HindIII restriction sites were incorporated onto the shRNA oligo 
preceding the N-19 sequence in the sense and antisense orientation, separated by a 9 
nucleotide spacer sequence. The 3’ end of this forward oligonucleotide includes a run of 
5 thymidines that denotes the termination signal. shRNAs and their duplex sequences 
were reconstituted to a concentration of 100 pM in 10mM TE, pH 8.0, of which 1 µl of 
each shRNA and its complementary oligonucleotide were mixed with 43 µl of annealing 
buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 50 mM NaCl; 10X) in a PCR reaction 
tube (ABI) containing 5 µl of ddH2O. Denaturation at 95°C on a heat block was followed 
by transfer of the heat block rack onto a room-temperature worktop for cooling. Forward 
and reverse oligonucleotides are listed in Table 2.2.2. Once at room temperature the 
annealed oligonucleotides were ligated to linearised pSUPER.retro.puro expression 
vector in an equimolar ratio and ligated according to Section 2.2.1.6.  
Table 2.2.2 shRNA oligonucleotides for cloning into pSUPER.retro.puro 
shRNA Sequence 
Sh3glb1-1F 5’GATCCCCACACATGGGCAGTGAGGAATTCAAGAGATTCCTCACTGCCCATGTGTTTTTTA 
Sh3glb1-1R 5’AGCTTAAAAAACACATGGGCAGTGAGGAATCTCTTGAATTCCTCACTGCCCATGTGTGGG 
Sh3glb1-2F 5’GATCCCCACGTAAAGGCCCAAGGAAATTCAAGAGATTTCCTTGGGCCTTTACGTTTTTTA 
Sh3glb1-2R 5’AGCTTAAAAAACGTAAAGGCCCAAGGAAATCTCTTGAATTTCCTTGGGCCTTTACGTGGG 
Sh3glb1-3F 5’GATCCCCATTAATGAGTGGAGGGTACTTCAAGAGAGTACCCTCCACTCATTAATTTTTTA 
Sh3glb1-3R 5’AGCTTAAAAAATTAATGAGTGGAGGGTACTCTCTTGAAGTACCCTCCACTCATTAATGGG 
Sh3glb1-4F 5’GATCCCCAGACAGAACTGGACGCTCATTCAAGAGATGAGCGTCCAGTTCTGTCTTTTTTA 
Sh3glb1-4R 5’AGCTTAAAAAAGACAGAACTGGACGCTCATCTCTTGAATGAGCGTCCAGTTCTGTCTGGG 
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Stambp-1F 5’GATCCCCAGACAGAGCTCTTGAGAAGTTCAAGAGACTTCTCAAGAGCTCTGTCTTTTTTA 
Stambp-1R 5’AGCTTAAAAAAGACAGAGCTCTTGAGAAGTCTCTTGAACTTCTCAAGAGCTCTGTCTGGG 
Stambp4A 5’GATCCCCGAGATGGATCACTGGGTAATTCAAGAGATTACCCAGTGATCCATCTCTTTTTA 
Stambp4B 5’AGCTTAAAAAGAGATGGATCACTGGGTAATCTCTTGAATTACCCAGTGATCCATCTCGGG 
Pacsin2-1F 5’GATCCCCTGACCAAGATAGAGGATGATTCAAGAGATCATCCTCTATCTTGGTCATTTTTA 
Pacsin2-1R 5’AGCTTAAAAATGACCAAGATAGAGGATGATCTCTTGAATCATCCTCTATCTTGGTCAGGG 
Pacsin2-2F 5’GATCCCCAGATATAGACACAGGAAGATTCAAGAGATCTTCCTGTGTCTATATCTTTTTTA 
Pacsin2-2R 5’AGCTTAAAAAAGATATAGACACAGGAAGATCTCTTGAATCTTCCTGTGTCTATATCTGGG 
Pacsin2-3F 5’GATCCCCAGATAGAGGATGAAGATGATTCAAGAGATCATCTTCATCCTCTATCTTTTTTA 
Pacsin2-3R 5’AGCTTAAAAAAGATAGAGGATGAAGATGATCTCTTGAATCATCTTCATCCTCTATCTGGG 
Pacsin2-4F 5’GATCCCCAGGTCAATGAGCAGACTTATTCAAGAGATAAGTCTGCTCATTGACCTTTTTTA 
Pacsin2-4R 5’AGCTTAAAAAAGGTCAATGAGCAGACTTATCTCTTGAATAAGTCTGCTCATTGACCTGGG 
Sept7-1F 5’GATCCCCTGAAGAAGATGGAGATGGATTCAAGAGATCCATCTCCATCTTCTTCATTTTTA 
Sept7-1R 5’AGCTTAAAAATGAAGAAGATGGAGATGGATCTCTTGAATCCATCTCCATCTTCTTCAGGG 
Sept7-2F 5’GATCCCCACAATGGAGTGGATAACAATTCAAGAGATTGTTATCCACTCCATTGTTTTTTA 
Sept7-2R 5’AGCTTAAAAAACAATGGAGTGGATAACAATCTCTTGAATTGTTATCCACTCCATTGTGGG 
Sept7-3F 5’GATCCCCTTGGAGATGCAGTGGATAATTCAAGAGATTATCCACTGCATCTCCAATTTTTA 
Sept7-3R 5’AGCTTAAAAATTGGAGATGCAGTGGATAATCTCTTGAATTATCCACTGCATCTCCAAGGG 
Sept7-4F 5’GATCCCCGATGCAGCCTATACAATAATTCAAGAGATTATTGTATAGGCTGCATCTTTTTA 
Sept7-4R 5’AGCTTAAAAAGATGCAGCCTATACAATAATCTCTTGAATTATTGTATAGGCTGCATCGGG 
BglII or HindIII restriction site sequence | spacer nucleotides | The suffixes F and R succeeding oligo 
names denote forward and  reverse shRNAs corresponding to the 5’ or 3’ ends, respectively that are 
subsequently annealed. For example, oligos Sh3glb1-1F and Sh3glb1-1R are annealed together prior to 
cloning and represent one shRNA targeting construct for Sh3gbl1. 
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2.2.2 RNA manipulation and analysis 
2.2.2.1 RNA recovery from cultured cells 
The Taqman® Gene Expression Cells to CT™ kit was used to recover RNA from cultured 
PK1/2 cells in which shRNA gene targeting was carried out. PK1/2 cell lines were seeded 
at a density of 104 cells in a 96-well tissue culture plate (Nunc), inclusive of two biological 
replicates for each knockdown line and control lines after which they were incubated for 
24 hours at 37°C/5% CO2. Cells were washed with 1X PBS (Life Technologies Ltd) to 
remove inhibiting FCS and then lysed for 5 minutes with a 50 µl solution of Cell Lysis 
Buffer (Ambion) with DNaseI at a 1:100 ratio to degrade genomic DNA.  The Cell Lysis 
Buffer contains inhibitors of endogenous RNases to preserve RNA integrity. 5 µl of Stop 
Solution was mixed with the lysates for 2 minutes to inactivate the lysis components as a 
preventative measure from potential inhibition of subsequent reverse transcription or 
qPCR reactions. RNA lysates were used immediately or stored at -70°C. 
 
2.2.2.2 Reverse transcription 
10% of the cell lysate (from Section 2.2.2.1) was used to reverse transcribe the RNA 
present in the lysates in a 96-well PCR plate (ABI). First strand cDNA was synthesized 
using a combination of 2.5 µl of 20X Reverse Transcriptase Enzyme Mix and 25 µl of 2X 
Reverse Transcriptase Buffer (Ambion), which includes a pre-mix of oligo(dT). The 
reaction was made up to 50 µl with nuclease free ddH2O, mixed gently and pulse 
centrifuged. The reaction was subjected to thermal cycling on the BioRad Thermal Cycler 
using the following parameters;  37°C for 60 minutes for reverse transcription, primed by 
oligo(dT) that hybridizes to the poly(A) tail of mRNA, 95°C for 5 minutes to inactivate 
the reverse transcription reaction, completed with a hold at 4°C to cool. Assembled 
reverse transcription reactions were stored at -20°C until ready for use. 
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2.2.2.3 Real time quantitative PCR 
Real time quantitative PCR, (qPCR), was used to detect and quantify mRNA using target 
gene-specific primers and probes by means of the 5’ nuclease activity of Taq DNA 
polymerase. Commercially available, TaqMan® Gene Expression primer and probe sets 
were purchased from Life Technologies Ltd as pre-validated assays. The target specific 
probes were fluorogenic and dual labelled with a reporter FAM™ dye and a nonfluorescent 
quencher linked to the 5’ and 3’ ends, respectively. A reaction totaling 16 µl in volume 
was comprised from 4 µl of target cDNA (Section 2.2.2.2) with 1 µl of gene-specific 20X 
TaqMan® Gene Expression Assay and 1 µl of 2X TaqMan® Gene Expression Master mix. 
This TaqMan® Gene Expression Master Mix contains a pre-mix of Taq DNA Polymerase, 
buffer and ROX™ passive reference dye for normalising fluorescence fluctuations 
independent of the PCR. Samples were duplexed with an endogenous GAPDH control 
(20X TaqMan® Mouse GAPDH Assay, Life Technologies Ltd), harbouring a VIC™ 
reporter dye. The ABI Prism 7700 Sequence Detection System was used to perform the 
following cycling parameters; 95°C for 10 minutes to activate Taq Polymerase followed 
by PCR amplification at 95°C for 15 minutes for 40 cycles and 60°C for 1 minute. 
Quantitation was determined by a comparative Ct method in which CT values represent 
the cycle number where the fluorescence signal for a given accumulated amplicon crosses 
the threshold set at the exponential phase of the amplification curve. Relative values for 
target expression, normalised to endogenous GAPDH, relative to control PK1/2 cells 
expressing non-targeting GFP-sh2 were given by 2-ΔΔCT, where ΔΔCT is defined by the 
difference in ΔCT of the sample and the reference PK1/2 cells expressing non-targeting 
GFP-sh2 (ΔΔCT  =C
T target 
– C
T reference:GFP-sh2). 
 
2.2.3 Transformation 
2.2.3.1 DH5α E.coli cells 
All procedures handling bacteria were performed using sterile aseptic techniques. 
Chemically competent bacterial cells (NEB5 DH5α or One Shot TOPO DH5α; NEB; Life 
Technologies Ltd) were thawed on ice for 10 minutes prior to incubation with 10ng of 
63 
 
plasmid DNA or ligation mix for 30 minutes. The cells were heat shocked at 42°C for 30 
seconds followed by a 5 minute recovery period on ice. 950 µl or 250 µl of SOC (Sigma), 
prewarmed to 37°C, was added to NEB5 or One Shot TOPO cells and incubated at 
37°C/225 rpm for 1 hour. One Shot TOPO cells required a lower volume of SOC 
according to the volume of cells. Transformants were concentrated by a 30 second spin at 
14, 000 x g and resuspended in 100 µl of SOC prior to plating out on appropriate selective 
LB agar plates supplemented with 100µg/ ml ampicillin or 50µg/ ml kanamycin 
(Appendix I). Plates were incubated at 37°C for 16-20 hours, faced upside down to 
prevent condensation that builds up on the inside of the plate lids from contaminating any 
colonies. 
 
2.2.3.2 Y2HGold yeast cells 
All procedures handling yeast were performed using sterile aseptic techniques. Competent 
Y2HGold cells were prepared and transformed using the Clontech Matchmaker 
Transformation System 2 kit following the manufacturer’s instructions. A 2mm Y2HGold 
colony was inoculated into 3 ml of YPDA broth in a 15 ml culture tube, (Falcon), and 
incubated at 30°C/250 rpm for 9 hours. 5 µl of the culture was transferred into 50 ml of 
YPDA broth in a 250 ml flask.  This was shaken at 30°C/250 rpm for 16 hours until cells 
had reached the phase of accelerating growth at an OD600 of 0.15 – 0.3, measured using 
the Jasco V-639 Spectrophotometer. The culture was pelleted at 700 x g for 5 minutes at 
room temperature and the cell pellet resuspended in 100 ml of fresh YPDA broth and the 
culture incubated 30°C/250 rpm for 2-5 hours. The OD600 was measured hourly until the 
phase of exponential growth had been reached at 0.4 - 0.5 in order that the greatest number 
of cells were made competent. The culture was then divided between two 50 ml tubes, 
(Falcon), and spun at 700 x g for 5 minutes at room temperature prior to resuspension in 
30 ml sterile dddH2O. The cells were spun at 700 x g for 5 minutes and each pellet 
resuspended in 1.5 ml of 1.1X TE/Lithium Acetate solution (detailed in Appendix 1) in 
separate microfuge tubes. The cell suspensions were spun for 15 seconds at 14, 000 x g, 
with the supernatant discarded and resuspension of the pellet in 600 µl of 1.1X 
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TE/Lithium Acetate solution. The competent cells were placed on ice and transformed 
immediately to avoid loss in efficiency. 
In a pre-chilled microfuge tube, 100 ng of high quality DNA was added to 5 µl of 
Yeastmaker Carrier DNA (10µg/ µl; Clontech Takara Bio Europe) that was cooled on ice 
following pre-denaturation at 95°C. 50 µl of competent Y2HGold cells were combined 
with the DNA and gently mixed. 500 µl of PEG/LiAc was added to the cell/DNA 
suspension, gently mixed and incubated at 30°C for 30 minutes during which the cells 
were tapped to mix in 10 minute intervals. Cell walls were made permeable by addition 
of 20 µl of DMSO (Sigma) prior to a 15 minute heat shock at 42°C, during which the tube 
was tapped at 5 minute intervals. The cells were spun at 14, 000 x g for 15 seconds and 
the supernatant discarded and the pellets resuspended in 1 ml of YPD Plus Medium. 
Transformants were incubated at 30°C/250 rpm for 90 minutes after which they were spun 
at 14, 000 x g for 15 seconds for a final resuspension in 0.9% (w/v) NaCl solution (Sigma). 
100 µl of 1:10 and 1:100 dilutions in YPDA broth were spread onto the appropriate 
selective media plates and incubated at 30°C for 5 days.  
For co-transformation into Y2HGold, Section 2.2.3.2 was followed, differing only in that 
500ng/ µl of each plasmid was combined with the 50 µl aliquot of cells and a 1:2 dilution 
was spread onto the appropriate selective plates (Appendix 1). 
 
2.2.4 Screening of clones 
2.2.4.1 Bacterial/yeast colony PCR 
To screen DNA constructs, bacterial or yeast colonies were touched lightly with a pipette 
tip and dispersed in 100 µl or 12.5 µl of ddH2O, respectively, in a 96 well PCR plate 
(ABI). 1 µl of bacterial suspension was transferred to 0.5 µl each of 10 µM forward and 
10 µM reverse primers (Table 2.2.3), (Sigma; Eurofins) and 8 µl of MegaMix Blue 
(Microzone), which contains a pre-mix of DNA polymerase, buffer and dNTPs. For yeast 
colonies, 12.5 µl of 2X Matchmaker™ Insert Check PCR Mix 2, a pre-mix of primers 
(Table 2.2.3), DNA polymerase, dNTPs and buffer, was transferred to 12.5 µl of the yeast 
suspension. The plates were sealed with a thermocycler PCR lid (ABI) and the reactions 
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mixed by flicking the wells prior to a spin at 4000 x g for 1 minute. Thermal cycling 
parameters were applied; for bacterial reactions: 94°C, 10 minutes for 1 cycle, 94°C, 30 
seconds, 55°C, 30 seconds, 72°C for a variable time length, where 1 minute extends 1 kb, 
for 39 cycles followed by a final extension step at 73°C for 5 minutes, unless otherwise 
stated; for yeast reactions: 94°C, 1 minute for 1 cycle, 98°C, 10 minutes, 68°C, 3 minutes 
for 30 cycles. The PCR products were analysed according to Section 2.2.4.2. 
Table 2.2.3 PCR screening primers  
Primer Sequence Vector 
M13 Uni (-20) 5’ TGTAAAACGACGGCCAGT pCRII-Blunt-TOPO 
M13 Reverse 5’ CAGGAAACAGCTATGACC pCRII-Blunt-TOPO 
HA Forward 5’ ATGTACCCATACGATGTTCCAGA pCMV-HA 
MYC Forward 5’ ATGGCATCAATGCAGAAGCTGAT  pCMV-MYC 
CMV Reverse 5’ GCGGCCGCGGTACCTCGA pCMV-HA/pCMV-MYC 
ADLD Forward 5’ CTATTCGATGATGAAGATACCCCA  pGADT7-recAB 
ADLD Reverse 5’ AGTGAACTTGCGGGGTTTTTCAGT pGADT7-recAB 
 
2.2.4.2 Agarose gel electrophoresis 
Analytical size separation of DNA fragments was carried out on a 1% or 2% (w/v) agarose 
gel, where the former was used for resolving products  >1.0 kb and the latter <1.0kb. Gels 
were made by constituting UltraPure™ agarose in 1X TBE and melting at ≥90°C for 2 
minutes. The agarose solution was cooled to hand temperature prior to addition of 0. 2 
µg/ml ethidium bromide solution (Sigma) and poured into a casting tray. Once set, the gel 
was transferred to an electrophoresis tank and 10 µl of DNA/1X gel loading dye (0.25% 
Orange G, 18% glycerol in 10mM TE, pH 8.0; 6X) were loaded alongside 5 µl of 
Hyperladder I or IV (Promega) to resolve products >1.0 kb or <1.0 kb, respectively. 
Electrophoresis in 1X TBE was carried out at 100V for 30 minutes - 1 ½ hours, depending 
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on the resolution required. Ethidium bromide-stained DNA was visualised on a UV Trans-
Illuminator Gel Doc imaging system (Biorad). 
 
2.2.4.3 Restriction digestion 
DNA inserts were verified by digesting 800 ng of plasmid DNA with 3 µl of 10X buffer 
of the appropriate enzyme and 1 µl of restriction endonuclease (40 U/µl). ddH2O was 
added to a final volume of 30 µl after which the reaction was mixed by flicking and pulse-
spun prior to incubation for 1 hour at 50°C for SfiI and at 37°C for all other restriction 
endonucleases used. For direct cloning of insert, the reaction volume was scaled up to 150 
µl with the reagents appropriately scaled up. The digests were screened according to 
Section 2.2.4.2. 
 
2.2.4.4 Gel excision and purification 
For subcloning purified inserts/vectors, the QIAGEN MinElute Gel extraction kit was 
used to purify gel excised fragments according to the manufacturer’s instructions.   
 
2.2.5 Bacterial/yeast culture 
2.2.5.1 Bacterial growth 
DH5α E.coli cells were cultured at 37˚C in LB broth (25g/L; Sigma) or LB agar base 
(30g/L; Sigma) with the appropriate selective antibiotics, 100µg/ml ampicillin or 50µg/ml 
kanamycin, for 16-20 hours and at 225 rpm for broth. Solution formulations for these are 
detailed in Appendix 1. Glycerol stocks were made with 1 ml of bacterial culture/200 µl 
of glycerol (99.9%; Sigma) and frozen at -70˚C. Stocks were recovered by streaking onto 
the appropriate selective LB agar plates and incubated at 37˚C for 16-20 hours. 
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2.2.5.2 Yeast growth 
Yeast strains were cultured at 30˚C in YPDA or the appropriate selective broth or agar 
medium as described in Appendix 1 and grown for 5 days on agar or 16-20 hours/250 rpm 
in broth unless otherwise stated. Glycerol stocks were made with a single colony 
resuspended into 500 µl of YPDA/25% (v/v) glycerol and frozen at -70˚C. Stocks were 
recovered by streaking onto YPDA or appropriate selective media plates and incubated 
for 5 days. 
 
2.2.6 Sequencing 
300ng of plasmid DNA or PCR product that was cleaned using the microCLEAN method 
in Section 2.2.1.5, was diluted in ddH2O to a final volume of 8.5 µl in a 96-well, non-
skirted, sequencing plate, (ABI). These were sequenced using the BigDye® Terminator 
v1.1 Cycle Sequencing Kit (Applied Biosystems). 0.5 µl of the appropriate primer (10 
µM; Sigma/Eurofins) and 5 µl of Better Buffer (Applied Biosystems) were transferred to 
the DNA dilution prior to addition of 1 µl of Big Dye Terminator v1.1. The reaction was 
mixed by flicking of the well and the plate sealed with a Thermocycler PCR lid (ABI). 
The plate was transferred to the Biorad PCR ThermoCycler, (Applied Biosystems) using 
the following thermal cycling parameters: 96°C for 1 minute, 96°C for 10 seconds, 50°C 
for 5 seconds, 60°C for 4 minutes with the cycling conditions repeated for an additional 
24 cycles. Post-sequencing precipitation followed by addition of 1 µl EDTA (0.125 µM; 
Sigma), 1 µl sodium acetate (0.3M, pH 5.2; Sigma) and 55 µl of absolute ethanol (Fisher). 
The solutions were mixed by vortexing and incubated at room temperature for 5 minutes 
followed by a spin at 4°C/4000 x g for 45 minutes. The plate was inverted to discard the 
supernatant and then spun inverted onto tissue paper at 4°C/100 x g for 1 minute. The 
resulting pellet was washed in 155 µl of 70% ethanol prior to a spin at 4°C/4000 x g for 
10 minutes. The ethanol was discarded by plate inversion onto tissue paper and an 
additional spin at 4°C/100 x g for 1 minute. The DNA pellet was then resuspended in 10 
µl of hi-di-formamide (Life Technologies Ltd) by vortexing. Following a spin at 4°C/4000 
x g for 1 minute, the DNA was denatured at 96°C, cooled rapidly at 4°C and loaded onto 
a 3730XL DNA Analyzer platform (Applied Biosystems). Sequencing parameters were 
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set according to those recommended in the ABI 3730XL user guide, using electrokinetic 
capillary injection times of 5, 15 and 60 seconds, (user guide referenced in Section 2.1.5). 
 
2.2.7 Yeast two-hybrid screen 
Interacting proteins of Hectd2 were identified using yeast two-hybrid screening against a 
library of unknown proteins, Mate & Plate™ Universal Normalised Mouse Library strain 
(Clontech product 630483, pre-transformed into Y187, detailed in Section 3.5). The 
Clontech Matchmaker™ Gold Yeast-Two-Hybrid User Kit and Manual was followed 
according to the manufacturer’s instructions and growth media was prepared according to 
Appendix 1. A concentrated culture of the bait strain, GAL4 DNA BD∙Hect414 was 
prepared by inoculating 3-5 colonies, ~1mm in size, into 50 ml of SD/-Trp broth. The 
culture was incubated at 30°C/270 rpm until the peak of the exponential growth phase had 
been reached at an OD600 of 0.8. The culture was spun at 1000 x g for 5 minutes prior to 
cell pellet resuspension in 4 ml of SD/-Trp broth, giving an estimated density of >1 x 108 
cells. 1 ml of Mate & Plate™ Universal Normalised Mouse Library strain was thawed 
and combined with the bait strain into 45 ml of 2X YPDA/50µg/ml of kanamycin in a 2L 
flask. Following 24 hours incubation at 30°C/45 rpm, the culture was spun at 1000 x g for 
10 minutes whilst the flask was rinsed twice with 50 ml of 0.5X YPDA broth after which 
it was used to resuspend the pelleted cells. A final spin at 1000 x g for 10 minutes was 
followed by removal of the supernatant broth and resuspension into fresh 10 ml of 0.5X 
YPDA/50µg/ ml kanamycin, giving a total volume of 11.5 ml. 100 µl of a 1:10, 1:100, 
1:1000 and 1:10000 dilutions were spread onto SD/-Trp, SD/-Leu and SD/-Trp/-Leu 
10cm agar plates. The remaining culture was spread across 50-55, SD/-Trp/-Leu, 15cm 
agar plates. The plates were incubated at 30˚C for 5 days. 
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2.2.8 Mammalian cell culture 
All tissue culture and preparation of solutions were performed in a Class II laminar flow 
hood. All materials were sterilised with 70% ethanol or bought pre-sterilised and 
media/solutions warmed to 37°C prior to use. 
 
2.2.8.1 Maintenance of COS-7, φ-NX Eco and N2aPK1/2 cells 
COS-7 cells, Phoenix Ecotropic (φ-NX Eco) cells and N2aPK1/2 cells were gifted by 
Emma Quarterman and Dr Craig Brown, MRC Prion Unit, London.  COS-7 and φ-NX 
Eco cells were maintained in Complete Dulbecco’s Modified Eagle Medium (DMEM) 
(Life Technologies Ltd) supplemented with 10% (v/v) Heat Inactivated FBS (Life 
Technologies Ltd) and 1% (v/v) PenStrep, (100U/ ml penicillin, 100ug/ ml streptomycin; 
Life Technologies Ltd). N2aPK1/2 cells were maintained in OPTIMEM supplemented 
with 10% (v/v) Heat Inactivated FBS (Life Technologies Ltd) and 1% (v/v) PenStrep, 
(100U/ ml penicillin, 100ug/ ml streptomycin; Life Technologies Ltd). All cell types were 
sub-cultured at 90% confluence and only φ-NX Eco and N2aPK1/2 cells were 
resuspended immediately into the fresh media detailed as above, respectively. COS-7 
cells are adherent cells and required to be trypsinised and so were washed with 1X PBS, 
(pH 7.0 Life Technologies Ltd) prior to incubation at 37°C with 3 mls of 0.05% trypsin-
EDTA (Life Technologies Ltd) to dislodge the cell monolayer. The trypsin was 
inactivated after 5 minutes with 10 ml of complete medium. COS-7 cells were harvested 
by spinning at 300 x g for 5 minutes, media removed and the cell pellet resuspended in 
complete medium. Cells were plated out at a sub-cultivation ratio of 1:8 and media was 
renewed 2-3 times a week or cells were counted with haemocytometer and a defined 
number of cells plated out, typically at a standard density of 1 x 106 cells in a 10 cm dish 
(Nunc). All cell types were grown in a humidified incubator at 37°C and 5% CO2 
atmosphere until confluent. 
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2.2.8.2 Cryopreservation of COS-7, φ-NX Eco and N2aPK1/2 cells 
Following trypsinisation, of COS-7 cells (Section 2.2.8.1), confluent cells from a 10 cm 
dish were spun for 125 x g for 7 minutes and resuspended in 750 µl of freezing medium 
(90% FBS and 10% v/v DMSO). This was transferred to a cryovial (Nunc) and placed in 
a Nalgene freezing container (Thermo Scientific) to achieve a -1°C/minute cooling rate 
in a -70°C freezer. 24 hours later, the cryovials were transferred to the liquid nitrogen 
vapour phase for long term storage. 
 
2.2.8.3 Recovery of COS-7, φ-NX Eco and N2aPK1/2 cells 
Frozen cryovials were thawed in a 37°C water bath for 1 minute after which the cells 
were resuspended in 10 ml of complete growth media (detailed in Section 2.2.8.1) in a 
15 ml tube (Falcon). The cells were spun at 300 x g for 5 minutes and the DMSO-
containing medium was discarded. The cell pellet was resuspended in 10 ml of complete 
growth media and transferred to a 10 cm dish (Nunc) and subcultured as in Section 
2.2.8.1. 
 
2.2.8.4 Transfections 
Cells were seeded at density of 1.2 x106 or 1.4 x 106 cells into 10 cm culture dishes (Nunc), 
24 hours prior to transfection. On the day of transfection, cells underwent media change 
to un-supplemented DMEM and incubated at 37°C/5% CO2 for 1 hour. To 1 ml of un-
supplemented DMEM was added 5 µg or 10 µg of plasmid DNA and mixed by vortexing. 
A ratio of 1:5 Lipofectamine 2000 Transfection Reagent (Life Technologies Ltd):DNA 
was used where the appropriate volume of lipofectamine was diluted in 500 µl of DMEM, 
pulse vortexed and incubated at room temperature for 5 minutes. The lipofectamine 
dilution was added to the DNA/DMEM mixture and left to form DNA/lipofectamine 
complexes by incubating at room temperature for 30 minutes. The complex mixture was 
added to cells drop-wise and incubated at 37°C/5% CO2 for 5 hours after which the media 
was changed to complete growth medium and cells grown for 24 or 48 hours. 
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2.2.9 Protein expression 
2.2.9.1 Preparation of yeast cell protein extract 
A 5 ml and 10 ml overnight culture in the appropriate selective media were prepared for 
extraction of total protein of transformed and untransformed yeast strains respectively. 
The cultures were pulse vortexed prior to inoculation into 50 ml of YPDA broth and 
incubated at 30°C/250 rpm for 4-8 hours until an OD600 of 0.4 - 0.6 was attained. Upon 
reaching this log phase peak, the total number of OD600 units was calculated by 
multiplying the OD600 of a 1 ml sample by the total culture volume, 55 or 60 ml. The 
cultures were transferred into a pre-chilled 175 ml centrifuge tube, (Falcon), half filled 
with ice prior to spinning at 1000 x g for 5 minutes at 4°C. The supernatant was discarded 
and the cell pellet resuspended in 50 ml of ice-cold H2O and spun at 1000 x g for 5 minutes 
at 4°C. The supernatant was discarded and the pellet snap frozen in dry ice and stored at 
-70°C until ready for extraction. 
Yeast pellets were thawed by resuspending in complete cracking buffer (detailed in 
Appendix 1) prewarmed at 60°C in a volume of 100 µl/7.5 OD600 units of cells, topping 
up with 1X PMSF at 1 µl/100 µl of cracking buffer every 7 minutes due to the degradative 
properties of PMSF. The cell/cracking buffer suspension was transferred to microfuge 
tubes filled with glass beads (425 µm in size; Sigma) at a ratio of 80 µl/7.5 OD600 units of 
cells. Samples were heated to liberate membrane associated proteins at 70°C for 10 
minutes followed by vigorous vortexing. Cell debris and any unbroken cells were pelleted 
at 14, 000 x g for 5 minutes at 4°C, the supernatant of which was transferred to a fresh 
microfuge tube and placed on ice. The pellets were boiled at 100°C for 5 minutes and 
vortexed vigorously prior to spinning at 14, 000 x g for 5 minutes at 4°C. The residual 
supernatant was transferred to the microfuge tube containing the first supernatant and run 
out using SDS PAGE (Section 2.2.9.3). 
 
2.2.9.2 Preparation of mammalian cell protein extract 
10 cm plates of cells were washed with 8 ml of 1X PBS twice following media removal. 
1 ml of cell lysis buffer (25mM HEPES, 1mM EGTA, 5% glycerol, 1mM MgCl2, 20mM 
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β-glycerophosphate, 0.5% triton x-100; pH 7.5; Sigma) with 1X Complete Protease 
Inhibitor Cocktail tablet (Roche) and 1X PhosStop Phosphatase Inhibitors (for Sh3glb1 
and Stmn2 only; Roche) were added to each cell plate and incubated at 4°C for 30 minutes. 
The lysed cells were scraped off using a 16 cm cell scraper (VWR) and transferred to a 
microfuge tube. The lysates were spun at 20, 000 x g for 20 minutes at 4°C after which 
the cell debris pellet was discarded and the lysate aliquotted as appropriate for subsequent 
testing prior to storage at -70°C. 
 
2.2.9.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) 
Novex® Tris-Glycine SDS sample buffer, (2X; Life Technologies Ltd) and β-
mercaptoethanol, (1:20; Sigma) were added to mammalian cell samples and boiled at 
100°C for 10 minutes. Samples were pulse-spun and 50 µl loaded onto a 16% or 12% 
Novex® Tris-Glycine 1.5 mm mini-gel (Life Technologies Ltd) and electrophoresed in 
the XCell SureLock® Mini-Cell system (Life Technologies Ltd) at 125V for 2 hours in 
1X Tris-Glycine buffer (Appendix I). SeeBlue® Plus2 Pre-Stained Standard was used as 
the molecular weight marker (Life Technologies Ltd). 
 
2.2.9.4 Western Blotting 
SDS PAGE separation of proteins was followed by electrophoretic transfer to a 
nitrocellulose membrane (BioTrace™; Pall Corporation) using the XCell II™ Blot 
Module (Life Technologies Ltd). The Blot Module was loaded from the anode with the 
following components that were pre-soaked in 1X Tris/Glycine/methanol electroblotting 
buffer (Fisher Scientific, detailed in Appendix I): blotting pad, filter paper, gel, 
membrane, filter paper and five blotting pads. For the transfer of two gels, the same 
arrangement follows, except that one blotting pad is placed after the last filter paper onto 
which filter paper/second gel/filter paper were transferred. The Blot Module was then 
packed to the cathode with 4 additional blotting pads. The Blot Module was inserted into 
the XCell SureLock® Mini-Cell and the proteins were transferred at 35V for 2½ hours in 
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1X Tris/Glycine/methanol electroblotting buffer (Appendix I). The transfer was kept cool 
by the loading of water surrounding the Blot Module.  
The membrane was incubated for 1 hour in 5% w/v skimmed milk powder (Marvel) 
constituted in 1X PBS + 0.0005% v/v Tween-20 (Sigma), (PBST). Following a brief rinse 
of the membrane with PBST, the membrane was incubated overnight with the appropriate 
primary antibody (Section 2.2.9.5) diluted in 1% BSA w/v constituted in PBST. The 
membrane was washed 3X for 15 minutes each with PBST.  The membrane was incubated 
in the dark with IRDye680 (red) conjugated goat anti-mouse IgG or IRDye800 CW 
(green) conjugated goat anti-rabbit IgG (LI-COR), diluted in 1% BSA in PBST for 1 hour. 
Following 3 x washes for 15 minutes each, the membrane was scanned using the LI-COR 
Odyssey infra-red imaging immunofluorescence system using the appropriate 800 nm or 
700 nm channel to detect fluorophores in the infrared region. 
 
2.2.9.5 Antibodies used 
Table 2.5 Antibodies 
Antibody Concentration Source 
Anti-c-MYC mouse monoclonal 2 µg/ml Clontech Takara BioEurope 
Anti-HA rabbit polyclonal 1 µg/ml Clontech Takara BioEurope 
IRDye680 (red) conjugated goat anti-mouse IgG 0.1 µg/ml LI-COR 
IRDye800 CW (green) conjugated goat anti-rabbit IgG  0.1 µg/ml LI-COR 
Anti-PrP monoclonal antibody, ICSM18* 0.6 µg/ml D-Gen, Ltd. 
Alkaline phosphatase-conjugated anti-mouse IgG1 0.2 µg/ml Southern Biotechnology 
Associates 
*ICSM18 used in ELISPOT for Scrapie Cell Assay. All other antibodies used for Western blots. 
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2.2.10 Co-immunoprecipitation 
Goat polyclonal anti-HA tag agarose antibody (Abcam) was washed 3 times with 1X PBS 
(Life Technologies Ltd) plus 1X Complete Protease Inhibitor Cocktail (Roche) with a 
volume equivalent to the bead slurry taken. Agarose bead-antibodies/PBS mixture was 
spun at 13,000 x g for 30 seconds between each wash and finally resuspended in a volume 
of 1X PBS equivalent to initial bead slurry. Cell lysates were thawed and transferred to 
ice. 50 µl of anti-HA tag antibody beads were added to each vial of lysate, mixed by 
inversion and placed on a roller for agitation at 4°C for 24 hours. The samples were spun 
at 1000 x g, 1 minute at 4°C, and the lysate discarded, leaving the beads undisturbed. 1 
ml of cell lysis buffer (25mM HEPES, 1mM EGTA, 5% glycerol, 1mM MgCl2, 20mM 
β-glycerophophate, 0.5% Triton x-100; Sigma; pH 7.5), was added to the beads, mixed 
by inversion and placed on a roller for agitation at 4°C for 10 minutes. The samples were 
spun as before and the lysis buffer washes repeated 8 or 9 times. The samples were given 
a final wash 1x or 2x with RIPA buffer (150mM NaCl, 10mM HEPES, pH 7.5, 1% Triton 
x-100, 0.1% SDS, 1% sodium deoxycholate; Sigma; pH7.5). The samples were spun as 
before and the remaining beads were resuspended into 50 µl of SDS sample buffer. 
Samples were boiled at 100°C for 10 minutes and analysed by SDS-PAGE and 
immunoblotted with anti-c-MYC monoclonal antibody and detected with IRDye680 (red) 
conjugated goat anti-mouse IgG secondary antibody (Sections 2.2.9.3and 2.2.9.4). 
 
2.2.11 Knockdown stable cell lines 
2.2.11.1 Virus generation 
Phoenix Ecotropic, φ-NX Eco, packaging cell line was selected to generate retroviral 
supernatant256. A transfection mix for each shRNA construct was diluted in 300 µl serum 
free OPTIMEM media using a 1 µg: 3 µl ratio of DNA to Fugene®.  Following pulse 
vortexing, 1 x 106 φ-NX Eco cells that were seeded 24 hours earlier, were transfected for 
a given shRNA construct. Media was changed 24 hours post-transfection after which the 
cells were incubated for a further 24 hours, a period of time that generates the highest 
viral titer. Transfection efficiency was visualised by GFP expression in the pRS-GFP 
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control φ-NX Eco plate, which showed ≥50 % expression of GFP. Retroviral supernatants 
were filtered to remove any cells or cell debris using a 0.45 µm filter and syringe assembly 
(Millipore) and used immediately or stored at -70°C until ready for transduction. 
2.2.11.2 Transduction 
N2aPK1/2 cells were seeded at a density of 5 x 105 into 10 cm culture dishes, (Nunc), 24 
hours prior to transduction. 5 ml of filtered retroviral supernatant was added to N2aPK1/2 
cells that were replenished with a fresh 5 ml of OPTIMEM supplemented with 10% (v/v) 
Heat Inactivated FBS (Life Technologies Ltd) and 1% (v/v) PenStrep, (100U/ ml 
penicillin, 100ug/ ml streptomycin; Life Technologies Ltd). Polybrene, (Sigma), was 
added to the cells at a concentration of 8 µg/ml, which is a cationic polymer that enhances 
retroviral adsorption to the cell surface257. After 6 hours incubation at 37°C/5% CO2 with 
retroviral supernatant, the media was changed to fresh OPTIMEM/10% FBS/1% 
PenStrep, as detailed above, and incubated again for 48 hours. Transductions were 
performed in parallel with a plate of uninfected N2aPK1/2 cells to serve as a control for 
subsequent drug selection of transduced cells. 
 
2.2.11.3 Drug selection of shRNA-expressing cells 
The pSUPER.retro.puro construct harbours a puromycin resistance cassette that was 
selected for in transduced N2aPK1/2 cells by adding 4 µg/ml puromycin (Life 
Technologies Ltd), a concentration determined by dose-response curve analysis (Dr Craig 
Brown, MRC Prion Unit). Media change with puromycin-supplemented OPTIMEM/10% 
OFCS/1% PenStrep media was carried out every 48 hours. Successfully transduced cells 
survived whilst uninfected negative control cells were dead within 3 days. Cells were 
maintained on puromycin selection for two weeks after which mRNA expression was 
measured by real time quantitative PCR (Section 2.2.2.3). 
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2.2.12 Scrapie Cell Assay 
Scrapie Cell Assays were performed by Dr Craig Brown, MRC Prion Unit, London. 
N2aPK1/2 cells were exposed to a 1 x 10-5 dilution of RML Mouse Scrapie for three days 
and propagated to confluence for three splits in order to dilute out the original RML 
Scrapie inoculum253. 25,000 cells of the RML infected lines were filtered onto the 
membranes of an ELISPOT plate in 10 replicates in parallel to two non-infected replicates 
to control for the signals recorded. These cells were subjected to lysis and subsequent 
proteinase K digestion and denaturation with guanidinium thiocyanate to eliminate PrPC, 
in order that only PrPSc particles remain. Incubation with 0.6 µg/ml monoclonal PrP 
antibody, ICSM18 was followed by alkaline phosphatase-linked anti-mouse IgG1 
antiserum detection of IgG1, thus allowing visualisation of PrPSc-positive cells upon 
reaction of the reporter alkaline phosphatase with alkaline phosphatase conjugate 
substrate (BioRad). These PrPSc positive cells were counted using the automated Zeiss KS 
ELISPOT system, which can readily resolve up to 3000 cells per well. The Scrapie Cell 
Assay was repeated three times to ensure reproducibility. 
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3 Identification of Hectd2 candidate substrates   
3.1 The Yeast-Two-Hybrid Principle 
The yeast-two-hybrid assay is a genetic technique, conceived by Fields and Song in 1989, 
to search for novel interactors to a protein of interest258. The concept was developed as an 
alternative approach to existing co-immunoprecipitation, co-fractionation and 
crosslinking methods to determine interactions but with the added advantage of 
immediate access to the cloned genes of the interacting proteins258, 259. The Clontech 
Matchmaker™ Gold Yeast Two-Hybrid version of the assay was selected for screening, 
which utilises the modular property of the yeast transcriptional activator GAL4. The 
GAL4 transcription factor is a key regulator of galactose metabolism. GAL4 is comprised 
of an N-terminal DNA binding domain (BD) that is sufficient for nuclear localisation and 
recognises a specific upstream activating DNA sequence (UAS) and a C-terminal acidic 
domain, the activation domain (AD), which activates transcription of the downstream 
reporter genes by recruitment of RNA polymerase II258, 260. The two components of this 
transcription factor are biologically functional without covalent linkage as proximity is 
sufficient to effectively activate GAL4 responsive genes258. This feature can be exploited 
to identify interactors of a known protein by expressing it in yeast as a hybrid to the GAL4 
BD, whilst the unknown proteins that it may bind to are expressed as a second hybrid to 
the GAL4 AD. When proteins of the GAL4 AD hybrid bind to the known protein, the 
GAL4 transcription factor is reconstituted by bringing the two domains into close 
proximity by virtue of the protein-protein interaction. This activates four downstream 
reporter genes regulated by the GAL4 specific UAS (Figure 3.1.1). These are a 
combination of nutritional reporters, HIS3 and ADE2, that permit growth in media 
auxotrophic for histidine and adenine, a drug reporter AUR1-C, which confers resistance 
to the toxic drug aureobasidin A and a MEL1 reporter which produces  a blue colony 
phenotype in the presence the chromogenic substrate X-α-gal. Yeast harbouring these 
interactions are identified by this blue colony phenotype, permitting their isolation and 
subsequent sequence analyses to determine the identity of the interacting prey proteins. 
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Figure 3.1.1 Principle of yeast-two-hybrid assay. A protein/domain of interest is expressed as a GAL4 
DNA BD fusion protein that is screened against a library of unknown prey proteins, expressed as GAL4 
AD fusions. When the bait protein interacts with a prey, the GAL4 BD and AD are brought into close 
proximity, sufficient for it to act as a functional transcription factor that activates the downstream reporter 
genes, indicating a two hybrid interaction. Adapted from Clontech Matchmaker Yeast-Two-Hybrid manual 
 
3.2 Selection of bait constructs 
Based on the existing knowledge of mammalian E3 ligases, the C-terminal domain bears 
the conserved HECT domain, and the N-terminal region is thought to contain the substrate 
binding domain162. This region has been identified as the primary determinant of substrate 
specificity for all known E3 ligases although other regions or specific residues of the 
protein cannot be ruled out as contact points in protein interactions162, 172. Thus to 
delineate interactors of Hectd2, using the protein in its entirety would shed light on its in 
vivo binding partners. However a caveat to this is that the HECT domain is functionally 
distinct in executing the ligase catalytic activity, hence interactions defined through this 
region are anticipated as substrate non-specific. This may lead to detection of a large 
number of interactions that would make for labour and cost intensive downstream 
analyses. Thus to filter out HECT domain binding partners, it is necessary to confine 
substrate searching to a region of Hectd2 that excludes this domain. A sequence alignment 
search of the Hectd2 protein sequence (Appendix 3) using the NCBI Basic Local 
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Alignment Tool (BLAST), (http://blast.ncbi.nlm.nih.gov/Blast.cgi), allows a comparison 
to existing biological protein sequences in the non-redundant protein sequences mouse 
database. Analysis of the protein sequence located the HECT domain at the C-terminal at 
residues 415 - 774 (Figure 3.2.1 a). The N-terminal region containing the preceding 414 
amino acids represents the region within which the putative substrate binding domain lies, 
which is referred to as Hect414 henceforth. To avert capture of proteins that bind the 
HECT domain rather than the putative substrate binding domain, the HECT domain was 
omitted from Hectd2. Thus, the Hect414 region was selected for yeast two-hybrid 
screening to ensure that only proteins that bind to the substrate specific region of Hectd2 
are drawn from the screen. 
The yeast two-hybrid system was exploited to further characterise Hectd2 in an attempt 
to map the region within the N-terminal sequence to which substrates bind. This binding 
region may span the entire length of the N-terminal domain or a section of sequence that 
is sufficient for binding. A series of C-terminal deletion mutants were selected using a 
systematic approach via BLAST search analysis to identify unique regions that showed 
no or low homology to other proteins. Such regions may be indicative of unique domain(s) 
or contact points specific to Hectd2 substrate binding. BLAST search of Hectd2 against 
the NCBI mouse protein database identified a number of matches of which a subset are 
depicted schematically in Figure 3.2.1 a. The matches were to a number of other E3 
ubiquitin ligases that also contained the HECT domain. This homology alignment 
revealed distinct regions to which there appeared to be no homologous matches (Figure 
3.2.1 a). These regions span 180 residues and 330 residues from the N-terminus (Figure 
3.2.1 a, b), and may determine the specificity of Hectd2 for its substrates. These regions 
were termed Hect180 and Hect330, respectively and were used to screen the candidate 
pool generated from library screening with Hect414. In this way it may be possible to 
determine the point at which interaction is abrogated, thus mapping the region of Hectd2 
that is important in binding its substrates.  
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Figure 3.2.1 Sequence analysis of Hectd2. a) BLAST search analysis against the NCBI non-redundant 
mouse protein database identified the C-terminal HECT domain from residue 415 to 774 and the N-terminal 
putative substrate binding domain, 414 amino acids in length. A subset of the hits to which homology was 
identified are shown. Residues 1-180 from the N-terminus were not found to have sequence homology to 
any known proteins and residues 180-330 showed some homology to known proteins. b) This suggests that 
Hect180 and Hect330 may represent regions in which there are unique domains for substrate binding. Thus 
Hect180 and Hect330 regions were selected as deletion mutants to map Hectd2 substrate binding. 
 
3.3 Designing the Hectd2 bait constructs  
The pGBKT7 vector was selected for constructing hybrid proteins as it can express the 
protein of interest as a C-terminal fusion to amino acids 1-147 of the GAL4 DNA BD. 
The cloning strategy used consisted of a series of steps, depicted in Figure 3.3.1. This was 
initiated by PCR amplification of the Hect414, Hect330 and Hect180 sequences onto 
which unique restriction sites were incorporated into the primers to facilitate cloning into 
the destination vector, pGBKT7. Choice of restriction site was made according to those 
that were available in the multiple cloning site, (MCS) of pGBKT7 (Appendix 2). 
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Absence of the restriction site from the insert sequence and vector sequences outside the 
MCS were required to avert digestion with the appropriate enzyme in subsequent steps. 
 PCR amplification of each insert sequence was performed using a pre-existing cDNA 
clone of Hectd2 as a template (Hectd2-TOPO, in the pCR®-Blunt II-TOPO vector). NcoI 
sites were engineered in at the 5’ ends of Hect414, -330 and -180 sequences using 
oligonucleotide primers that were designed to prime the insert sequence from the 5’ end 
where the primer is preceded by an NcoI site (Section 2). The 3’ ends of the insert 
sequences had PstI sites engineered in using primers that were complementary to the end 
of each sequence, succeeded by a PstI site. The 3’ primers were inclusive of a stop codon 
to mark the end of each insert sequence to ensure that only fragments of the required sizes 
are translated precisely. Base pair insertions were made where necessary to maintain the 
sequences in frame with the GAL4 BD tag and thus the translational integrity of the fusion 
protein, as depicted in Figure 3.3.2.  
These modified PCR products were cloned initially into the shuttle vector, pCR®-Blunt 
II-TOPO, in order to generate a high yield of good quality insert sequences harbouring 
the correct restriction ends. The insert sequences were then digested from the TOPO 
vectors prior to transfer to the pGBKT7 destination vector via ligation of overhanging 
ends generated by NcoI/PstI digestion. The resultant clones were screened by PCR using 
primers complementary to the 5’ and 3’ ends of the pGBKT7 backbone flanking the DNA 
insert and inclusive of a 126 and 167 bp region of the vector either side of the MCS, 
respectively (Section 2).  Size resolution of the PCR products by agarose gel 
electrophoresis identified positives for Hect414, -330, and -180, consistent with the 
appropriate size (Table 3.3.1). The corresponding clones were cultured and purified 
according to Section 2. Restriction digestion with NcoI and PstI, confirmed insert sizes 
reflecting Hect414, -330 and -180 (Figure 3.3.3). These constructs were verified by 
sequencing for accuracy and integrity of the GAL4 BD fusion junction. 
 
82 
 
 
 Figure 3.3.1 Cloning strategy for construction of bait plasmids. a) Hect414, Hect330 and Hect180 
sequences were PCR amplified using primers designed to span the required region and engineer in 
restriction sites, which were blunt cloned into the pCRII-Blunt-TOPO vector. b) The destination vector, 
pGBKT7, was linearised using the cognate restriction enzymes and dephosphorylated to prevent re-ligation. 
The DNA inserts were prepared from the TOPO plasmids for subsequent ligation into linearised pGBKT7 
(c). 
 
 
 
 
 
 
 
5’ …………AGT AAC AAA GGT CAA AGA CAG TTG ACT GTA TCG …TCC ATG GAG ATG AGT GAG… 
                                                GAL4 DNA BD tag                                              NcoI site              Hect414 
 
Figure 3.3.2 Construction of the GAL4 BD tagged fusion proteins.  The translation frame of the fusion 
construct for the cloning of Hect414, -330 or -180 into pGBKT7. Hect414, -330 or -180 insert sequences 
with their ATG site were maintained in frame with the GAL4 BD by PCR amplification using primers that 
engineer in a 2 base pair insertion indicated in red, preceded by an NcoI site, for transfer between vectors. 
 
Table 3.3.1 Molecular weight of Hectd2 fragments 
Gene Hectd2 DNA insert (bp) Hectd2/GAL4 BD fusion (kDa) 
Hect414 1232 67 
Hect330 990 57 
Hect180 540 40 
 
 
 
Start of insert ATG start of tag 
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Figure 3.3.3 Insert release from GAL4 BD fusion constructs. To verify that the bait plasmids contain 
the appropriate inserts, restriction digestion was performed with NcoI and PstI for pGBKT7∙Hect414, 
pGBKT7∙Hect330 and pGBKT7∙Hect180. The expected insert sizes of 1.2 kb, 990 bp and 540 bp were 
observed in addition to the liberated pGBKT7 at 7.3 kb. 
 
3.4 Pre-screening preparation of Hectd2 fusion constructs 
 
Expression in yeast 
 
Prior to use, it is important to ascertain that pGBKT7∙Hect414, pGBKT7∙Hect330 and 
pGBKT7∙Hect180 constructs are expressed as fusion proteins to the GAL4 BD in yeast. 
The S. cerevisiae strain, Y2HGold, was used to express each BD∙bait protein by 
transforming each clone independently in parallel to a negative control, untransformed 
Y2HGold. Protein extracts for the fusions to be tested and control were generated by yeast 
lysis methods (Section 2). Size resolution by SDS PAGE/Western blotting is shown in 
Figure 3.4.1, where bands of the expected molecular weights were observed for 
BD∙Hect414, BD∙Hect330 and BD∙Hect180. The band for BD∙Hect414 runs slightly 
lower than the 67 kDa predicted for it, which may be accounted for by the differences that 
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lie between calculated molecular weights and the actual migration profile. Furthermore, 
pre-stained molecular weight markers may migrate slightly differently to those that are 
predicted because proteins used in the marker have covalently attached dye molecules. 
Thus pre-stained standards determine the approximate molecular weight of a protein but 
are by no means an accurate prediction of the molecular weight. BD∙Hect330 and 
BD∙Hect180 show expression correlating to their expected sizes of 57 and 40 kDa. The 
untransformed Y2HGold showed no bands as anticipated, indicating that the bands 
observed for the fusion proteins reflect that of Hect414, -330 and -180. 
 
 
          
 
Figure 3.4.1 Expression of Hectd2 bait proteins. Western blot analysis of Y2HGold protein extracts of 
GAL4 BD fusions to Hect414, Hect330 and Hect180, electrophoresed on a 10% polyacrylamide gel. Fusion 
proteins were detected using anti-c-MYC mouse monoclonal antibody which binds to the MYC tag that is 
expressed in frame with the GAL BD. BD·Hect414, BD·Hect330 and BD·Hect180 expressed at their 
expected molecular weights while untransformed Y2HGold shows an absence of these bands. The asterisk 
represents the band for BD·Hect414, which shows a migration profile that is slightly lower than its predicted 
molecular weight of 67 kDa. 
 
85 
 
Toxicity testing 
It is possible that the bait fusion proteins may be toxic to the yeast cells precluding any 
downstream analyses. If expression of the fusion proteins produces toxic effects in yeast, 
then impaired growth of solid and liquid cultures may be observed by the number of 
colonies and their sizes, which would be fewer and/or appear distinctly smaller relative to 
those formed for control colonies. pGBKT7∙Hect414, pGBKT7∙Hect330 and 
pGBKT7∙Hect180 were transformed into Y2HGold cells under standard conditions in 
parallel to the transformation of pGBKT7 vector only control, (Section 2). The 
transformants were plated onto SD/-Trp media, which selects for the pGBKT7 plasmid 
by virtue of its TRP gene, permissive of growth on media auxotrophic for tryptophan. 
Following a three day growth period, 418 colonies of an average of ~2 mm in size 
emerged for the empty vector, pGBKT7, which expresses the BD only. Colonies 
expressing BD∙Hect414, BD∙Hect330 or BD∙Hect180 formed 412, 253 and 389 colonies 
respectively, grown to a size circa 2 mm (Figure 3.4.2). It is possible that the BD∙Hect330 
or BD∙Hect180 fusions may be inhibiting growth, however they appear to grow well and 
thus this does not preclude their use in downstream analyses (Figure 3.4.2).  
  
 
Figure 3.4.2 Toxicity testing of bait proteins. Hect414, Hect330 and Hect180 fusion proteins to the BD 
were expressed in Y2Hgold cells and plated onto SD/-Trp media that selects for the bait plasmids. The 
resulting colony sizes were compared to those formed from transformation of an empty bait plasmid, 
pGBKT7, which expresses the BD only. Y2HGold colonies were ~2mm in size for those expressing the BD 
only control and also for BD∙Hect414, BD∙Hect330 or BD∙Hect180. The red pigmentation of some colonies 
reflects the accumulation of a purine precursor that results from low concentrations of adenine in the 
medium. 
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Investigating the autoactivity of bait proteins 
 
In order for the yeast-two-hybrid screen to be valid, the bait fusion proteins must not 
autonomously transactivate the downstream reporter genes. Such an event would hinder 
the possibility of finding candidate interactors because the downstream reporter genes 
would always be activated in the presence of only the bait protein. The GAL4 BD∙bait 
constructs were transformed into Y2Hgold cells and plated onto SD/-Trp, SD/-Trp/X and 
SD/-Trp/X/A selection media. X and A are abbreviations for X-α-gal and aureobasidin A, 
which are selective for yeast that can activate the MEL1 and AUR1-C reporter genes, 
respectively. MEL1 encodes α-galactosidase which confers the blue colony phenotype in 
the presence of the chromogenic substrate X-α-gal. The AUR1-C gene encodes a dominant 
mutant form of inositol phosphoryl ceramide synthase that is expressed upon two-hybrid 
interaction of a bait and prey. This in turn confers resistance to media containing the toxic 
antibiotic aureobasidin A, permitting growth of yeast that harbour bait-prey interactions.  
Thus SD/-Trp selects for the bait plasmid, indicative of successful transformation, SD/-
Trp/X selects for the bait plasmid and for activation of the MEL1 reporter and SD/-
Trp/X/A selects for the bait plasmid in addition to activation of the GAL4 controlled 
reporter genes, MEL1 and AUR1-C. BD∙Hect414, BD∙Hect330 and BD∙Hect180 fusion 
proteins did not autoactivate reporter gene expression suggesting that the bait-prey hybrid 
is necessary for reporter gene activation (Figure 3.4.3).  
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Figure 3.4.3 Testing for autoactivation of Hectd2 bait proteins. Y2HGold cells were transformed with 
pGBKT7∙Hect414, pGBKT7∙Hect330 and pGBKT7∙Hect180 and plated onto SD/-Trp, SD/-Trp/X and SD/-
Trp/X/A. Y2HGold expressing each of these constructs grew on SD/-Trp and SD/-Trp/X plates, which 
select for the tryptophan biosynthesis gene carried on the bait plasmids. Colonies that grew on SD/-Trp/X 
were not blue indicating that the bait fusion proteins do not autoactivate the MEL1 gene. SD/-Trp/X/A 
selects for two-hybrid interactions, growth on which is indicative of autonomous activation of reporter 
genes. BD·Hect414, BD·Hect330 and BD·Hect180 fusion proteins do not autoactivate the downstream 
reporter genes in the absence of the GAL4 AD. 
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3.5 The library screen using the yeast two-hybrid system 
 
The library of unknown proteins 
 
In order to fish for possible prey interactors that bind to the bait, the Clontech Normalised 
Universal mouse library was used (Section 2). This is composed of pre-transformed prey 
plasmids, constructed from fragments of cDNA inserts fused to the GAL4 activation 
domain of pGADT7-recAB plasmid so that a functional fusion protein is expressed. These 
prey plasmids were pre-transformed in the haploid Y187 strain such that the prey library 
can be readily mated to the haploid Y2HGold strain in which the bait proteins are 
expressed.  
 
The library screen 
 
A concentrated culture of the bait strain, Y2HGold expressing BD·Hect414, was prepared 
in SD/-Trp broth (Figure 3.5.1, Section 2). This was grown to an OD600 of 0.8, a marker 
of concentrated growth, wherein high level expression of the bait protein is anticipated by 
virtue of the ADH1 promoter having its highest activity in the exponential phase of the 
yeast growth curve261. The bait culture was combined with the Clontech Mouse 
Normalised Universal library which was pre-transformed in the Y187 strain and allowed 
to mate. The library titre was ascertained by plating onto SD/-Leu agar, which selects for 
the pGADT7-recAB plasmids into which the library was cloned, by virtue of its LEU 
gene, permissive of growth on media auxotrophic for leucine. The titre was determined 
by calculating the number of colonies as a function of the dilution factor and the volume 
plated (Section 2). This amounted to >2 x 107 cfu/ml, where cfu represents the number of 
colony forming units, which is an estimate of the number of Y187 cells containing prey 
plasmids. The greater the number of cells there are, the greater the number of potential 
matings between bait- and prey-containing haploids, thereby increasing the possibility of 
identifying two-hybrid interactions.                                                         
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Figure 3.5.1 Library screening workflow. Following transformation of bait plasmid into Y2HGold, a 
concentrated culture of the bait strain was prepared by shaking at 30°C overnight. This is mated to the prey 
library strain, overnight by shaking at 45 rpm at 30°C. The clone pool was plated onto low stringency double 
dropout media auxotrophic for tryptophan and leucine and supplemented with X-α-gal and aureobasidin A 
(abbreviated to DDO/X/A). This allows detection of all possible interactions prior to high stringency 
confirmation on quadruple dropout media, (QDO/X/A), which is the same as DDO/X/A media except that 
it is additionally auxotrophic for histidine and adenine. This confers growth selection of two hybrid 
interactions that activate all four reporter genes, which are detected by virtue by the blue colony phenotype 
upon activation of the MEL1 reporter Adapted from Clontech Matchmaker™ Yeast-Two-Hybrid manual 
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Mating of the haploid strains of yeast results in the budding of diploid daughter cells in 
which it is expected that the bait and a prey plasmid have been propagated (Section 2). 
The resultant clone pool was plated onto the low stringency SD/-Trp/-Leu/X/A agar, 
(termed DDO/X/A, where DDO is double dropout), deficient in the essential amino acids 
tryptophan and leucine. This double dropout media was supplemented with X-α-Gal and 
aureobasidin A in order to capture as many interactions as possible. Yeast expressing both 
the bait and prey plasmids were selected for by means of their tryptophan or leucine 
biosynthesis genes harboured by the bait or prey plasmids respectively. Two-hybrid 
interactions were detected by selective activation of these genes as well as MEL1/AUR1-
C reporter expression. 
To ensure that the cells containing bait and prey proteins were growing on the media and 
for subsequent calculation of the number of colonies screened, the culture was also plated 
onto SD/-Trp, SD/-Leu and SD/-Trp/-Leu agar plates for selection of the bait or prey or 
both bait and prey plasmids, respectively. The mating efficiency was determined by 
calculating the viability of diploids as a function of the viability of the rate limiting 
partner, which was the prey library. Viabilities were measured by the number of cfu/ml 
of diploids, of the bait or the prey on the appropriate selective media, i.e. SD/-Trp, SD/-
Leu, or SD/-Trp/-Leu, respectively. This totalled to 17%, indicating that the mating 
occurred at a low frequency, thereby reducing the number of viable diploids that can be 
screened. The number of screened clones was calculated from the product of the number 
of colony forming units/ml on DDO plates and the volume that the diploids were 
suspended in, where 32 colonies grew after plating 100 µl of a 1/1000 dilution of an 11.5 
ml suspension of the mated culture. This amounted to 3.68 x 106 independent clones, thus 
surpassing the threshold for that which provides a representative pool of diploids, that are 
each likely to harbour a bait and prey plasmid i.e. 1 x 106 (Clontech Matchmaker™ Gold 
Yeast Two-Hybrid System User Manual). Of these clones, there were 36 true blue 
colonies and 94 colonies of a paler blue form that could represent potential interactions. 
All of these colonies were picked and subject to verification by further analyses.  
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High stringency confirmation of positives 
 
The positives identified from the library screen were subjected to a higher stringency 
selection screen by transferring the 130 colonies from DDO/X/A selection to a quadruple 
dropout media formulation that has additional levels of discrimination (Appendix 1, 
Figure 3.5.2). These high stringency plates (QDO/X/A) are so called as they additionally 
select for the activation of HIS3 and ADE2 reporter genes in addition to MEL1 and AUR1-
C. Each of the blue positive colonies were picked from the DDO/X/A plates and patched 
onto QDO/X/A plates for growth over three days, shown in Figure 3.5.2 for a subset of 
the library positives. This transferral to QDO/X/A sustained the 36 true blue positives but 
the 94 colonies with a pale blue phenotype were observed as white colonies, thus 
eliminating them from subsequent analyses (Figure 3.5.2).  
 
                
Figure 3.5.2 High stringency selection of library positives. The N-terminal domain of Hectd2, Hect414, 
was used to screen a Universal Mouse Normalised Library for binding proteins. 36 true blue colonies and 
94 pale blue colonies were patched onto high stringency QDO/X/A plates, shown here for a representative 
group of the library positives. QDO/X/A plates are auxotrophic for histidine, adenine, leucine and 
tryptophan, supplemented with X-α-Gal and aureobasidin A, to select for all four reporter genes. 36 
positives conferred growth on transfer to QDO/X/A, shown here for a subset, whilst the 94 pale blue 
colonies failed to sustain growth on this high stringency screen. 
Yeast have the capacity to uptake multiple plasmids, which introduces a level of 
uncertainty as to whether the blue positive colonies contain more than one prey. It is thus 
necessary to isolate each clone in order to capture the prey plasmid that is responsible for 
a given two-hybrid interaction and to separate it from any mixed colony populations. 
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Attempts to delineate each of the library positives by serial single streaking of each colony 
resulted in a mixture of blue and white colonies. This, in effect, segregated the interactors 
from the non-interacting prey proteins by means of their ability to activate the reporter 
genes on QDO/X/A media.  From these, one prey candidate was not sustained on the high 
stringency media, leaving 35 prey candidates to be carried forward. 
Positive interactions that confer growth on QDO/X/A may represent the same interactor 
although the normalisation of the library prey proteins significantly reduces this 
possibility. Putative duplicate clones were eliminated by performing a yeast colony PCR 
using the Matchmaker Insert Check PCR Mix 2, which allows the specific amplification 
of the prey insert (Section 2). PCR amplification showed that all 35 of the potential 
positives harboured cDNA inserts of varying sizes with some inserts showing PCR 
products of similar size, suggestive that 8 of the clones may be duplicates (Figure 3.5.3). 
The amplified cDNA inserts were end-sequenced from which partial sequences for each 
clone were obtained. It was apparent that there were indeed 5 duplicates; clone 12 is a 
duplicate of clone 2, clones 13 and 23 are duplicates of clone 4 and clones 24 and 29 are 
duplicates of clone 21. Such identification of multiple copies of a cDNA insert strengthens 
the likelihood that these clones are true positives. This elimination of duplicates resulted 
in 30 unique clones that were taken forward for prey plasmid isolation.  
93 
 
 
Figure 3.5.3 Prey plasmids insert screening. Inserts of pGADT7 plasmids were amplified using yeast 
colony PCR and size resolved by electrophoresis on a 1% agarose gel. All 35 positives that grew on high 
stringency QDO/X/A showed single inserts, indicating each pGADT7 contained one prey insert, although 
this does not eliminate the possibility of two prey inserts of the same size within the same cell. Similar sized 
bands may represent duplicate clones, which can be verified by sequence analyses. 
 
Thirty prey plasmids were rescued from their respective yeast colonies using the Easy 
Yeast Plasmid Isolation Kit, which generates a DNA preparation of both bait and cognate 
prey plasmids for a given clone (Section 2). To retrieve only the prey plasmid, each clone 
was transformed into E. coli and plated onto ampicillin-containing media, which 
specifically selects for transformants bearing the prey and not the bait plasmid, by virtue 
of its ampicillin resistance gene. Four of these clones were cultured and purified for each 
prey in order to establish whether the prey inserts for a given clone were the same (Section 
2). The cDNA inserts were PCR screened using primers complementary to the 5’ and 3’ 
ends of the vector backbone flanking the MCS into which the inserts were cloned (Section 
2). Size resolution of the PCR products by agarose gel electrophoresis identified that each 
set of four clones harboured an insert of equal size. This indicates the identical nature of 
each prey plasmid, suggesting that one prey plasmid per clone have been captured, in 
concurrence with the sizes identified in the initial yeast colony PCR (Figure 3.5.3).  
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3.6 Candidate interactors 
 
For each prey plasmid, one clone was selected from the set of four for sequencing. Full 
length sequence was obtained for all the prey inserts using a primer walking strategy to 
sequentially sequence the entire length of each insert (Appendix 3). The sequence 
generated was analysed at the GAL4 AD-insert junction to ensure that the prey cDNA is 
expressed in frame with the GAL4 AD tag. This confirms that activation of reporter genes 
are the result of two-hybrid interactions between a correctly expressed GAL4 AD∙prey 
fusion and BD∙bait fusion. A BLAST search was performed against the NCBI mouse 
genomic and transcript database to identify the interactors by sequence similarity (Table 
3.6.1). As the prey plasmids were generated from fragments of cDNA of a given gene, 
the proportion of the expressed full length protein is given to indicate the size of the prey 
protein expressed from the pGADT7 plasmids (Table 3.6.1). However for one candidate, 
Nt5dc3, the cDNA was a match to the 3’ UTR rather than the coding section. This 
candidate was later found to be a false positive, described in Section 3.7, thereby 
providing confidence in the screening methods applied. The cDNA sequence for one 
candidate, Nrp1, was not in frame with the GAL4 AD and thus expressing a spurious 
protein. BLAST search analysis of this spurious protein did not identify any matches to 
any known proteins in the NCBI mouse protein database. For one of the candidates, the 
prey cDNA was identified as a match to the genomic region on chromosome 15, position 
832157 – 832830 as an mRNA transcript is not available. This resulted in a total of 27 
novel candidate binding partners of Hectd2 (Table 3.6.1). 
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Table 3.6.1 Candidate genes and proportional match to full length protein 
Candidate gene by homology % of full 
length 
protein 
Reporter 
gene 
activation 
Klhdc2 (Kelch domain containing 2)  73  
Sh3glb1 (SH3-domain GRB2-like B1 (endophilin) 89  
Pbld (Phenazine biosynthesis-like protein domain containing), 80  
Cpe (Carboxypeptidase E) 61 autoactivates 
Pacsin2 (Protein kinase C and casein kinase substrate in neurons 2) 39  
Crtac1 (Cartilage acidic protein 1) 22  
Stambp (Stam binding protein) 72  
Zbed4 (Zinc finger, BED domain containing 4  16  
Pcca (Propionyl-Coenzyme A carboxylase, alpha polypeptide)  48 autoactivates 
Catsperb (Catsper channel auxiliary subunit beta) 22 autoactivates 
Vps13d (Vacuolar protein sorting 13 D) 11 autoactivates 
Cop9 (Constitutive photomorphogenic) homolog, subunit 4 100  
Pcnx14 (Pecanex-like 4) 12  
Sept7 (Septin 7) 26  
Stmn2 (Stathmin-like 2) 100  
Gvin1 (GTPase, very large interferon inducible 1)  11  
Ppp2ca (Protein phosphatase 2 catalytic subunit alpha isoform ) 62  
Stk16 (Serine/threonine kinase 16) 67  
Rbm39 (RNA binding motif protein 39) 67 autoactivates 
Sh3yl1 (Sh3 domain YSC-like 1) 67  
Mfsd6 (Major facilitator superfamily domain containing 6) 17  
Strn3 (Striatin, calmodulin binding protein 3) 31  
LOC100046859 20  
HtrA2 (Serine peptidase 2) 26 autoactivates 
Ces3 (Carboxylesterase 3) 40  
Gbl (G protein beta subunit-like) 89  
Atp6v1h (ATPase, H+ transporting, lysosomal V1 subunit H) 51 autoactivates 
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3.7 Co-transformational confirmation of interactions in yeast 
Although the incidence of false positives have been reduced by the high stringency screen, 
it remains a possibility that a prey protein may not interact with the BD∙Hect414 in a direct 
interaction assay or it might be that what appears to be an interaction may be autonomous 
activation of reporter genes by the prey. This was addressed by independently co-
transforming each prey plasmid with pGBKT7∙Hect414 or the empty vector, pGBKT7 
into competent Y2HGold cells (Section 2). The transformants were plated onto QDO/X/A 
and DDO/X agar, the former to select for two hybrid interactions and the latter to serve 
as a control for successful co-transformations. This is important to ensure that detection 
of two-hybrid interactions are not limited by the number of yeast cells expressing the bait 
and prey plasmids.   
True interactions between bait and a prey are expected to show growth on both low 
stringency selection, DDO/X, and on high stringency QDO/X/A but no growth when the 
prey/empty vector combinations are plated onto QDO/X/A. If prey/empty vector 
combinations show growth on QDO/X/A plates, this would indicate that the prey activates 
the reporter genes in the absence of the BD∙Hect414. All colonies harbouring prey/bait or 
prey/empty-vector combinations showed growth on DDO/X media, as expected, but only 
20 of the prey/bait combinations showed growth on QDO/X/A media, supported by an 
absence of growth for the equivalent prey/empty-vector combination on this higher 
stringency selection (Table 3.6.1, Figure 3.7.1). This indicates that the presence of 
BD∙Hect414 is necessary and definitive for a two-hybrid interaction, as reporter gene 
expression is abrogated in its absence. 7 of the prey proteins were identified as 
autoactivators of the downstream reporter genes as both prey/bait and prey/empty-vector 
co-transformations resulted in colony growth on QDO/X/A. The growth discrepancy 
observed between DDO/X and QDO/X/A media is expected owing to the stress imposed 
on Y2HGold by the toxicity of aureobasidin A (Clontech Matchmaker™ Gold Yeast Two-
Hybrid System User Manual). Figure 3.7.1 shows a representative set of co-
transformations, which shows that candidates Sh3glb1, Stmn2, Pacsin2, Stambp and 
Sept7 bind to Hect414. An example of an autoactivating prey is shown, where Htra2-
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expressing yeast activate reporter gene expression in the absence of BD∙Hect414 (Figure 
3.7.1). 
    
 
 
Figure 3.7.1 Representative set of Hect414/prey interactions confirmed in yeast. Positives were 
confirmed by co-transformation of the Hect414 bait and each of the 27 prey interactors in yeast 
independently. Cultures were plated out onto high stringency QDO/X/A plates, which selects for all 4 
markers representative of a two-hybrid interaction and also on DDO/X plates that select for the presence of 
both bait and prey plasmids and activation of the MEL1 reporter gene. Prey plasmids were also tested for 
autoactivity to check that downstream reporter genes were not activated in the absence of the bait. This was 
done by co-transforming each prey plasmid with the empty vector, pGBKT7. Successful interacting proteins 
included Sh3glb1, Pacsin2, Stambp, Sept7 and Stmn2, which only activate in the presence of BD∙Hect414 
and not BD on its own. In contrast, Htra2 is an autoactivator, whereby growth is seen on QDO/X/A in both 
the presence and absence of BD∙Hect414.  
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3.8 Mapping the region of Hectd2-substrate binding 
Protein interactions are mediated by points of contact with specific amino acid residues 
that form binding pockets and it is these regions that are important in understanding the 
molecular mechanism by which a given protein performs its functions. The yeast two-
hybrid system was manipulated to provide an insight into mapping the location of Hectd2 
substrate binding by using two C-terminal deletion mutants that overlap within the N 
terminal putative substrate binding region (Figure 3.2.1). Mapping of Hectd2 binding was 
investigated by testing whether the deletion mutants, Hect330 and Hect180 maintain 
interaction with the prey proteins that were identified as interactors of Hect414. If each of 
the prey proteins retained interaction with either Hect330 and/or Hect180, this would 
highlight the region of the Hectd2 sequence that is important for substrate binding (Figure 
3.2.1.).  
The Hect330 deletion mutant was co-transformed with each of the 20 positives and plated 
onto DDO/X and QDO/X/A plates. Only 4 prey clones conferred growth on the high 
stringency QDO/X/A plates, indicative of a positive interaction with Hect330. This 
suggests that Hect330 contains a component of the substrate binding domain that is 
sufficient for the binding of some substrates. (Figure 3.8.1, Figure 3.8.2, Table 3.8.1).  
These positive interactors were Sh3glb1, Zbed4, Sh3yl1 and LOC100046859. The screen 
was then repeated for the Hect180 deletion mutant for which there appeared to be no 
growth on the QDO/X/A plates with any clones (Table 3.8.1). This indicates that the 
interaction is abrogated with the Hect180 construct, suggesting that the 234 residues 
upstream of Hect180 are important for the binding of substrates (Figure 3.8.2). Taken 
together, the data suggests that residues 331-414 of Hect414/N-terminal domain are 
critical for the binding of the majority of Hectd2 substrates although this region is 
dispensable for interaction with Sh3glb1, Zbed4, Sh3yl1 and LOC100046859 (Figure 
3.8.1, Figure 3.8.2). It is postulated that residues 181-414 forms an integral component of 
the Hectd2 substrate binding domain (Figure 3.8.2). This region may comprise of multiple 
binding domains that are substrate-specific or contains key contact points that form 
binding pockets that are sufficient for protein interactions.  
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Figure 3.8.1 Locating the region of Hectd2-prey interaction. Each prey plasmid was co-transformed 
with Hect330 and Hect180 bait plasmids independently into yeast. Only four potential interactors showed 
binding to Hect330 and none showed binding to Hect180. This suggests that residues 331-414 of Hectd2 
serve an indispensable role in forming the contact points for interaction of many of the prey binding partners, 
although Hect330 is sufficient for binding Sh3glb1, Zbed4, Sh3yl1 and Loc100046859. p53 was co-
transformed with large T antigen for positive control testing which conferred the growth of blue colonies 
across DDO/X and QDO/X/A plates, indicative of successful co-transformations and appropriate activation 
of the reporter genes. 
 
Figure 3.8.2 Putative binding region. The region of Hectd2 substrate binding may be substrate specific 
and may compose of multiple domains.  a) Represents the region that binds Sh3glb1, Zbed4, Sh3yl1 and 
Loc10004685, and is thus necessary for binding some substrates but not sufficient for binding of all other 
substrates.  b) Denotes the region containing the contact points for interaction of Hectd2 with all other 
identified candidates listed in Table 3.8.1. c) The region from amino acid 181 – 414 is thus important for 
binding Hectd2 substrates and may contain multiple domains.  
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Table 3.8.1 Locating the region of binding to Hectd2 via co-transformation of bait with prey 
 Activation of reporter genes  
Candidate gene Hect330 Hect180 
Klhdc2   
Sh3glb1    
Pbld    
Pacsin2   
Crtac1    
Stambp    
Zbed4    
Cop9    
Pcnx14   
Sept7    
Stmn2   
Gvin1    
Ppp2ca    
Stk16    
Sh3yl1    
Mfsd6   
Strn3   
LOC100046859    
Ces3   
Gbl   
 
 
 
 
 
 
 
101 
 
Results summary 
Yeast two-hybrid screening was employed in search of Hectd2 binding partners, for which 
no interactors exist to date. 27 candidates were identified from the screen and subjected 
to follow up analyses by independent two-hybrid interaction assays in yeast for each 
putative candidate. 20 of these were confirmed as binding partners of Hectd2 in yeast. 
The yeast two-hybrid system was further exploited in an endeavor to map the region of 
Hectd2 to which the candidate interactors bind. By using C-terminal deletion mutants, it 
has been possible to determine that residues 181-414 of Hectd2 contain the region in 
which substrates make contact with Hectd2. These findings indicate that the prey 
interactors do not all bind Hectd2 at the same location as some substrates require different 
regions, which may be suggestive of multiple binding domains. 
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4 Validation of interactions in a mammalian cell system 
 
4.1 Candidate gene selection for co-immunoprecipitation assays 
 
Protein-protein interactions are integral to a myriad of cellular mechanisms and can alter 
the kinetic properties of enzymes, the specificity of a protein for its substrate or serve 
regulatory roles to refine signalling262. Elucidation of these interactions can thus provide 
information on protein crosstalk within a pathway and thus functional implications in a 
given process. To date, Hectd2 remains a protein for which there are no known interactors, 
such that it has not been possible to place this E3 ubiquitin ligase within any protein 
network. Yeast-two-hybrid screening identified 20 binding partners of Hectd2, however, 
interactions in yeast do not necessarily reflect the binding characteristics of a given protein 
in mammalian cells. Yeast cells may not facilitate the correct folding of a protein into its 
quaternary conformation, which may require machinery specific to mammalian cells. In 
addition cellular targeting or location of a given protein may define the interactions that 
it makes and those identified in yeast may not be biologically relevant. Mammalian cells 
have the capacity to perform complex post-translational modifications that may adapt a 
protein for correct structure or render it active or localise it to a specific cellular 
component263. Thus the importance of validating such interactions in a mammalian cell 
line is apparent. The COS-7 cell line was selected to characterise interactions captured in 
the yeast-two-hybrid screen. COS-7 cells are fibroblast-like kidney cells originating from 
the African green monkey and represent an adherent line commonly used as a transfection 
host264.  
Of the 20 candidates that emerged from the co-transformations in yeast, 5 were selected 
for further analyses. The basis for their selection was that of a putative functional or 
topographical significance that may link the candidates with disease pathology and thus 
Sh3glb1, Stmn2, Pacsin2, Stambp and Sept7 were chosen for co-immunoprecipitation 
analyses. Endophilin B1 (Sh3glb1) has a neuronal function in regulating NGF/TrkA, a 
neurotrophin and its receptor which modulates neuronal survival and differentiation265, 
266. Endophilin B1 has been associated with neuronal loss and induced autophagy in 
Parkinson’s disease models267 and has been reported as an interactor of Huntingtin268. 
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Stambp, a deubiquitination enzyme involved in endosomal sorting of a number of cell 
surface molecules, is required to degrade ubiquitinated proteins in the CNS269 and  mice 
deficient in Stambp show loss of neurons in the hippocampus and cerebral cortex270. 
Stmn2 is a microtubule destabilizing protein and has been identified as a risk factor for 
vCJD in a human genome wide association study138. Pacsin2 is also a regulator of 
microtubule stability and plays a key role in membrane curvature and is implicated in 
endocytosis271-274. Microtubule stability is of particular interest owing to PrP mediated 
tubulation that disrupts microtubular cytoskeleton by inducing tubulin oligomerisation275. 
Sept7 is a cytoskeletal GTPase that is required for normal organisation of the actin 
cytoskeleton276, 277. Its implication in trafficking278, a function shared by Pacsin2279, 
Sh3glb1266, 280 and Stambp281, 282, may indicate a common molecular pathway. Sept7 has 
also been reported to interact with Sept2, which is one of three septins found in 
neurofibrillary tangles in Alzheimer’s disease283, 284. 
Co-immunoprecipitation assays were performed to capture Hect414, the N-terminal 
region in which the putative binding domain lies or Hectd2 in complex with its native 
interactions, described in detail below, (Section 4.3). It was important to test full length 
Hectd2 in parallel to Hect414 to confirm the interactions identified in the yeast system in 
addition to providing evidence of biological relevance by demonstrating that the full 
length proteins also bind. Absence of validated antibodies for Hectd2 and probable 
binding partners required tagging of the proteins of interest to epitopes for which high 
affinity antibodies were available. The pCMV-MYC/pCMV-HA vector set (Clontech) 
was selected to transiently express interacting proteins as either MYC or HA tagged 
fusions, for which Hectd2/Hect414 and the candidate interactors were chosen to express 
with the MYC or HA epitopes, respectively.  
 
4.2 Design and construction of c-MYC/HA tagged fusion proteins 
 
The pCMV·MYC/HA tag vector set allows the design of constructs that have MYC/HA 
tags that are N-terminally expressed (Appendix 2). MYC/HA tagged fusion proteins are 
thought to have minimal interference with the functional activity of the protein fused to it 
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owing to their small molecular weight (Appendix 2). The Hect414/Hectd2 sequences were 
cloned in frame with the MYC tag in pCMV-MYC using the strategy depicted in Section 
3.3, Figure 3.3.1. The cDNA clones of the candidate genes isolated from yeast represent 
a partial sequence of the full length protein except for Stmn2, for which the cDNA clone 
was already in its full length form (Table 3.6.1).  The candidate genes, in both their partial 
and full length sequences were cloned in frame with the HA tag in pCMV-HA. Full length 
cDNA clones of Sh3glb1 (IRAVp968D0874D), Pacsin2 (IRAVp968C0763D), Stambp 
(IRAVp968B0179D) and Sept7 (IRAVp968C04100D) were purchased from Source 
Bioscience in the pCMV-SPORT6 vector. Cloning was carried out by PCR amplification 
of each insert sequence from the templates described above and a pre-existing Hectd2-
TOPO clone for amplification of Hectd2/Hect414 (Section 2), through which restriction 
sites were incorporated at the 5’ and 3’ ends. This was achieved by using oligonucleotide 
primers that were designed to prime the insert sequence from its 5’ and 3’ ends, each 
preceded by a SalI or SfiI site for Hectd2/Hect414 or the candidate genes, respectively. 
These sites were selected based on their absence in the translated region of 
Hect414/Hectd2 or the candidate genes, thus preventing cutting of the sequence following 
digestion with SalI or SfiI respectively (Appendix 2). Base pair insertions were made 
where necessary to keep the sequences in frame with the tags and thus to retain the 
translational integrity of the fusion proteins, as depicted in Figure 4.2.1. This was only 
required for Hect414 and Hectd2 to maintain its frame with the MYC tag. 
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5’ ATG GCA TCA ATG CAG AAG CTG ATC TCA GAG GAG GAC CTG………ATG TCG ACC ATG AGT GAG…… 
                                                MYC tag                                                   SalI site          Hect414 
 
 
 
 
 
5’ ATG TAC CCA TAC GAT GTT CCA GAT TAC GCT………ATG GCC ATG GAG GCC ATG AAC ATC ATG…… 
                                               HA tag                                  SfiI site                        Sh3glb1 
 
 
Figure 4.2.1 Construction of the tagged fusion proteins.  The translation frame of the fusion construct 
for the cloning of Hect414 into pCMV-MYC and Sh3glb1 into pCMV-HA are shown as examples. 
Sequences of Hect414 and Sh3glb1 were maintained in frame with the N-terminal MYC or HA tags with 
their respective ATG start codons (green). Restriction sites were incorporated into PCR primers to amplify 
each gene sequence with either a SalI or SfiI site for Hect414/Hectd2 or Sh3glb1, respectively.  Base pair 
insertions were made where necessary, indicated in red, to retain the open reading frame.  
 
PCR products were cloned into the TOPO shuttle vector prior to transfer to the pCMV-
MYC/HA destination vector via ligation of overhanging ends generated by restriction 
digestion with SalI or SfiI, respectively (Section 2). The resultant clones were screened 
by PCR amplification using primers complementary to the 5’ and 3’ regions of the pCMV-
MYC or pCMV-HA vector flanking the MCS, inclusive of 200 base pairs of the vector 
backbone flanking the MCS (Section 2). Size resolution of the amplified PCR products 
by agarose gel electrophoresis identified positives of each cloned gene consistent with the 
appropriate size (Table 4.2.1). The corresponding positive clone was cultured and purified 
according to Section 2. Restriction digestion with SalI or SfiI confirmed their insert sizes, 
Figure 4.2.2, which was verified by comprehensive sequence analyses for accuracy and 
integrity of the MYC or HA fusion junction. 
 
 
 
Start of insert ATG start of tag 
Start of insert ATG start of tag 
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Table 4.2.1 Molecular weight of candidate genes and Hectd2/Hect414 
Gene 
DNA insert size 
(bp) 
Fusion protein predicted molecular weight 
(kDa) 
Hectd2 2322 90 
Hect414 1242 49 
tcSh3glb1 987 39 
Sh3glb1 1098 43 
Stmn2 540 22 
tcPacsin2 570 26 
Pacsin2 1461 58 
tcStambp 924 37 
Stambp 1275 50 
tcSept7 345 19 
Sept7 1311 52 
The prefix tc represents the truncated form of a candidate gene as identified in the yeast two-hybrid 
screen.  
    
Figure 4.2.2 Insert release from MYC/HA fusion constructs.  The truncated (tc) and full length forms of 
the candidate genes cloned into pCMV-HA were restriction digested with SfiI and Hect414/Hectd2 in 
pCMV-MYC with SalI. The cleaved inserts corresponded to sizes that were consistent with those that were 
expected for each gene in base pairs, detailed in Table 4.2.1. 
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4.3 Co-expression and co-immunoprecipitation of interacting complexes 
Characterisation of protein-protein interactions using co-immunoprecipitation is a 
common method that has been successfully applied to dissect the biological activities of 
a multitude of proteins262. The underlying principle of the method relies on the stable 
physiological interaction of proteins that can be captured by immunoprecipitating one of 
the interactants and thus co-precipitating its binding partner. This is facilitated by use of 
an antibody linked to a beaded support that detects one of the proteins in an interaction, 
by which the complex can be ‘pulled down’ from the lysate. The complex is isolated and 
denatured, from which the binding proteins can be identified by Western blotting with an 
antibody to specific to the interacting partner. 
The putative substrate binding domain, Hect414 and its full length sequence, Hectd2 were 
co-expressed with each candidate by transfecting the respective fusion constructs in COS-
7 cells, an overview of which is depicted in Figure 4.3.1.  Whole cell lysates were 
harvested post-transfection and expression of MYC-tagged Hect414/Hectd2 or HA-
tagged candidates were detected from 5% of a 1 ml total lysate using anti-c-MYC mouse 
monoclonal or anti-HA tag rabbit polyclonal on a Western blot (Section 2). The remaining 
95% of the cell lysate was incubated with a Goat anti-HA tag immunoprecipitating 
antibody (Abcam), immobilised to an agarose bead support. The antibody binds 
specifically to the HA tag, forming a complex with the candidate interactor-
Hectd2/Hect414. Following serial washing and centrifugation steps to eliminate non-
specific binding proteins, the immunoprecipitants were eluted in denaturing SDS buffer. 
The proteins bound to the HA-tagged candidates were detected by Western blotting using 
anti-c-MYC antibody. Antibody combinations were selected based on the species they 
were raised in, in order to avoid cross-reactivity between the co-eluted antibody light and 
heavy chains in the precipitated complex and the secondary antibody used to detect the 
proteins within that complex. Thus anti-c-MYC mouse monoclonal antibody was used to 
detect MYC tagged Hectd2/Hect414 that was bound to the interactant, which was 
immunoprecipitated with Goat anti-HA tag antibody.  
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Figure 4.3.1 Overview of co-immunoprecipitation assay. Constructs were designed to express Hect414 
or Hectd2 as MYC-tagged fusions and the candidate interactors as HA-tagged proteins. Whole COS-7 cell 
lysates were harvested post-transfection and expression of the tagged proteins detected by SDS 
PAGE/Western blotting using anti-c-MYC mouse monoclonal or anti-HA tag rabbit polyclonal antibodies. 
Goat anti-HA tag agarose beads were incubated with crude cell lysates and the interacting-HA-tagged 
fusions are captured, co-precipitating the bound protein. The complex is eluted in denaturing sample buffer 
and followed by SDS PAGE/Western blotting to detect MYC-tagged Hect414/Hectd2 using anti-c-MYC 
mouse monoclonal antibody. 
To authenticate the co-immunoprecipitation experiments several criteria need to be met. 
Firstly, the immunoprecipitated protein must be recognised by the surface bound antibody 
and conversely the co-precipitated protein must not. Secondly, the interaction must 
require both proteins so as to ensure that the interaction is specific. To account for this, a 
combination of constructs were co-transfected into COS-7 cells as outlined in Table 4.3.1. 
To standardise the nomenclature, the truncated form of a protein obtained from the yeast-
two-hybrid screen is denoted with a ‘tc’ preceding its name, otherwise an implicit 
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assumption should be made that the full length protein has been expressed. Plasmids are 
described as pCMV-MYC∙Hect414/Hectd2 or pCMV-HA∙Interactor, which represent the 
MYC or HA plasmids from which Hect414/Hectd2 or the interacting protein are 
expressed. Their protein counterparts are denoted by MYC∙Hect414/Hectd2 or 
HA∙Interactor, respectively. All co-immunoprecipitations were repeated to ensure 
reproducibility.  
 
Table 4.3.1 Construct combinations for co-immunoprecipitations 
Construct combinations for co-immunoprecipitation controls 
 pCMV-MYC∙Hect414/Hectd2                            +                             pCMV-HA∙Candidate* 
 pCMV-MYC∙Hect414/Hectd2                            +                             pCMV-HA 
 pCMV-MYC                                                       +                             pCMV-HA∙Candidate* 
 pCMV-MYC                                                       +                             pCMV-HA 
* Candidate represents Sh3glb1, Stmn2, Pacsin2, Stambp or Sept7 in truncated or full length forms 
 
Hectd2 binds to Sh3glb1 
 
MYC∙Hect414, putative substrate binding domain or MYC∙Hectd2 co-
immunoprecipitated with truncated or full length forms of Sh3glb1 in COS-7 cells in 
which they were both expressed (Figure 4.3.2 c, f). MYC∙Hect414 and MYC∙Hectd2 were 
observed as ~49 or 90 kDa bands, respectively, and were absent in control samples (Figure 
4.3.2 a, d). Immunoprecipitants were undetectable in samples where HA∙tcSh3glb1 or 
HA∙Sh3glb1 were co-expressed with MYC tag empty vector (Figure 4.3.2 c, f). The 
Sh3glb1 fusions migrate at ~39 or 43 kDa respectively, while the co-expressed tags on 
their own are not observed owing to their low molecular weight of 1.4 kDa (Figure 4.3.2 
b, e). Co-expression of both empty vectors failed to precipitate any proteins confirming 
that non-specific MYC- or HA-tagged proteins were not falsely detected. Together, these 
data indicate a Hect414/Hectd2 dependent co-immunoprecipitation with Sh3glb1.  
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Figure 4.3.2 Sh3glb1 co-immunoprecipitates with Hectd2 in COS-7 cells. 50 µl of cell lysate containing 
MYC-tagged Hect414 or Hectd2 and HA-tagged Sh3glb1 in both truncated (tc) and full length forms were 
electrophoresed on 16 and 12% gels respectively (panels a-c and d-f). Western blotting was followed by 
detection of MYC or HA epitopes using anti-c-MYC mouse monoclonal antibody (a, c, d and f) or anti-HA 
tag rabbit polyclonal antibody (b and e). Signals were detected with secondary IRDye680 (red) conjugated 
goat anti-mouse IgG or IRDye800 CW (green) conjugated goat anti-rabbit IgG using an Odyssey infra-red 
imaging immunofluorescence system (Li-Cor). MYC∙Hect414 (a-c) or MYC∙Hectd2 (d-f) were co-
expressed with tcSh3glb1 (a-c) or Sh3glb1 (d-f) or with their respective vector only controls (a-f). Both 
tcSh3glb1 and Sh3glb1 show interaction with Hect414 or Hectd2 when both proteins are present in the 
lysate but not when Sh3glb1 forms were absent (c and f). 
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Hectd2 binds to Stmn2 
 
Expression of HA∙Stmn2, was observed as a band running at a molecular weight slightly 
higher than the 22 kDa size expected for the Stmn2 fusion, Figure 4.3.3 b, e. This may be 
attributed to the discrepancies that sometimes occur in the migration profile of a protein 
and its calculated molecular weight or perhaps due to post-translational modifications, 
such as phosphorylation, which is a known alteration for Stmn2285. Co-expression with 
MYC∙Hect414 or MYC∙Hectd2 in COS-7 cells identified that Stmn2 co-
immunoprecipitated with both MYC∙Hect414 and MYC∙Hectd2 (Figure 4.3.3 a-f). This 
is supported by an absence of the MYC∙Hect414/Hectd2 proteins in control samples 
where MYC∙Hect414/Hectd2 was expressed with the HA tag empty vector (Figure 4.3.2 
c, f). Furthermore, presence of HA∙Stmn2 solely with the MYC tag is not sufficient to 
immunoprecipitate the ~49 or 90 kDa bands observed in Figure 4.3.3 c, f. Co-expression 
of the MYC and HA tags alone fails to precipitate any proteins suggesting that the 
interactions between Hect414/Hectd2 and Stmn2 are specific.  
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Figure 4.3.3 Stmn2 co-immunoprecipitates with Hectd2 in COS-7 cells. 50 µl of cell lysate containing 
MYC-tagged Hect414 or Hectd2 and HA-tagged Stmn2 were electrophoresed on 16 and 12% gels 
respectively (panels a-c and d-f). Samples were immunoblotted with anti-c-MYC mouse monoclonal 
antibody (a, c, d, f) or anti-HA tag rabbit polyclonal antibody (b and e) and secondary IRDye680 (red) 
conjugated goat anti-mouse IgG or IRDye800 CW (green) conjugated goat anti-rabbit IgG using an Odyssey 
infra-red imager (Li-Cor). Stmn2 was co-expressed with MYC∙Hect414 (a-c) or MYC∙Hectd2 (d-f) with 
their respective vector only controls (a-f). The band corresponding to HA∙Stmn2 is represented by an 
asterisk to denote the difference in migration profile and its predicted molecular weight of 22 kDa (b and 
e). Stmn2 shows interaction with Hect414 and Hectd2 only when co-expressed but not when Stmn2 was 
absent from the lysate (c and f). 
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Hectd2 binds to Pacsin2 
MYC∙Hect414 or MYC∙Hectd2 were found to co-immunoprecipitate with HA∙Pacsin2 in 
its truncated or full length forms when co-expressed (Figure 4.3.4 c, f). The truncated 
form of HA∙Pacsin2 runs at a molecular weight of 26 kDa while its full length counterpart 
runs at a molecular weight of 58 kDa (Figure 4.3.4 b, e).  However, when Hect414 or 
Hectd2 are expressed with the HA tag only, in the absence of the Pacsin2 proteins, 
Hect414 and Hectd2 both fail to co-immunoprecipitate, indicative of Pacsin2-dependent 
precipitation (Figure 4.3.4 a-f). Conversely, this was also true when HA∙tcPacsin2 or 
HA∙Pacsin2 were co-expressed with the MYC tag only, such that immunoprecipitation of 
the proteins fails to detect the binding protein (Figure 4.3.4 a-f). The vector only control, 
supports these findings whereby co-immunoprecipitation is abrogated in the absence of 
interacting Pacsin2 and Hectd2 (Figure 4.3.4 c, f). 
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Figure 4.3.4 Pacsin2 co-immunoprecipitates with Hectd2 in COS-7 cells. 50 µl of cell lysate containing 
MYC-tagged Hect414 or -Hectd2 and HA-tagged Pacsin2 in both truncated (tc) and full length forms were 
electrophoresed on 16 and 12% gels respectively (panels a-c and d-f). Samples were immunoblotted with 
anti-c-MYC mouse monoclonal antibody (a, c, d, f) or anti-HA tag rabbit polyclonal antibody (b and e) and 
secondary IRDye680 (red) conjugated goat anti-mouse IgG or IRDye800 CW (green) conjugated goat anti-
rabbit IgG using an Odyssey infra-red imager (Li-Cor).  Panels a, b, d and e show that Pacsin2 in its 
truncated or full length complement were co-expressed with Hect414 or Hectd2 or with the MYC or HA 
empty vectors. tcPacsin2 or its full length protein show interaction with Hect414 or Hectd2, respectively, 
when co-expressed but not when Pacsin2 proteins were absent from the lysate (c and f). 
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Hectd2 binds to Stambp 
HA∙tcStambp migrates as a ~37 kDa band and HA∙Stambp shows a molecular weight that 
is slightly higher than the predicted ~50 kDa, (Figure 4.3.5 b, e). Immunoprecipitation of 
HA∙tcStambp or HA∙Stambp co-precipitated Hect414 or Hectd2, respectively, in samples 
where both proteins were present, (Figure 4.3.5 a-c and d-f). However in the absence of 
one or the other putative interacting protein, where they were expressed with their 
respective MYC or HA tags only, MYC∙Hect414 or MYC∙Hectd2 failed to be detected as 
co-precipitating proteins (Figure 4.3.5 c, f). The vector only control sample in which the 
MYC and HA tags are co-expressed support these data in that the presence of both Stambp 
and Hectd2 are required to co-immunoprecipitate Hectd2 (Figure 4.3.5 c, f).  
       
Figure 4.3.5 Stambp co-immunoprecipitates with Hectd2 in COS-7 cells. 50 µl of cell lysate containing 
MYC-tagged Hect414 or Hectd2 and HA-tagged Stambp in both truncated (tc) and full length forms were 
electrophoresed on 16 and 12% gels respectively (panels a-c and d-f). Western blotting was followed by 
detection of MYC or HA epitopes using anti-c-MYC mouse monoclonal antibody (a, c, d and f) or anti-HA 
tag rabbit polyclonal antibody (b and e). Signals were detected with secondary IRDye680 (red) conjugated 
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goat anti-mouse IgG or IRDye800 CW (green) conjugated goat anti-rabbit IgG using an Odyssey infra-red 
imaging immunofluorescence system (Li-Cor). Truncated Stambp or full length proteins were co-expressed 
with MYC∙Hect414 or MYC∙Hectd2 or their complementary empty vector (a-f). The band corresponding 
to HA∙Stambp (e) is represented by an asterisk to denote the difference in migration profile and its predicted 
molecular weight of 50 kDa. tcStambp or its full length protein show interaction with Hect414 or Hectd2, 
respectively, when co-expressed but not when Stambp forms  were absent from the lysate (c and f). 
 
Hect414 binds to Sept7 
When MYC∙Hect414 was co-expressed with HA∙tcSept7, a protein that runs at ~19 kDa, 
MYC∙Hect414 was found to co-immunoprecipitate with HA∙tcSept7 (Figure 4.3.6 a-c). 
Samples in which MYC∙Hect414 was expressed with the HA tag only, failed to detect 
Hect414 as a co-precipitant, suggesting that HA∙tcSept7 is required for interaction with 
MYC∙Hect414 (Figure 4.3.6 a, c). Furthermore, an interaction with Hect414 is not 
detected in the absence of MYC∙Hect414, where HA∙tcSept7 is co-expressed with the 
MYC tag only (Figure 4.3.6 a-c). The vector only control supports these data, which 
shows no detectable protein, suggesting that interaction between Hect414 and tcSept7 is 
necessary for co-immunoprecipitation (Figure 4.3.6 c). 
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Figure 4.3.6 Sept7 co-immunoprecipitates with Hect414 in COS-7 cells. 50 µl of cell lysate containing 
MYC-tagged Hect414 and HA-tagged Sept7 were electrophoresed on 16% gels (panels a-c) Western 
blotting was followed by detection of MYC or HA epitopes using anti-c-MYC mouse monoclonal antibody 
(a and c) or anti-HA tag rabbit polyclonal antibody (b). Signals were detected with secondary IRDye680 
(red) conjugated goat anti-mouse IgG or IRDye800 CW (green) conjugated goat anti-rabbit IgG using an 
Odyssey infra-red imaging immunofluorescence system (Li-Cor). Truncated Sept7 was co-expressed with 
MYC∙Hect414 or with the complementary MYC or HA vectors (a-c). tcSept7 was found to interact with 
Hect414 when co-expressed, but not when tcSept7 proteins were absent from the lysate (c). 
 
Results summary 
 
We selected five candidates from the yeast-two-hybrid screen for confirmation of their 
interaction in a mammalian cell system. By tagging Sh3glb1, Stmn2, Pacsin2, Stambp 
and Sept7 to the HA epitope and co-expressing with MYC-tagged Hect414 and full length 
Hectd2 in COS-7 cells, it has been possible to establish that each of these candidates binds 
Hectd2.  
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5 Effect on cell susceptibility to prion infection  
 
5.1 shRNA gene knockdown in N2aPK1/2 cells 
 
The standard method to test the effects of a candidate gene in prion disease is through the 
use of mouse models that are transgenic or knockout for the gene of interest. A phenotype 
can be measured by challenging such mice with prions after which a quantitative trait such 
as incubation time can be measured that can be followed by histopathological assessment 
relative to control mice. However, functional validation of candidate genes that modulate 
incubation time by generating mouse models is costly and labour intensive. Cell based 
assays are therefore often sought to identify phenotypic perturbations that define gene 
function. One such method is the Scrapie Cell Assay (SCA), developed by Klöhn et al., 
which is an alternative in vitro assay for the quantification of prion infectivity253. The 
underlying principle of this method relies on the high susceptibility of the neuroblastoma 
N2a derivative, N2aPK1/2 cell line, (PK1/2) to RML mouse scrapie prions. Transmission 
of the infectious species to cells can be measured by automated counting of PrPSc positive 
cells following exposure to prions. Application of this approach can be exploited by 
measuring the susceptibility of cells to prion infection following manipulation of a given 
candidate gene by knockdown or overexpression. This may shed light on the role of a 
candidate gene with respect to its propensity to propagate prion infection and its ability to 
clear prions. 
 
The Hectd2 binding partners, Sh3glb1, Pacsin2, Sept7 and Stambp were selected for 
functional validation using the Scrapie Cell Assay. Expression of these genes in PK1/2 
cells was previously determined by a microarray study (unpublished data, MRC Prion 
Unit, London) and thus we chose to knockdown each gene independently. The 
knockdown technology selected for gene silencing was by short hairpin RNA (shRNA) 
that would be stably expressed to suppress expression of the candidate gene. Stable rather 
than transient expression was the preferred method to achieve sustainable gene 
knockdown over the duration of the assay (Section 2). This allows the measurement of 
cell susceptibility to prion infection over time. Stable cell lines for each candidate gene 
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were generated and quantified to ascertain knockdown levels prior to screening with the 
Scrapie Cell Assay.  
 
 
5.2 Construction of the pSUPER.retro.puro recombinant plasmid 
 
The pSUPER.retro.puro vector was selected to clone target-specific shRNAs as it can 
direct stable intracellular expression of the shRNA, to facilitate knockdown of the target 
mRNA transcript when stably maintained within a cell256, 286 (Figure 5.2.1) . To mediate 
transcript silencing of the target gene, custom made 60-nucleotide forward and reverse 
oligonucleotides including a 19 nucleotide sequence, N-19, derived from the target 
mRNA, were designed (Section 2). The N-19 target sequences were generated using the 
siDESIGN Center, an algorithm developed by Dharmacon, to identify functional siRNA 
sequences (Section 2). This tool was used to generate four shRNAs for each candidate 
gene to ensure that downstream results are supported by at least two shRNA knockdown 
lines per gene to provide confidence that a given phenotype is not an artifact. Furthermore, 
the algorithm generates the shRNA as a prediction of what may serve as a functional 
siRNA, thus there is a possibility that an shRNA may not silence the target transcript.  
Cloning of the N-19 oligonucleotide into the pSUPER.retro.puro vector (OligoEngine) 
was facilitated by use of the BglII and HindIII sites to position the oligonucleotide 
downstream of the H1 promoter’s TATA Box. The forward oligonucleotide was 
engineered to contain a 5’ BglII restriction site preceding the N-19 sequence in the sense 
and antisense orientation, separated by a 9 nucleotide spacer sequence that would in turn 
form the hairpin structure (Figure 5.2.1.) The 3’ end of this forward oligonucleotide 
includes a run of 5 thymidines that denotes the termination signal and includes HindIII 
specific nucleotides (Section 2).  
 
The forward and reverse complement oligonucleotides were annealed to form double 
stranded units (Section 2). Their BglII and HindIII overhanging ends were thus available 
for ligation to BglII/HindIII-digested pSUPER.retro.puro. The shRNA constructs were 
verified by sequencing. A non-targeting shRNA control construct, pRS-GFP-sh2, and a 
120 
 
marker plasmid control, pRS-GFP, were gifted by Dr Craig Brown (MRC Prion Unit, 
London). The pRS-GFP-sh2 construct represents an shRNA directed against GFP and was 
used to control for changes to the cells due to the procedure, particularly the antibiotic 
selection that was used to achieve stable knockdown. The marker plasmid, pRS-GFP, 
represents the GFP protein cloned into pSUPER.retro.puro and was used to observe the 
transfection efficiency of candidate gene-specific shRNA constructs.  
 
 
 
 
Figure 5.2.1 Transcription of shRNA targeting Sh3glb1. a) Oligonucleotides were designed to target a 
19 bp region of the cognate mRNA, shown here for Sh3glb1, including sense and antisense strands 
connected by the 9 nucleotide spacer. b) The H1 promoter of pSUPER.retro.puro drives expression of the 
60 nucleotide single stranded RNA, which folds to form a hairpin structure. c) This is processed post-
transcriptionally into functional si-RNA-like molecules. Adapted from OligoEngine pSUPER.retro.puro 
manual. 
 
 
5.3 Relative quantitation of target gene shRNA knockdown 
 
To generate stably expressing shRNAs for each gene, retroviral delivery of the constructs 
was used. The Phoenix Ecotropic, φ-NX Eco packaging cell line was selected to produce 
retroviruses for infection of PK1/2 cells256. Following transduction of PK1/2 cells with 
retroviruses harbouring each shRNA construct, drug selection with puromycin was 
performed. Stable cell lines with the relevant integrated constructs were derived following 
maintenance in puromycin-supplemented media for two weeks (Section 2). These lines 
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were subject to analysis by measurement of the effect of each shRNA construct on the 
target mRNA levels. Knockdown shRNA cell lines for Hectd2 were generated by Dr 
Craig Brown, MRC Prion Unit, London, using the same procedures. 
 
The mRNA levels of Sh3glb1, Pacsin2, Sept7, Stambp and Hectd2 in their respective 
PK1/2-shRNA knockdown cell lines were quantified relative to control PK1/2 cells in 
which the non-targeting construct pRS-GFP-sh2 was expressed. Comparative mRNA 
quantification in this manner allows the determination of how effective an shRNA is for 
knockdown of a given target gene. This is expressed as an n-fold difference relative to 
non-targeting control cells (GFP-sh2), which has been normalised to the endogenous 
reference control, glyceraldehyde-3-phosphate dehydrogenase, (GAPDH), to generate a 
unit of relative expression.  
 
The Taqman® Gene Expression Cells to CT™ kit was used to recover RNA from PK1/2 
cell lysates from which cDNA was transcribed by reverse transcription for analysis by 
qPCR. Two independent lysates per cell line were used, which have been defined herein 
as separate lysis reactions and three technical replicates per lysate were made for the PCR 
reactions described below (Section 2). 
 
The concentration of cDNA for a given gene was quantified by qPCR, which measures 
real time detection of specific PCR amplification. TaqMan® Gene Expression Assays 
specific for Sh3glb1, Pacsin2, Sept7 and Stambp were used for relative expression 
analyses (Section 2). Quantitation was determined by the ΔCT method which generates 
relative values for target expression, normalised to endogenous GAPDH, relative to non-
targeting control cells, given by the formula 2-ΔΔCT (Section 2). A minimum of 50% 
difference in target gene expression relative to controls was arbitrarily selected to define 
sufficient gene knockdown. Thus for each candidate gene, at least two shRNA lines at 
>50% knockdown were required to provide confidence in the results generated in 
downstream SCA analyses. 
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Cells expressing construct Sh3glb1-sh4, which targets the ORF of Sh3glb1, had 59 % 
knockdown, relative to reference PK1/2-GFP-sh2 cells as shown in Figure 5.3.1, Table 
5.3.1. However, Sh3glb1-sh1, -sh2 and -sh3 did not show statistically significant 
differences in knockdown relative to control cells. Targeting of Pacsin2 showed more 
promising results as Pacsin2-sh2, -sh3 and –sh4 constructs knocked down expression by 
57, 86 and 88%, respectively, although Pacsin2-sh1 only produced a moderate reduction 
of 33%. Sept7 mRNA expression levels demonstrated that shRNAs 1, 2 and 4 targeting 
Sept7 reduced expression by 59, 86 and 93%, respectively, relative to PK1/2-GFP-sh2 
cells whilst Sept7-sh3 did not show significant gene knockdown. Rather, Sept7-sh3 
appeared to have a 10% increase in Sept7 mRNA, which may be attributed to natural 
variation. Stambp-sh1, and -sh4 showed knockdown of Stambp mRNA by 83 and 90% 
respectively, relative to the non-targeting control. Table 5.3.1 shows the knockdown cell 
lines selected for each gene to undergo SCA validation of candidates. 
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Figure 5.3.1 Relative mRNA expression of candidate genes. Cell lysates from each PK1/2 line expressing 
gene specific shRNA targeting Sh3glb1, Pacsin2, Sept7 and Stambp or non-targeting shRNA, GFP-sh2, 
were used to obtain cDNA by reverse transcription from which their levels were quantified by qPCR using 
a comparative CT method. Error bars are SD, * = p<0.01, *** = p<0.0001, t test.  
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Table 5.3.1 shRNA knockdown lines for Scrapie Cell Assay 
Stable shRNA PK1/2 line Knockdown (%) SD (± %) 
Sh3glb1-sh1 19 20 
Sh3glb1-sh2 18 31 
Sh3glb1-sh3 22 21 
Sh3glb1-sh4 59 12 
Pacsin2-sh1 33 22 
Pacsin2-sh2 57 6 
Pacsin2-sh3 86 6 
Pacsin2-sh4 88 4 
Sept7-sh1 59 10 
Sept7-sh2 86 3 
Sept7-sh3 * * 
Sept7-sh4 93 5 
Stambp-sh1 83 6 
Stambp-sh4 90 2 
Hectd2-sh1** 96 0.4 
Hectd2-sh3** 96 0.4 
Hectd2-sh4** 98 0.4 
shRNA lines showing >50% knockdown were selected for the SCA 
*Sept7-sh3 construct shows no knockdown of Sept7 expression relative to control GFP-sh2 non-targeting 
cells **Lines generated by Dr Craig Brown 
 
 
 
 
 
 
 
 
125 
 
5.4 Effect of target knockdown on the Scrapie Cell Assay, SCA 
The SCA allows the visualisation of proteinase-K (PK) resistant PrP signals, PrPSc, arising 
from single cells. Data generated from the assay can be utilised to provide information on 
the effect of candidate gene knockdown on cell susceptibility to prion infection. The 
Scrapie Cell Assays described herein where performed by Dr Craig Brown, MRC Prion 
Unit, London.  
The shRNA knockdown cell lines detailed in Table 5.3.1 were infected with RML Scrapie 
from which a subset of 25,000 cells were filtered onto ELISPOT membranes for which 
10 replicates were made (Section 2). PK-digestion eliminated PK-sensitive PrP in order 
that only PrPSc is adsorbed to the membranes. PK-resistant PrP positive cells were counted 
following detection with anti-PrP ICSM18 and alkaline phosphatase linked anti-IgG1 in 
the presence of its conjugate substrate (Section 2). 
The PK-resistant PrP spot numbers generated from 3 independent assays were normalised 
to the non-targeting GFP-sh2 controls to calculate the mean of the PrPSc-positive signals 
and their standard deviations. In order to have confidence in a modulatory role for a given 
gene, replication of the result is required in an independent cell line for the same gene 
knockdown. The results, shown in Figure 5.4.1 a, show that knockdown of Sh3glb1 in 
PK1/2 cells expressing Sh3glb1-sh4, produces an increase in PK-resistant spot number 
relative to the non-targeting control, GFP-sh2 and PK1/2 cells. The p value corresponding 
to this difference in signal was 7.8 x 10-22, calculated by a t test, indicating that Sh3glb1 
is an interesting candidate although not confirmed as data for only one cell line was 
available. Pacsin2 knockdown showed variation in that cells expressing shRNA construct, 
Pacsin2-sh2 and –sh4, showed no significant difference to the non-targeting control or 
PK1/2 cells using a t test. However, Pacsin2-sh3 mediated knockdown resulted in a 
decrease of spot number, marked by a p value of 0.002, using a Mann-Whitney test as the 
data deviate from a Gaussian distribution. Thus it is unlikely that Pacsin2 modifies prion 
propagation or clearance, although this cannot be definitively ruled out. PK1/2 cells in 
which Sept7 knockdown was targeted by Sept7-sh1 or Sept7-sh4 showed an increase in 
the PK-resistant PrP spot signal. This was supported by highly significant p values of 7.9 
x 10-16 and 1.0 x 10-7, respectively, using t tests. Sept7-sh2 conversely appeared to reduce 
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the spot number, indicative of a possible off-target effect. Stambp knockdown by –sh4 
resulted in no significant difference relative to controls although targeting by construct 
Stambp-sh1 produced an increase in PK-resistant PrP signal; p value 0.003 (t test), thus 
confounding the data due to lack of replication as a conclusion cannot be drawn. To 
account for the effects of multiple testing, a Bonferroni correction was applied to bring a 
1% level of significance to p<0.001 for which Pacsin2-sh3, Sept7-sh2 and Stambp-sh1 do 
not reach significance. 
The SCA results for Hectd2 knockdown cell lines are shown in Figure 5.4.1 b.  Hectd2-
sh1 and Hectd2-sh4 mediated silencing of Hectd2 produced an increase in PK1/2 cell 
susceptibility to prion propagation relative to the non-targeted control GFP-sh2 cells. 
Statistical testing found that cells expressing Hectd2-sh1 or Hectd2-sh4 had p values of 
4.1 x 10-6 or 0.0001 in reference to the non-targeting control, (t test). However, one 
knockdown line, Hectd2-sh3, presented a decrease in PrPSc spot number, with statistical 
significance at p = 0.0007, (t test). Since an increased PrPSc propagation effect is supported 
by the two other Hectd2 knockdown lines, this conflicting data may perhaps be 
attributable to an off-target effect. 
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Figure 5.4.1 Effect of candidate gene knockdown in the Scrapie Cell Assay. Knockdown cell lines were 
exposed to 1 x 10-5 RML/Chandler inocula and the data analysed following the 4th split. PK-resistant PrP-
responsive cells were counted using an automated Zeiss KS Elispot system.  Error bars are SD, n=3, * = 
p<0.001, ** = p<0.0001 calculated by t test except for Pacsin2-sh3 data that deviate from a Gaussian 
distribution, calculated using the non-parametric, Mann-Whitney test. Panel a) Knockdown of Sh3glb1 and 
Sept7 show modulatory effects in cell susceptibility to prion propagation relative to non-targeting control 
GFP-sh2. Data for Pacsin2 and Stambp are inconclusive due to lack of replication of the significant 
differences in propagation, observed only for one cell line each. Panel b) Hectd2-sh1 and –sh4 knockdown 
lines for Hectd2 show significant increases in the PrPSc signal. However, Hectd2-sh3 knockdown line 
presents a decrease in propagation, which may represent an off-target effect as increased propagation is 
demonstrated by two Hectd2 knockdown lines. 
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Results summary 
 
From the SCA, it can be inferred that some of the candidate genes affect cell susceptibility 
by either serving to increase or decrease propagation when knocked down. The significant 
difference of Sh3glb1 relative to controls presents it as a promising candidate in prion 
propagation although this has not been tested in a second cell line. The SCA has shown 
that Sept7 may serve as a genetic modifier of cell susceptibility as two knockdown lines 
for this gene support an increase in prion propagation. Pacsin2 and Stambp are unlikely 
to modulate prion propagation or clearance following prion infection although there is 
insufficient evidence to rule these genes out as factors. Thus the candidate genes do not 
all affect susceptibility to prion propagation in the same manner suggesting different 
modes of action may apply. The SCA data for Hectd2 provides convincing evidence for 
a modulatory role in cell susceptibility to prion infection. Together, these data provide 
support for Hectd2 and specific components of its interactome as genetic modifiers of 
pathology. These interacting proteins and the molecular networks in which they are placed 
shed light on pathways that have not been previously implicated in the molecular basis of 
prion propagation and clearance. 
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6 Supporting work: Hectd2 knockout and transgenic mouse models - role 
in incubation time  
 
6.1 Mouse models of Hectd2  
 
Hectd2 knockout and transgenic mouse models were developed and experiments carried 
out by colleagues at the MRC Prion Unit for which I have analysed the data. Mouse 
models of prion disease are useful in that they can faithfully recapitulate features of prion 
disease such as neuropathology and biochemical characteristics. Such models can be 
exploited to measure incubation times of mice challenged with prions following 
manipulation of a given candidate gene by knockout or overexpression. Incubation time 
is defined as the time (in days) from inoculation to the point at which clinical diagnosis 
of prion disease is made following transmission of a given prion strain.  
 
6.2 Generation of the Hectd2 knockout mice 
 
The Hectd2 knockout mouse model was generated by inGenious Targeting Laboratory, 
Inc. Exon 2 of Hectd2 was targeted for deletion by homologous recombination by 
constructing a targeting vector from a C57BL/6J BAC clone (RPCI23) in which a 
neomycin cassette was cloned such that it replaces exon 2 (Figure 6.2.1 a). Exon 2 was 
selected for deletion because it induces a frameshift mutation that results in a stop codon 
at the start of exon 3. This was expected to result in the translation of a truncated 103 
amino acid protein for Hectd2-/- mice (Figure 6.2.1 b and Figure 6.2.2 b), whilst wild type 
mice express the full length protein of 774 residues (Figure 6.2.1 b and Figure 6.2.2 a).  
The neomycin cassette was flanked at its 5’ and 3’ ends by short and long arms that extend 
~2.3 kb and ~9.4 kb, which are homologous to the genomic locus into which the construct 
integrates (Figure 6.2.1 a). The targeting construct was inserted into C57BL/6J embryonic 
stem cells by electroporation prior to injection into blastocysts from Balb/c mice. The 
resultant chimeric mice were crossed with wild type C57BL/6J mice until germline 
transmission was achieved. Heterozygote mice were intercrossed to homozygosity. The 
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resultant Hectd2-/- mice were phenotypically normal, fertile and showed a normal life 
span. 
 
To confirm correct targeting, PCR amplification of the Hectd2-/- genomic region was 
performed with UNI and A1 primers which bind respectively within the neomycin 
cassette and outside of the homology region used to create the targeting construct, (Figure 
6.2.1 a). This PCR amplification was performed in a duplex reaction with primers Hex2F 
and Hex2R, shown in Figure 6.2.1 a, that flank exon 2 to amplify exon 2. This amplified 
a ~2.7 kb region of the Hectd2 gene inclusive of the ~1.8 kb neomycin cassette that 
replaced exon 2 (Figure 6.2.1 c), indicating that exon 2 has been deleted. Confirmation of 
exon 2 deletion at the mRNA transcript level was performed by RT-PCR (Figure 6.2.1 d). 
PCR amplification was performed on cDNA derived from whole brain RNA extracts of 
Hectd2-/- and wild type C575BL/6J mice, (Figure 6.2.1 d). This amplification was carried 
out using primers that flank exon 2 (HectSL4F and HectSL4R), depicted in the Hectd2 
sequence schematic in Figure 6.2.2. Bands corresponding to 323 bp were observed for 
Hectd2-/- cDNA indicative of exon 2 deletion (Figure 6.2.1 d). Wild type C57BL/6J mice 
expressed a transcript containing exon 2 as shown by amplification of a 452 bp band 
(Figure 6.2.1 d). Correct splicing of the exons was confirmed by sequencing. However, 
knockout at the protein level remains undetermined owing to an absence of specific anti-
Hectd2 antibodies for mouse Hectd2.  
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Figure 6.2.1 Construction of targeting allele to generate Hectd2 knockout mice.  a) Exon 2 of Hectd2 
was targeted on a ~15 kb region cloned from C57BL/6J wild type (WT) mice via homologous 
recombination with the targeting vector pGK-gb2 containing a loxP/FRT-flanked neomycin cassette (~1.8 
kb). b) Exon 2 targeting induces a frameshift stop mutation at the start of exon 3 thus translation of the 
transcript is expected to result in a truncated 103 amino acid protein whilst wild type C57BL/6J mice express 
the full length 774 residue protein.  c) PCR amplification of genomic DNA surrounding exon 2 of Hectd2 
knockout (KO) mice in a duplex reaction using A1/UNI and Hex2F/Hex2R primers, where UNI anneals 
within the neomycin cassette and A1 anneals 5’ to the short homology arm outside the region used to create 
the targeting construct and Hex2F/Hex2R flank exon 2. The ~2.7 kb band indicates the presence of the 
neomycin cassette, spanning the region in which exon 2 was deleted. To amplify the region surrounding 
exon 2 for WT, Hex2F and Hex2R primers were used to amplify a ~480 bp product. *Negative control 
represents a non-template H2O control.  d) PCR amplification of cDNA derived from Hectd2 knockout and 
wild type (C57BL/6J) mouse brains. Lanes 1 and 2 represent separate samples of Hectd2 knockout mice, 
for which exons 1, 3 and 4 are amplified (323 bp) while wild type samples show that exons 1, 2, 3 and 4 are 
amplified (452 bp).  
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Figure 6.2.2 Hectd2 mRNA sequence. a) A region of Hectd2 mRNA sequence is shown with the 
corresponding coding sections of exons 1-4, with the ‘atg’ start codon highlighted in green. Exon 2 is 
indicated in red, which was shown to be deleted in cDNA of Hectd2-/- mice using the HectSL4F and 
HectSL4R primers (b). Exon 2 deletion induces a frameshift mutation, creating a ‘tga’ stop codon at the 
start of exon 3, highlighted in red. Deletion of exon 2 was confirmed by sequencing. 
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6.3 Transmission of prions to Hectd2-/- mice 
Hectd2-/- and C57BL/6J control mice were anaesthetised with isofluorane/O2 and 
intracerebrally inoculated into the right parietal lobe with three different prion strains. 
These consisted of two mouse adapted scrapie strains, RML and ME7 and a mouse 
adapted BSE strain, MRC2103, 287, of which 30 μl of a 1% brain homogenate were 
inoculated. These strains differ in their glycoform ratios with respect to mono-, di- or un 
glycosylated PrPSc following protease digestion. Strain types can be distinguished by 
Western blot although classically defined by their characteristic incubation times and 
neuropathological targeting following passage in mice103. The RML strain shows an 
abundance of the mono-glycosylated, low molecular mass glycoform. MRC2 is defined 
by the presence of predominant di-glycosylated, high molecular mass glycoform and ME7 
represents all glycoforms equally103, 287. 
The onset of first signs of prion disease and the point at which clinical diagnosis was made 
i.e. the incubation time, were recorded. Signs of disease onset consisted of piloerection, 
erect ears, rigid tail, ungroomed appearance, hunched posture or clasping of hind limbs 
when lifted by the tail. Although these signs are indicative of prion disease, they are not 
specific to prion disease as they may occur due to alternative reasons such as old age. 
Diagnostic criteria for clinical prion disease included ataxia, tremor, limb paralysis or loss 
of righting reflex. Mice were examined daily for the signs of clinical onset and were culled 
when a definitive diagnosis was made or earlier if mice showed health concerns or signs 
of distress. Data for male and female mice were obtained and analysed separately as it has 
been established that sex differences can have a significant effect on incubation time288. 
Kaplan-Meier survival curves were derived for each group of males and females using 
GraphPad Prism 6 for which Log-rank (Mantel-Cox) testing was applied. The mean 
number of days following prion transmission for clinical onset and diagnosis/incubation 
time data are listed in Table 6.3.1.  
Figure 6.3.1 shows the curves for the onset of first signs of clinical symptoms for Hectd2-
/- and WT mice. RML transmission to Hectd2-/- female, mice resulted in an 8% reduction 
in the onset of first signs of clinical symptoms relative to control mice (p = 0.0001, log-
rank (Mantel-Cox) test, where the mean first signs occur at 138 ± 0 days for Hectd2-/- and 
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150 ± 0 days for WT mice), Figure 6.3.1.a, Table 6.3.1. This difference in the time of 
onset in Hectd2-/- mice relative to WT but not in the time of diagnosis results in an increase 
in duration of disease until clinical endpoint for Hectd2-/- relative to wild type mice 
(significant at p = 1.5x10-42, t test, where Hectd2-/- had a mean duration of 23 ± 8 days 
whilst wild type mice showed a duration of 8 ± 2 days). Data for male mice challenged 
with RML were not available. Table 6.3.1 and Figures 6.3.1 b, c, d and e show the onset 
times for ME7 and MRC2 transmissions to Hectd2-/- and control mice. However, there is 
a caveat to the MRC2 data because these mice suffered health issues concerning sore skin 
in the genital area, possibly due to incontinence-related wetness, which may be linked to 
prion disease. However, as this is not a well characterised sign of prion disease and thus 
mice could not be definitively diagnosed, these mice were required to be culled early, 
before a diagnosis of clinical prion disease could be made. Thus we cannot confirm that 
the onset symptoms were that of prion disease as these animals did not progress to 
diagnosis because criteria for early signs are not specific for prion disease.  
 
Table 6.3.1 shows that the incubation times for female Hectd2-/- and control mice 
challenged with RML were not statistically significant (Figure 6.3.2 a). ME7 transmission 
to male or female Hectd2-/- and control mice also did not show statistical significance in 
incubation times (Kaplan-Meier log-rank survival), Figure 6.3.2 b and c.  
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Table 6.3.1 Mean incubation times for Hectd2-/-  and WT mice  
Prion 
Strain 
Sex 
Line 
(n mice) 
Onset of first 
signs ± SD (days) 
p value 
Mean incubation 
time ± SD (days) 
p value 
RML 
Female 
Hectd2-/- 
(n=17) 
138 ± 0 
<0.0001 
161 ± 8 
0.32 
WT  
(n=17) 
150 ± 0 158 ± 2 
Male Data not available 
ME7 
Female 
Hectd2-/- 
(n=8) 
164 ± 0 
0.91 
165 ± 1 
0.15 
WT 
(n=13) 
164 ± 1 167 ± 4 
Male 
Hectd2-/- 
(n=9) 
167 ± 2 
0.34 
175 ± 5 
0.21 
WT 
(n=11) 
168 ± 3 175 ± 7 
MRC2 
Female 
Hectd2-/- 
(n=16)* 
179 ± 6 
0.28* 
178 ± 6† 
(n=4) 
n/a† 
WT 
(n=10)* 
177 ± 4 
186 , 175† 
(n=2) 
Male 
Hectd2-/- 
(n=6)* 
174 ± 4 
0.72* 
186† 
(n=1) 
n/a† 
WT 
(n=15)* 
173 ± 1 
180 ± 4† 
(n=12) 
Statistical analyses were performed using Kaplan-Meier log-rank (Mantel-Cox) tests (GraphPad Prism 6). 
*Group sizes include animals that showed multiple early (non-specific) signs of prion disease but did not 
progress to a confirmed diagnosis due to intercurrent health problems. †Statistical testing was not performed 
for diagnosis times as sample sizes were too small due to culling of animals before a diagnosis could be 
made, (shown by n/a = not applicable).  
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Figure 6.3.1 Kaplan-Meier curves for onset of first clinical signs for Hectd2 knockout mice. Wild type 
and Hectd2-/- mice were challenged with RML, ME7 and MRC2 prions and the first signs of disease onset 
plotted as the percentage of surviving animals against the number of days post inoculation. a) Shows the 
onset times for female Hectd2-/- and wild type (WT) following transmission of RML (p = < 0.0001, Log-
rank (Mantel-Cox) test). Data for male mice were unavailable. b) and c) Show the onset times for Hectd2-/- 
and wild type mice following transmission of ME7 prions. d) and e) Show onset times following 
transmission of MRC2 prions to Hectd2-/- and wild type mice. The group size includes animals that showed 
multiple early (non-specific) signs of prion disease but did not progress to a confirmed diagnosis due to 
health problems. Only onset data for RML transmission in female mice was statistically significant 
according to Kaplan-Meier log-rank (Mantel-Cox) test (GraphPad Prism 6). 
ME7 (female) ME7 (male) 
MRC2 (female) 
WT onset of first clinical signs 
Hectd2-/- onset of first clinical signs 
MRC2 (male) 
a 
b c 
d e 
RML (female) 
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Figure 6.3.2 Kaplan-Meier survival curves for Hectd2 knockout mice. Wild type and Hectd2-/- mice 
were challenged with RML, ME7 and MRC2 prions and plotted as the percentage of surviving animals 
against the number of days post inoculation. a) Shows diagnosis of disease for Hectd2-/- and wild type (WT) 
mice defined as the incubation time following transmission of RML. Data for male mice were unavailable.  
b) and c) show diagnosis of ME7 transmission to Hectd2-/- and wild type mice. Incubation time data for 
MRC2 transmission to Hectd2-/- and wild type mice are not shown due to small sample sizes as some mice 
were culled due to health concerns before a diagnosis of clinical disease could be made (see Table 6.3.1). 
 
 
6.4 Generation of Hectd2-overexpressing mice (Tg260+/+)  
The Hectd2 ORF was amplified from cDNA derived from brains of C57BL/6J mice, onto 
which the SalI and XhoI restriction sites were engineered. This was to facilitate cloning 
into the cosmid vector SHaCosTt, in which expression is driven by the hamster PrP 
promoter86. The construct was inserted into F2 CBA x C57BL/6J fertilised eggs by 
pronuclear microinjection and implanted into an F1 CBA x C57BL/6 recipient mother289. 
One founder was identified by screening genomic DNA extracted from tail biopsies by 
a 
ME7 (male) 
Hectd2-/- diagnosis 
WT diagnosis 
ME7 (female) 
RML (female) 
b c 
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PCR. The founder was bred to FVB/NHsd mice to establish the colony from which 
heterozygotes were generated. Wild type and homozygote mice were produced by inter-
crossing heterozygotes, which were subsequently distinguished by quantitative PCR. The 
resultant Tg260 mouse line thus was of a mixed genetic background comprised of CBA, 
C57BL/6J and FVB. Mixed genetic backgrounds provide less power to detect small 
differences and thus identification of small changes may be obscured. The level of mRNA 
expression of Hectd2 overexpressing mice was determined by real time RT-PCR, for 
which heterozygotes (Tg260+/-) were found to overexpress Hectd2 mRNA two fold 
relative to endogenous levels (Figure 6.4.1). Although Tg260+/+ mice were not tested for 
Hectd2 expression, by extrapolation it is anticipated that they may overexpress by 4 fold. 
    
 
Figure 6.4.1 Relative expression of Hectd2 overexpressing, Tg260, heterozygous mice. Expression 
levels of Hectd2 mRNA derived from the brains of wild type and Tg260+/- mice were measured by 
quantitative RT-PCR, relative to an endogenous control, GAPDH. The quantity of Hectd2 expressed by 
heterozygous mice was normalised to that expressed by wild type C57BL/6J mice, showing that Tg260+/- 
show a 2-fold relative expression of Hectd2. Group sizes for Tg260+/- are n=6 and 3 technical replicates for 
each, WT controls n=4 with 3 technical replicates (p = 1x10-5, t test). 
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6.5 Transmission of prions to Hectd2-overexpressing transgenic mice 
 
Tg260+/+ mice overexpressing Hectd2 and littermate wild type controls Tg260-/- were 
challenged with RML and ME7 prions in addition to a mouse adapted BSE strain, 
MRC2103, 287. Table 6.5.1 details the averages for the first signs of clinical onset and the 
mean diagnosis/incubation time. Figure 6.5.1 panels a-e show the onset of first signs for 
female and male Tg260+/+ mice and their respective controls to which RML, ME7 or 
MRC2 prions were transmitted. These mice showed no statistical differences with respect 
to their onset times relative to those shown by control mice (Kaplan-Meier log-rank 
(Mantel-Cox) tests). 
 
Figure 6.5.2 a, c and e shows the survival curves for RML, ME7 or MRC2 transmission 
in female mice, for which there are no significant differences between incubation times 
(Kaplan-Meier log-rank (Mantel-Cox) test. Similar data were observed for male mice for 
RML and MRC2 strains. However, transmission of ME7 to male Tg260+/+ mice showed 
a 13% reduction in incubation time (160 ± 11 days relative to wild types, 181 ± 21 days). 
This incubation time was significant at p = 0.004 log-rank (Mantel-Cox) test, Table 6.5.1 
and Figure 6.5.2 d. However, to account for the effects of multiple testing, a Bonferroni 
correction was applied to bring the 5% significance level to p<0.003. This reduction in 
incubation time for male Tg260+/+ mice to which ME7 was transmitted thus does not reach 
the significance level and may be considered of border line significance.  
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Table 6.5.1 Mean incubation times for Hectd2-overexpressing (Tg260+/+)  and WT mice  
Prion 
Strain 
Sex 
Line 
(n mice) 
Onset of first 
signs ± SD (days) 
p value 
Mean incubation 
time ± SD (days) 
p value 
RML 
Female 
Tg260 
(n=13) 
149 ± 10 
0.53 
156 ± 7 
0.08 
WT  
(n=11) 
149 ± 8 165 ± 14 
Male 
Tg260 
(n=9) 
149 ± 10 
0.96 
164 ± 15 
0.44 
WT  
(n=12) 
151 ± 10 160 ± 12 
ME7 
Female 
Tg260 
 (n=11) 
159 ± 10 
0.36 
173 ± 11 
0.11 
WT 
(n=13) 
154 ± 1 169 ± 6 
Male 
Tg260 
 (n=10) 
140 ± 11 
0.33 
160 ± 11 
0.004 
WT 
(n=10) 
151 ± 30 181 ± 21 
MRC2 
Female 
Tg260 
 (n=12) 
163 ± 13 
0.05 
182 ± 12 
0.30 
WT 
(n=12) 
177 ± 20 188 ± 15 
Male 
Tg260 
 (n=8) 
146 ± 32  
 
0.60 
 
182 ± 10 
0.96 
WT 
(n=12) 
155 ± 9 181 ± 9 
Statistical analyses were performed using Kaplan-Meier log-rank (Mantel-Cox) tests (GraphPad Prism 6).  
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Figure 6.5.1 Kaplan-Meier curves for onset of first clinical signs for Tg260, Hectd2-overexpressing 
mice. Wild type and Tg260+/+ mice were challenged with RML, ME7 and MRC2 prions and the first signs 
of disease onset plotted as the percentage of surviving animals against the number of days post inoculation. 
a) and b) Show the onset times for female and male Tg260+/+ and wild type (WT) mice following 
transmission of RML. c) and d) Show the onset times for Tg260+/+ and wild type mice following 
transmission of ME7 prions. e) and f) Show onset times for transmission of MRC2 prions to Tg260+/+ and 
wild type mice. Onset times for transmission with any prion strain were not statistically significant 
according to Kaplan-Meier log-rank (Mantel-Cox) test (GraphPad Prism 6).  
d c 
a b 
e  f 
Hectd2-overexpressing (Tg260) onset of first clinical signs 
WT onset of first clinical signs 
ME7 (female) ME7 (male) 
MRC2 (male) MRC2 (female) 
RML (male) RML (female) 
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Figure 6.5.2 Kaplan-Meier survival curves for Tg260, Hectd2-overexpressing mice.  Wild type and 
Tg260+/+ mice were challenged with RML, ME7 or MRC2 prions. Data are plotted as the percentage of 
surviving animals against the number of days post inoculation. Panels a-f show the incubation times for 
Tg260+/+ and wild type (WT) defined here as the point of diagnosis of disease following transmission of 
RML for female and male mice. a) and b) show transmission of RML to Tg260+/+ and wild types. c) and 
d) show ME7 transmission for which male Tg260+/+ incubation time  (p = 0.004, log-rank (Mantel-Cox) 
test), which is borderline significance following Bonferroni correction at the 5% significance level. e) and 
WT diagnosis 
Hectd2-overexpressing (Tg260) diagnosis 
diagnosis 
a b 
c d 
e f 
RML (female) RML (male) 
ME7 (female) ME7 (male) 
MRC2 (female) MRC2 (male) 
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f) show transmission of MRC2 prions to Tg260+/+ and wild type female and male mice. Data were 
analysed using the Kaplan-Meier log-rank (Mantel-Cox) test). 
 
 
6.6 Prion strains in infected mouse brains and histology 
In order to check if the modification of Hectd2 expression affects the strain type and that 
the prion strains that were inoculated retained their strain properties following 
propagation, Western blot analyses was performed on brains of infected animals. Figure 
6.6.1 shows the strain patterns of PrPSc  for RML, ME7 and MRC2 prions transmitted to 
Hectd2-/- or Tg260+/+ mice, left and right panels respectively.  Although not quantitative, 
the ratios appear to show the characteristic strain pattern typical of RML, ME7 and 
MRC2103, 287. This suggests that the strains did not change PrPSc type following replication 
in wild type mice or in the experimental model.  
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Figure 6.6.1 PrPSc type determination from infected mouse brains. 10% w/v of Hectd2-/- or Tg260+/+ 
(Hectd2-overexpressing) brain homogenates (n = 3 for each mouse line) were treated with proteinase K. 
The digested proteins were immunoblotted with anti-PrP ICSM35. a) Transmission of RML to Hectd2-/- 
and wild type C57BL/6J mice. b) Transmission of ME7 to Hectd2-/- and wild type C57BL/6J mice. c) 
Transmission of MRC2 to Hectd2-/- and wild type C57BL/6J mice. d) Transmission of RML to Tg260+/+ 
and wild type mice. e)  Transmission of ME7 to Tg260+/+ and wild type mice. f) Transmission of MRC2 to 
Tg260+/+ and wild type mice No differences in prion strains were observed between Hectd2-/- or Tg260+/+ 
over-expressors and their respective controls. 
 
Histopathological analyses were performed on brain sections from Hectd2-/-, Tg260+/+, and 
their respective wild type controls for each prion strain transmitted (Figures 6.6.2 – 6.6.7). 
These sections were derived from brains taken at the end stage of disease. The pattern of 
PrPSc deposition, neuronal loss and spongiosis was similar between Hectd2-/- and wild 
type mice for each transmission. Figure 6.6.2 shows the histopathology in Hectd2-/- and 
WT mice challenged with RML, for which mild spongiform degeneration in the thalamus 
and neuronal loss in the hippocampus were observed, typical of RML transmissions. 
Figure 6.6.3 shows characteristic ME7 transmission in that mild neuronal loss in the 
hippocampus and very mild spongiform degeneration in the thalamus were observed in 
wild type mice and similar changes were seen in Hectd2-/- mice also challenged with ME7. 
d 
e 
f 
a 
b 
c 
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Evaluation of MRC2 transmissions found that in wild type mice, mild spongiform 
degeneration in the thalamus and moderate neuronal loss in the hippocampus was 
observed (Figure 6.6.4). Hectd2-/- transmission of MRC2 showed similar spongiform 
changes in the thalamus and similar neuronal loss (Figure 6.6.4). Transmission of RML 
to Tg260+/+ and wild type mice showed mild neuronal loss and mild spongiosis (Figure 
6.6.5). Transmission of ME7 to Tg260+/+ and wild type mice showed variable neuronal 
loss and spongiosis (Figure 6.6.6). MRC2 transmissions to Tg260+/+ and wild type mice 
showed severe neuronal loss and variable spongiosis (Figure 6.6.7). However, overall, 
neuropathologic examination found that there were no clear differences between the two 
groups of mice for a given prion strain.  
 
 
      
Figure 6.6.2 RML transmission to Hectd2-/-: histological analysis. Histological features of RML 
transmission to wild type C57BL/6J controls (A-C) and Hectd2-/- (D-F). Panels A and D show the 
distribution of PrPSc using immunohistochemistry with anti-PrP ICSM35 monoclonal antibody. Panels B, 
C, E and F were stained with haematoxylin and eosin to show spongiform degeneration and neuronal loss 
in the thalamus and hippocampus. There appears to be no differences in the pattern of PrP distribution and 
spongiosis between wild type and Hectd2-/- mice. Scale bar corresponds to 3 mm (A, D), 330 µm (B, E) and 
660 µm (C, F). 
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Figure 6.6.3 ME7 transmission to Hectd2-/-: histological analysis.  Histological features of ME7 
transmission to wild type C57BL/6J controls (A-C) and Hectd2-/- (D-F). Panels A and D show the 
distribution of PrPSc using immunohistochemistry with anti-PrP ICSM35 monoclonal antibody. Panels B, 
C, E and F were stained with haematoxylin and eosin to show spongiform degeneration and neuronal loss 
in the thalamus and hippocampus. The pattern of PrP distribution, degree of neuronal loss and spongiosis 
are similar between wild type and Hectd2-/- mice. Scale bar corresponds to 3 mm (A, D), 330 µm (B, E) and 
660 µm (C, F). 
      
Figure 6.6.4 MRC2 transmission to Hectd2-/-: histological analysis.  Histological features of MRC2 
transmission to wild type C57BL/6J controls (A-C) and Hectd2-/- (D-F). Panels A and D show the 
distribution of PrPSc using immunohistochemistry with anti-PrP ICSM35 monoclonal antibody. Panels B, 
C, E and F were stained with haematoxylin and eosin to show spongiform degeneration and neuronal loss 
in the thalamus and hippocampus. Overall, there are no differences in the pattern of PrP distribution and 
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spongiosis between wild type and   Hectd2-/- mice following transmission of MRC2. Scale bar corresponds 
to 3 mm (A, D), 330 µm (B, E) and 660 µm (C, F). 
 
         
Figure 6.6.5 RML transmission to Tg260+/+: histological analysis. Histological features of RML 
transmission to Tg260+/+ (A-C) and wild type controls (D-F). Panels A and D show the distribution of PrPSc 
using immunohistochemistry with anti-PrP ICSM35 monoclonal antibody. Panels B, C, E and F were 
stained with haematoxylin and eosin to show spongiform degeneration and neuronal loss in the 
hippocampus. C and F show detail from the hippocampus (inset in B and E, respectively). Arrows indicate 
apoptotic cells. There appears to be no differences in the pattern of PrP distribution and spongiosis between 
wild type and Tg260+/+ mice. Scale bar corresponds to 2 mm (A, D), 400 µm (B, E) and inset (C, F) is 100 
µm.  
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Figure 6.6.6 ME7 transmission to Tg260+/+: histological analysis. Histological features of ME7 
transmission to Tg260+/+ (A-C) and wild type controls (D-F). Panels A and D show the distribution of PrPSc 
using immunohistochemistry with anti-PrP ICSM35 monoclonal antibody. Panels B, C, E and F were 
stained with haematoxylin and eosin to show spongiform degeneration and neuronal loss in the 
hippocampus. C and F show detail from the hippocampus (inset in B and E, respectively). Arrows indicate 
apoptotic cells. There appears to be no differences in the pattern of PrP distribution and spongiosis between 
wild type and Tg260
+/+
 mice. Scale bar corresponds to 2 mm (A, D), 400 µm (B, E) and inset (C, E) is 100 
µm. 
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Figure 6.6.7 MRC2 transmission to Tg260+/+: histological analysis. Histological features of MRC2 
transmission to Tg260+/+ (A-C) and wild type controls (D-F). Panels A and D show the distribution of PrPSc 
using immunohistochemistry with anti-PrP ICSM35 monoclonal antibody. Panels B, C, E and F were 
stained with haematoxylin and eosin to show spongiform degeneration and neuronal loss in the 
hippocampus. C and F show detail from the hippocampus (inset in B and E, respectively). Arrows indicate 
apoptotic cells. There appears to be no differences in the pattern of PrP distribution and spongiosis between 
wild type and Tg260 mice. Scale bar corresponds to 2 mm (A, D), 400 µm (B, E) and inset (C, F) is 100 
µm. 
Results summary 
The data show that incubation times were not modified by Hectd2 deficient mice, 
although the duration of disease and the first signs of clinical symptoms differed 
statistically for RML transmission to female Hectd2-/- relative to wild type mice, 
suggestive of a protective role for Hectd2. Transgenic overexpressing Hectd2 (Tg260+/+) 
mice showed that females did not modify incubation time with any strain of prion. 
However, male Tg260+/+ to which ME7 prions were transmitted, decreased incubation 
time by 13% relative to wild type mice. However, taking into consideration the effects of 
multiple testing, this did not reach the significance level required for it be considered a 
real effect but is suggestive that Hectd2 may serve a modulating role. This was not 
replicated for female Tg260+/+ mice and nor for any other prion transmissions. Together 
these data show that Hectd2 does not modulate genetic susceptibility to incubation time 
universally but may have an effect in a strain and sex dependent manner. 
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7 Discussion  
 
7.1 Discovery of novel candidate interactors of Hectd2  
 
Prion diseases are fatal neurodegenerative diseases, characterised by a clinically silent 
incubation period that can exceed 50 years in humans19. This variability has been 
attributed to a number of factors, with genetic composition serving a major role. Hectd2 
was identified as one of these genes using the Northport Heterogeneous stock of mice, by 
which it was found to be linked to prion disease incubation time120. Further analysis 
showed a significant upregulation of Hectd2 at the terminal stage of disease in prion-
infected mouse brains relative to normal brains, which may be suggestive of a protective 
role. The authors performed a human association study and identified an association 
between HECTD2 haplotypes and susceptibility to the acquired human prion diseases, 
vCJD and kuru120. This was the first demonstration of a mouse incubation time candidate 
gene that influences susceptibility to human prion diseases. Thus the functional analysis 
of such genes and the molecular networks in which they lie, may shed light on the 
underlying mechanism of incubation period and outline new targets for therapy. 
 
The data presented in this thesis have attempted to characterise Hectd2 with respect to its 
possible roles in prion pathology. By homology to other family members, Hectd2 is an 
HECT E3 ubiquitin ligase, with no other functional information assigned162. E3 ubiquitin 
ligases are enzymes that determine the fate of a protein at the post-translational level by 
ubiquitination160. Ubiquitination regulates a plethora of cellular processes including 
protein quality control via proteasome or autophagy-mediated degradation, cell cycle, 
transcription, DNA repair, apoptosis, endocytosis and trafficking of transmembrane 
proteins by serving as a signal for downstream effectors to direct its fate160, 162, 165. E3 
ligases have been implicated in the pathogenesis of a number of neurodegenerative 
diseases, including Parkinson’s, Alzheimer’s and polyglutamine diseases230, 237, 290-292. 
Thus E3 ligases in concert with their target substrates are important in orchestrating the 
downstream pathways that they operate in, deregulation of which may underlie 
pathogenesis. The discovery of Hectd2 as a candidate gene that modulates prion disease 
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incubation time substantiates the role of E3 ligases in neurodegeneration. In order to 
gauge an understanding of the underlying mechanism by which prion pathogenesis is 
affected, a functional analysis of Hectd2 is required to delineate the downstream processes 
that it governs. 
 
The yeast two-hybrid system was selected to initiate a screen to search for candidate 
interactors of Hectd2 as prior knowledge of its binding partners is not required. The use 
of yeast as a host for screening provides an in vivo environment that has a greater relative 
resemblance to mammalian systems than a bacterial host. The N-terminal region of E3 
ligases is thought to dictate the substrate specificity of a given ligase162, 172. Thus for 
Hectd2, the 414 residues preceding the HECT domain, i.e. the putative substrate binding 
domain which was termed Hect414, was used to screen for interactors of Hectd2.  
 
The yeast two-hybrid system was successfully applied to yield an initial 130 positive 
colonies bearing candidate binding partners of Hectd2. Large-scale screening assays 
typically capture false positive interactors and the yeast two-hybrid system is no exception 
in this regard293. Prey proteins that were detected may activate the reporter genes 
autonomously in the absence of the Hectd2 bait. Furthermore colonies identified as 
containing a positive interaction may indeed harbour more than one prey protein, where 
only one prey protein may actually be responsible for the two hybrid interaction with 
Hectd2. Such false interactors were eliminated by a series of additional screening levels. 
Transfer of all the positive colonies to a higher stringency selection media sustained only 
35 of the 130 colonies. End sequencing of each isolated prey plasmid identified five of 
these candidates as duplicates. This was followed by comprehensive sequencing, which 
identified that one candidate, Nrp1, was not in frame with the GAL4 AD, thereby 
producing a spurious non-functional protein. Nt5dc3, also did not reach the next level of 
screening as it was found to be a match to the 3’ UTR rather than the coding section, 
which was subsequently identified as a false positive, when co-expressed with Hect414 
independently of the library screen, thereby providing confidence in the screening 
methods applied. The prey cDNA for another candidate was identified as a match to the 
genomic region on chromosome 15, position 832157 – 832830 rather than an mRNA 
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transcript. It is possible that this may represent a new cDNA sequence that is not available 
in the database or perhaps it may be the result of genomic contamination of the library. 
Although it may be premature to eliminate this candidate at this stage, the main purpose 
of the search for Hectd2 substrates is to identify those candidates that are involved in prion 
disease. Due to the lack of information available for this candidate, the decision was made 
to not include it in the follow-up analyses as more promising candidates were available 
for investigation. The remaining 27 candidates were subjected to independent co-
transformation experiments to ascertain whether the interactions captured by the library 
screen were maintained in yeast expressing both the prey and Hectd2. Each candidate was 
also tested for its potential to autonomously activate the reporter genes, of which 7 
autoactivators were found. This generated a final list of 20 novel putative binding partners 
of Hectd2.  
 
These candidates represent proteins of a number of different molecular pathways and 
some that may be implicated in related pathways such as autophagy and endocytic 
trafficking where Sh3glb1 and Stambp serve roles in both of these functions266, 267, 280-282. 
Pacsin2 and Stmn2 are implicated in the regulation of microtubule stability, however, 
whether their functions are complementary or redundant is not yet known146, 273. Sept7 is 
a cytoskeletal GTPase that is required for normal organisation of the actin cytoskeleton276, 
277, 294. It is possible that Hectd2 has a predominant role in autophagy and cytoskeletal 
maintenance as the functions of a number of the interactions identified include those that 
are implicated in these pathways. For example, G protein beta subunit-like (Gbl) also 
known as mLST8, is a component of the mTOR complexes 1 and 2 (mTORC1 and 
mTORC2, respectively), of which autophagy and regulation of the actin cytoskeleton are 
downstream pathways295, 296. The Hectd2 candidate interactor, Cop9 subunit 4, is a 
component of the Cop9 signalosome, an evolutionary conserved multi-protein complex 
for which functions are still being determined. Recent work has identified that the Cop9 
signalosome regulates proteasome-mediated degradation as well as autophagy297. Yeast 
two-hybrid screening also identified the candidates, Ppp2ca and Strn3, which also interact 
with each other; Strn3 forms a regulatory unit of Ppp2a, which directs the downstream 
activity of Ppp2ca298. Ppp2ca is a serine/threonine phosphatase that regulates a plethora 
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of processes including gene transcription, protein translation, cell growth and apoptosis 
and most interestingly it serves a regulatory role in neuronal autophagy299, 300. However, 
the majority of the candidate genes do not have clearly defined functions and thus it is 
difficult to group the remaining candidates into functionally related pathways. Whether 
Hectd2 interacts with all 20 of these proteins is yet to be determined, but this is plausible 
because E3 ligases regulate the specificity of a multitude of processes, which are mediated 
through interaction with their substrates162. Whilst Hectd2 may have substrates outside of 
the CNS, it is expected that those interactions that occur within the CNS may be 
implicated in prion pathology based on disease topography and it is expected that very 
few of these interactions will show a modulatory role in disease. 
 
It is also of note that the genes listed in Table 3.6.1 may not represent a comprehensive 
list of Hectd2 interactions formed in vivo. This is because the two-hybrid system relies on 
nuclear targeting of bait and prey proteins to activate the GAL4 responsive reporter genes, 
which may be challenged if a prey protein harbours a strong non-nuclear or extracellular 
signal. The candidate prey proteins may only be expressed in a specific cell compartment 
or interact with Hectd2 in a given subcellular location, which may define the interactions 
that it makes. It may be that some of these interactors are false positives; if prey proteins 
that are physiologically expressed in a particular tissue or compartment or at a particular 
time during development are induced in yeast, we may find that it binds to the bait 
although such an interaction may not normally occur293. Thus, the genes identified in this 
screen may not be representative of all Hectd2 interactions that occur in vivo.  
 
A further caveat generated by the candidates from the screen is that the prey proteins are 
not all full length proteins, but fragments of cDNA. Although the expressed fragment may 
bind to Hect414, this may be due to the lack of steric hindrances in the folding of the 
protein for which the HECT domain has been omitted, thus the entire ORF may not 
replicate the same binding. Of particular importance is the correct folding of proteins into 
their native structures, which may be challenged in the absence of a mammalian cell line 
context. Yeast cells may not facilitate the correct folding of a protein into its quaternary 
conformation, which may require machinery specific to mammalian cells. These issues 
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were addressed by validating the interactions of selected candidates with both Hect414 
and Hectd2 by co-immunoprecipitation in the COS-7 mammalian cell line. These 
fibroblast-like kidney cells264 are a commonly used transfection host and present an 
environment that is capable of performing complex post-translational modifications that 
would be observed physiologically and may more closely represent Hectd2 interactions 
in humans.  
 
Five candidates were selected for confirmation of their interaction with Hect414 and their 
full length proteins with Hectd2. Sh3glb1, Stmn2, Pacsin2, Stambp and Sept7 were 
chosen to be tested based on their possible functional or topographical significance in 
neurons that may link the candidates with disease pathology. The decision to overexpress 
the putative interacting proteins with epitope tags was made owing to the absence of 
validated antibodies for Hectd2 or the binding partners. Through this method, it has been 
possible to determine that Sh3glb1, Stmn2, Pacsin2 and Stambp bind to both the putative 
substrate binding domain, Hect414, as well as the full length protein, Hectd2. The binding 
of Hect414 to truncated Sept7, derived from the cDNA library used in the library screen 
has also been demonstrated. However, the binding of full length Sept7 to Hectd2 is yet to 
be determined. 
 
All co-immunoprecipitation assays performed were confirmed by replication of the 
experiment for each candidate, thereby validating findings from the yeast two-hybrid 
screening. Overexpressing putative interactors may not represent a real physiological 
event due to the fold increases in expression relative to the endogenously expressed 
proteins. It is thus important that these interactions are confirmed with the endogenous 
proteins. These interactions could also be confirmed in brain tissue as prion pathology 
specifically affects the brain. However, overexpression of putative binding proteins also 
runs the risk of detecting interactions for which the proteins may have been mislocalised 
and thus spuriously interact. This can be addressed by the use of fluorescent tags to 
antibodies to the endogenous proteins to visualize subcellular localisation by microscopy 
or by FACS sorting to identify whether two proteins that are thought to interact are 
expressed in the same vicinity.  Yeast two-hybrid screening relies on the direct interaction 
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between bait and prey proteins and this suggests that it is unlikely that an ancillary protein 
bridges the interaction between Hectd2 and its putative interactor. However, this can be 
confirmed by mass spectrometric analyses of the proteins within a co-immunoprecipitated 
sample.  Despite these caveats, this is the first demonstration of interactome mapping for 
Hectd2, providing an insight into the biological networks of Hectd2. 
  
7.2 Mapping the region of Hectd2 binding 
 
The yeast two-hybrid system was further exploited to map the region to which substrates 
bind Hectd2. C-terminal deletion mutants of Hect414, spanning 180 (Hect180) or 330 
(Hect330) residues from the N-terminus were co-expressed with each candidate for which 
two-hybrid interactions were determined by detection of reporter gene expression. It was 
found that Hect180 did not bind to any of the candidates that interacted with Hect414, 
suggesting that the substrate binding domain is upstream of residue 180 from the N-
terminus. The C-terminal mutant, Hect330, retained its interaction with four of the 
candidates, Sh3glb1, Zbed4, Sh3yl1 and LOC100046859, thus providing an indication of 
where the contact points for substrate interaction may be harboured. From this data we 
can conclude that for some substrates, i.e. Sh3glb1, Zbed4, Sh3yl1 and LOC100046859, 
residues 180-330 of Hectd2 are sufficient for interaction but the majority of candidates 
require residues 331-414. It has thus been possible to confine an area to which putative 
substrates bind to Hectd2. It is hypothesised that residues 180-414 residue region may 
form an integral component of the Hectd2 substrate binding domain (Figure 3.7.2). This 
could be subject to further investigation by generating an extensive series of deletion 
mutants across the length of Hect414. The binding chemistry of these mutants can then 
be analysed using co-immunoprecipitation assays with each candidate interactor in 
mammalian cells. Combining such approaches with biophysical techniques such as X-ray 
crystallography to co-crystallise Hectd2 and its substrate may provide insight into the 
functional mechanism through which it operates.   
 
 
 
156 
 
7.3 Mechanism of action of candidate genes in prion propagation and pathology  
 
7.3.1 Sh3glb1 modulates prion propagation 
 
Knockdown PK1/2 cell lines for 4 candidate genes in their full length forms and Hectd2 
were made and tested using the Scrapie Cell Assay (SCA). This assay measures the 
susceptibility of cells to prion infection by quantifying the level of PrPSc-infected cells 
which have been cultured over time. Thus stable rather than transient knockdown was 
chosen to achieve sustainable gene knockdown over the duration of the assay. The SCA 
allows the detection of modulatory effects exerted by the manipulation of gene expression 
with respect to infectivity and by extrapolation, propagation and clearance of prions. The 
SCA assay is the only available in vitro method to delineate a phenotypic function of a 
gene in prion disease for which the alternative is to generate mouse models, which are 
costly and time consuming whilst the SCA is an order of magnitude more rapid and less 
costly253. The SCA uses a derivative of the N2a neuroblastoma cell line, (PK1/2), and thus 
of neuronal lineage, which can be used to model characteristics of prion infection 
following gene manipulation. The advantage of using this assay is that the PK1/2 cells are 
immortal and thus prion infection over time can be measured. However, this also forms 
its disadvantage because prion infection cannot be sustained in neurons without ultimately 
leading to death.  
 
A major limitation of the SCA is that it does not fully model the disease process in the 
brain and it may not report genes that may be important in pathogenesis and those that 
function outside of the CNS. Also, the SCA has been highly optimised for the RML strain 
and for the PK1/2 cell line, which may obscure the detection of genes that do not work in 
concert with the RML strain in these cells. The changes that are detected in the SCA also 
do not necessarily correlate with incubation time thus genes that may have a genuine 
effect on incubation time may not report in the SCA. Thus, the SCA models a narrow 
phenotype of the disease process but aspects that are considered fundamental, i.e. 
infection, propagation and clearance. The SCA thus serves as a triage for the identification 
of genes that show profound effects in the fundamental aspects of disease. The SCA 
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therefore allows us to follow prion infection in cells that have altered gene expression for 
the gene of interest for which a proof of principle has been provided in that PrPC 
knockdown in the SCA results in no propagation of prions and thus PrPC is necessary for 
infection and propagation301. The SCA can thus indicate whether a given gene presents a 
positive or negative role in the modulation of susceptibility to infection. 
 
In Hectd2 knockdown PK1/2 cells, a significant increase in PrPSc signal was observed in 
two independent cell lines. Sh3glb1 knockdown PK1/2 cells also showed a highly 
significant increase in PrPSc signal. This suggests that both Hectd2 and Sh3glb1 modulate 
susceptibility to prion infection and affect prion propagation in the same direction, which 
may indicate that Hectd2 and Sh3glb1 function in the same pathway. Although data for 
Sh3glb1 was only demonstrated for the one cell line available, follow up work has 
confirmed this data with two additional, independent Sh3glb1-knockdown PK1/2 cell 
lines (unpublished data, Dr Craig Brown, MRC Prion Unit, London).  
 
To date, prion diseases of humans or animals have not been linked to Sh3glb1, however 
there is a wealth of data indicative of a modulating role in neurodegenerative disorders. 
Sh3glb1 alias Endophilin B1 or Bif-1 (Bax-interacting factor) is a member of the 
endophilin family of cytosolic proteins and was discovered as the binding partner of the 
pro-apoptotic protein Bax through yeast-two-hybrid screening302, 303. Sh3glb1 has been 
reported to orchestrate apoptosis and mitochondrial morphology with substantial evidence 
pointing towards a key role in the regulation of autophagy304-306. Deregulation of 
autophagy has been implicated in a number of neurodegenerative diseases and has even 
been proposed as a possible cause in Parkinson’s disease183, 198. Wong and others found 
that Sh3glb1 is phosphorylated by the neuronal activator Cdk5 at Thr145 to induce 
autophagy in models of Parkinson’s disease267. Phosphorylation of Sh3glb1 leads to its 
interaction with Beclin 1, which in turn regulates the activation of class III PI3 kinase 
(PI3KIII), to promote the biogenesis of autophagosomes267, 307, 308. The authors observed 
autophagy-mediated neuronal loss in these models, suggestive of a role of Sh3glb1 in 
concert with Cdk5 in the pathology of Parkinson’s disease. It is thus plausible that the 
interplay between Cdk5 and Sh3glb1 may coordinate autophagic processes in prion 
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diseases to mediate PrPSc clearance and that deregulation of the pathway may abrogate 
the route to clearance of prions, giving way to prion accumulation.  
 
Concurring with the theme of autophagy, Sh3glb1 has also been found to be a regulator 
of mitophagy, which is the selective autophagic degradation of mitochondria309. 
Takahashi and others found that loss of Sh3glb1 suppressed mitophagy in Parkin-
expressing mouse embryonic fibroblasts following treatment with the mitochondrial 
uncoupler, carbonylcyanide m-chlorophenylhydrazone, (CCCP)309. Mitochondrial 
dysfunction is an emerging theme in neurodegenerative diseases and has been postulated 
as a key event underlying pathogenesis in Alzheimer’s and Parkinson’s diseases310, it is 
thus possible that Sh3gb1 may serve a modulating role. Thus Sh3glb1 knockdown in 
PK1/2 cells may impair autophagy/mitophagy, affecting neuronal health and this may be 
a contributing factor to the increased level of cells that are infected relative to controls.        
This evidence provides strength to the notion that Sh3glb1 is important in orchestrating 
autophagy and mitophagy, and that dysfunction may be associated with pathology in prion 
disease. Interestingly, Sh3glb1 has been shown to regulate NGF/TrkA endocytic 
trafficking and is involved in the activation of the ERK module on endosomes to mediate 
downstream TrkA effectors such as NGF-induced neurite growth265, 266. It is thus plausible 
that Sh3gbl1 may also regulate the survival effects of neurotrophins by trafficking of TrkA 
and possibly other neurotrophic receptors and may promote neuronal survival. 
The precise mechanism by which prion propagation is sustained within knockdown 
Sh3glb1 cells is yet to be determined, however key evidence shown by other groups point 
towards a pathway that may involve autophagic processes. It is possible that Hectd2 
ubiquitinates Sh3glb1 to promote autophagy induction following neurotoxic stress based 
on the observations by Wong et al267. These authors found that in the absence of 
neurotoxic insult, Cdk5-mediated phosphorylation of Sh3glb1 did not trigger 
autophagy267. Challenge with RML prions in the SCA thus supports this hypothesis as 
knockdown of Sh3glb1 may impair induction of autophagy-mediated clearance of PrPSc, 
facilitating the accumulation of prions and thus the increase in propagation. I propose that 
Hectd2 may ubiquitinate Sh3glb1 for proteasomal degradation to regulate basal levels of 
159 
 
Sh3glb1 and that under pathological conditions, this switch is shifted towards enhancing 
autophagy. This notion is in line with the observed increase in prion infection in Hectd2 
knockdown lines, which may be the result of a failure to ubiquitinate accumulating 
Sh3glb1. I hypothesise that the sole accumulation of Sh3glb1 may not be sufficient to 
activate autophagic processes and that this is dependent on ubiquitination by Hectd2. Thus 
the increase in PrPSc signal observed in knockdown Hectd2 PK1/2 lines may be the result 
of an inability to activate autophagic processes. 
 
7.3.2 Sept7 modulates prion propagation 
 
Application of the SCA on PK1/2 cells in which Sept7 was knocked down, showed a 
significant increase in prion propagation. These results were supported by two 
independent knockdown lines, providing confidence that Sept7 modulates prion 
propagation. However, one knockdown line for Sept7 showed a reduction in prion 
propagation. This conflicting result may be due to off-target effects caused by artefactual 
dysregulation of non-target genes by the shRNA used. This can occur when there are short 
sequence matches between the shRNA and a non-target gene311. 
 
Sept7 is a member of the highly conserved septin family of polymerising GTPases, which 
form homo- and heterologous complexes that organise into filaments276, 277. Septins serve 
as scaffolds for the recruitment of other proteins and are important for maintaining 
neuronal integrity312, 313 and they have been reported to participate in a myriad of cellular 
processes from cell division, vesicle trafficking, cytoskeletal organisation, dendrite 
branching to dendritic spine morphology276, 277, 313-317.  
 
Sept7 localises at presynaptic terminals and dendritic branch points in neurons, suggestive 
of a role in pre and postsynaptic nerve terminals313. Based on this topography, it may be 
that reduction in Sept7 concentrations at synapses might have an effect on its downstream 
processes. Septins are enriched in the CNS283, 313, 318, 319, where they have been implicated 
in exocytosis278, 313, 320, 321. Sept7 in mammalian brains has been observed to co-precipitate 
with the exocyst, a vesicle tethering complex that also complexes with Sept1, - 4 and -
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6277. This septin-exocyst complex has been suggested to be involved in the recruitment of 
secretory vesicles to the appropriate exocytic targeting site and cellular location, and thus 
may regulate vesicle trafficking and the delivery of proteins which may affect downstream 
exocytic processes that may be important in normal functioning of the cell278, 313.  
 
Recent work has identified that Sept7 functions downstream of p35, the neuronal activator 
of Cdk5, and has been associated with a decreased expression in schizophrenic brains322, 
323.The authors found that in a mouse model overexpressing p25, Sept7 levels were 
upregulated and this was accompanied by an increase in dendritic spine count, which may 
be accounted for by the increase in Sept7 levels322. Generation of p25 is mediated by p35 
cleavage by calpain and has been regarded as an event that leads to neurotoxicity324. Thus 
the finding that Sept7 is upregulated when p25 is overexpressed is suggestive that Sept7 
may be neuroprotective. Engmann et al., suggest that the Cdk5 activator p35, regulates 
the expression of synaptic proteins, such as Sept7323. p35 is a known activator of 
autophagy325 and thus its cleavage to p25 may well be a regulatory factor that might 
downregulate autophagy by depleting p35 levels. It has been reported that p25 deregulates 
Cdk5 activity via constitutive activation, thereby altering its cellular location and substrate 
specificity which may ultimately lead to neuronal dysfunction326. It is thus plausible that 
loss of Sept7 may lead to accumulation of p25, to upregulate Sept7 expression. Generation 
of p25 may alter Cdk5 induction of autophagic mechanisms, disabling cells from being 
relieved of their prion burden. If Sept7 does have a protective role in this regard, whether 
its downstream functions include appropriate activation of autophagy or activation of 
alternative mechansims that switch on autophagic processes is yet to be determined. 
However, such a hypothesis may implicate Sept7 and Sh3glb1 in convergent pathways. 
 
Thus the increase in prion propagation observed in PK1/2 cells knocked down for Sept7 
may be the result of abrogation of normal Sept7 function. Although it is expected that 
knockdown of Hectd2 would result in an opposing effect, the increase in propagation 
observed in Hectd2 knockdown cells may be accounted for by the accumulating Sept7 
that is no longer subject to turnover by Hectd2, abnormal expression of which could also 
deregulate normal Sept7 function. Whether vesicle trafficking mediated by Sept7 and 
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other septins converges with endocytic trafficking mediated by Sh3glb1 will be an 
interesting point of investigation. The effect of Hectd2 knockdown may represent the 
cumulative effect of deregulated functions of Sept7 and Sh3glb1 and that of any other 
substrates of Hectd2.  
 
Although it may be intuitive that Hectd2 knockdown in the SCA results in an opposing 
effect to that observed by knockdown of its substrates, Sept7 or Sh3glb1, there are 
explanations that counter this. Sept7 or Sh3glb1 may be reliant on Hectd2-dependent 
ubiquitination to target each of these substrates to activate their downstream pathways. 
When Hectd2 is knocked down, Sept7 or Sh3glb1 may not be functionally effective 
without the ubiquitin signal conferred by Hectd2. It may be that the interaction of Hectd2 
with a substrate other than those investigated here, may have an opposing effect to that of 
Sh3glb1 and/or Sept7. This might mean that knockdown of Hectd2 may accumulate 
Sh3glb1 and Sept7 but the accumulation of other Hectd2 substrates may pose a stronger 
effect that is permissive for prion infection. If Sept7 or Sh3glb1 do in fact accumulate, 
this may be suggestive that the primary function of Hectd2 is to direct these substrates for 
degradation although it does not rule out the possibility that it can target substrates to 
activate a particular pathway. 
 
Septin proteins have been implicated in a diversity of neurodegenerative diseases detailed 
below, positioning Sept7 as a plausible candidate gene for prion disease modulation. 
Sept7 has been recorded as an interactor of CD2AP, a recently identified susceptibility 
gene for Alzheimer’s disease327, 328. Furthermore, in Alzheimer’s disease, Sept4, Sept1 
and Sept2 were identified in neurofibrillary tangles283. Sept9 has been identified as a 
disease causative gene for hereditary neuralgic amyotrophy329, suggesting that the septins 
may serve a key function in the CNS. The septins have also been implicated in Parkinson’s 
disease as Sept4 and Sept5 were identified as substrates for Parkin330, 331. Interestingly, 
Sept4 deficiency diminishes dopaminergic neurotransmission and enhances alpha 
synuclein mediated neurotoxicity by exacerbating alpha synuclein aggregation330, 
suggesting that the septins may serve a protective role, although the underlying 
mechanism remain elusive. Whether Sept7 modulates neurotransmission and impacts on 
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neurotoxicity in prion disease is yet to be determined but data from the SCA indicates a 
protective role for Sept7 and it is thus tempting to speculate that Sept7 may help to protect 
against prion infection.  
 
To conclude there is insufficient evidence to rule out any of these proposed mechanisms 
by which neurodegenerative events in prion disease may occur. Genes that operate 
downstream of Hectd2 may collectively contribute to the increase in propagation seen in 
Hectd2 knockdown cells. It is expected that manipulation of gene expression of Sept7 or 
Sh3glb1 would deregulate the effectors in the pathways that they function, which may 
result in altered cell metabolism and neuronal health. 
 
7.3.3 Stambp, Pacsin2 and Stmn2: possible candidate genes that modulate prion 
propagation 
 
The results of the SCA for Stambp and Pacsin2 knockdown cells are inconclusive because 
although they showed modulatory effects in prion propagation, there was only one cell 
line for each gene that demonstrated this. PK1/2 cells knocked down for Stambp, showed 
an increase in prion propagation in one out of two independent cell lines. Pacsin2 
knockdown reduced prion propagation in one out of three cell lines, suggesting that 
Pacsin2 may not be a promising candidate in the modulation of prion pathology, although 
this cannot yet be ruled out. These conflicting results may be due to off-target effects 
caused by sequence complementarity between the shRNA used and non-target genes311. 
Although from these preliminary results it seems that Pacsin2 and Stambp may not have 
modulatory roles, until support is provided for these data by at least a further independent 
cell line targeted for both of these genes, it is difficult to gauge the direction, if any, in 
which prion propagation is affected.  
 
Failure to report in the assay does not render these genes irrelevant in prion disease due 
to the limitations of the SCA that were described earlier. However, as the aims of this 
project were to identify genes that are important in modulating the fundamental aspects 
of prion disease, modelled in the SCA, it has thus been possible to triage the candidate 
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genes, for which Stambp and Pacsin2 may not have an effect as profound as Sh3glb1 and 
Sept7. Although Hectd2 may have a number of different substrates, it is likely that very 
few of these interactions, perhaps one or two, will be important in prion disease. Thus it 
is unsurprising that all of these candidate genes have not shown an effect in the SCA and 
that Sh3glb1 and Sept7 may be the only candidates that confer a modulatory role. 
 
As Stambp and Pacsin2 remain as possible candidates in prion disease, their functions are 
thus discussed herein. Stambp, also known as AMSH (Associated Molecule with the SH3 
domain of STAM) is a deubiquitinating enzyme that associates with ESCRT-I and 
ESCRT-III complexes, which mediate the sorting and trafficking of ubiquitinated cargoes 
for lysosomal targeting281, 282, 332-334. It has been reported to have a positive regulatory role 
in autophagy mediated degradation and is known to specifically deubiquitinate lysine 63-
linked ubiquitin chains, which have been reported as targets of the autophagy-lysosomal 
pathway335. Recent evidence has linked Stambp to a central role in the CNS, where 
Stambp dysfunction leads to missorted ubiquitinated cargoes in vitro and severe 
neurodegeneration in vivo, indicative of a key role in the CNS269, 270.  
Pacsin2 or protein kinase C and casein kinase substrate in neurons protein 2, is a 
ubiquitously expressed protein274 for which a role in neuron morphogenesis has been 
reported. Pacsin2 is involved in actin cytoskeleton organisation and may regulate 
vesicular traffic272, 274. Pacsin2 has also been reported to regulate microtubule growth273. 
Interestingly, PrPC has also been shown to bind tubulin, which inhibits microtubule 
assembly by inducing tubulin oligomerisation275, 336-338. Thus PrPC can serve as a 
microtubule destabilizing factor, mirroring Pacsin2 in its role in regulating microtubule 
stability, substantiating the role of microtubule stability in prion pathogenesis337, 338. 
The effect of Stmn2 on prion propagation has not yet been established. However, this 
candidate gene has been identified as a vCJD risk factor in an independent GWAS study 
by Mead et al., whilst more recently Lloyd et al, found that it associated with incubation 
time in mice. Stmn2 is a microtubule-destabilising factor that impairs the stability of 
microtubules. Loss of Stmn2 can result in axonal retraction and neuronal degeneration339, 
whilst excessive microtubule stability can impair axonal health and result in 
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neuropathy340, 341. Deregulated microtubule stability has been implicated in Huntington’s 
disease and hereditary spastic paraplegia342, and may affect axonal health due to 
impairment in the trafficking of axonal cargo339. Interestingly Stmn2 is involved in the 
homeostasis of mitochondrial trafficking339, strengthening the evidences for 
mitochondrial involvement in prion pathology.  
Phosphorylation by JNK leads to Stmn2 degradation by methods which are yet unknown. 
It is possible that Hectd2 functions downstream of JNK to target Stmn2 for degradation 
either basally, or in cells subjected to neuronal stress to orchestrate the balance between 
microtubule stabilisation and destabilisation. Together the hypotheses outlined in this 
thesis for how all of these novel candidate genes may function, position Hectd2 as a switch 
in the regulation of a myriad of processes, making it a promising candidate for prion 
pathology. 
To summarise, interactome mapping of Hectd2 identified 20 potential candidate 
interactors, of which five were verified. The evidence and literature detailed in this thesis, 
have shown cross talk between Hectd2 and other proteins that may serve to modulate 
susceptibility of cells to prion propagation. Although the underlying mechanisms by 
which these candidates modulate disease is yet to be determined, autophagy and 
cytoskeletal regulation appear to be emerging themes.  
It is anticipated that of the remaining 16 candidates, a proportion of these will represent 
true Hectd2 binding partners owing to the stringent selection criteria used for the initial 
pool of positive interactors. These candidates include a range of proteins for which 
functions have not been clearly defined although some of these show brain-specific 
expression and some may operate in the same pathway. Characterisation of Hectd2 and 
its binding partners has thus positioned Hectd2 as a possible regulatory molecule that may 
govern such interactions by fine tuning their activation or degradation to modulate 
downstream processes. 
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7.4 Evidence from mouse models: Is Hectd2 a genetic modifier of prion disease? 
 
An important aspect of functional testing of a potential candidate implicated in disease is 
to generate mouse models to correlate phenotypic effects in prion pathology. Hectd2 
knockout and overexpressing transgenic mouse lines were developed to address this 
question. The data detailed in Chapter 6 indicate that when Hectd2-/- female mice were 
challenged with RML, there was a significant difference in disease onset relative to 
control mice, where Hectd2-/- showed an earlier onset by 12 days. Furthermore, the 
duration of disease for these RML infected Hectd2-/- mice was prolonged relative to 
controls although there was no significant difference in the time to diagnosis of disease 
(incubation time). These data therefore suggest a protective role for Hectd2, supporting 
the hypothesis that Hectd2 deficiency facilitates propagation of prions and deregulated 
clearance. This is in concurrence with the data obtained for knockdown of Hectd2 in the 
SCA, which showed that prion propagation was increased in the absence of Hectd2. This 
data is lent support by previous findings by Lloyd et al., who showed that there was a 
significant upregulation of Hectd2 at the end stage of disease in prion-infected mouse 
brains relative to normal brains, perhaps suggestive of a protective role120. Although 
incubation time in mouse and the SCA are not directly correlative, it is expected that a 
reduction in incubation time correlates with an increased propagation of prions in the 
SCA. However all other prion strains tested in knockout mice did not show any 
differences in onset or incubation time. 
 
Hectd2 overexpressing mice, Tg260+/+, challenged with ME7 prions287 showed a 13% 
reduction in incubation time in males. However, taking into consideration the effects of 
multiple testing, the significance level for this reduction in incubation time was 
borderline. This is suggestive that Hectd2 may serve a modulating role although the lack 
of replication in female mice and in those to which RML and MRC2 were transmitted 
indicates that this data may not be real. It is postulated that the downstream functions of 
Hectd2 are neuroprotective and that overexpressing the gene would prolong incubation 
time and thus this reduction is surprising as it also conflicts with the SCA data for Hectd2.  
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Significant differences in incubation time were not seen for any other prion strain tested 
in Tg260+/+ mice. Overall, for both Hectd2 knockout and transgenic mice, we did not 
observe a universal effect shown by all prion strains tested in modulating incubation time. 
However, the differences outlined above suggest that Hectd2 modulates disease onset and 
diagnosis in a strain and sex- specific manner. It is possible that Hectd2 may have a larger 
effect than that observed in these models owing to a number of caveats inherent in both 
of the mouse models. Currently, neither of the lines have been confirmed at the protein 
level that Hectd2 is completely knocked out or overexpressed, respectively due to a lack 
of specific mouse anti-Hectd2 antibodies. The start codon for Hectd2 in exon 1 is its 
predicted initiator ATG but it is possible that an alternative start site is the second 
methionine in exon 3, which would translate all but 103 residues of Hectd2. This would 
mean that Hectd2 is still expressed in its most part, hindering the possibility of identifying 
an association in mice. Of note is that the level of endogenous PrPC expression was not 
tested in these mouse models to ensure that there were no differences relative to controls 
that could account for any changes in incubation time. Furthermore, there is only one 
transgenic line for overexpressing Hectd2 thus it is necessary to have more than one 
mouse line in case of an aberrant transgene integration effect. It should be also noted that 
the transgenic Hectd2 overexpressing line is of a mixed genetic background, which could 
obscure small effects and thus work is underway to address this by backcrossing these 
mice. However, it could be argued that small effects may not be interesting in terms of 
identifying genes that profoundly modulate the disease process.  Thus it is possible that 
Hectd2 may only show modest effects in modulating disease incubation time, however 
this does not detract from its importance in the disease process as genes that show 
moderate effects may serve key roles that implicate pathways that underlie pathogenesis. 
 
Together, data from the knockout and overexpressing transgenic mouse models suggest 
that Hectd2 may serve as a genetic modulator of prion disease. These findings are 
corroborated by data obtained from the SCA, which provides convincing evidence that 
Hectd2 and its downstream effectors possess roles in neuroprotection with respect to prion 
infection. 
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7.5 Continuing research 
 
7.5.1 Does Hectd2 confer E3 ubiquitin ligase activity? 
 
Hectd2 is an E3 ligase by homology and thus its catalytic ligase activity is putative. To 
assess whether the substrates of Hectd2 are subject to ubiquitination, ubiquitinated forms 
of the endogenous protein must be identified. An antibody to ubiquitin could be used to 
distinguish the ubiquitinated form of a given Hectd2 substrate in cells expressing 
physiological levels of the substrate or when the substrate is knocked down or 
overexpressed. Furthermore knockdown of Hectd2, should result in the accumulation of 
its potential substrates. Owing to the complexity of the ubiquitination system, substrates 
are not necessarily targeted for proteasomal degradation (see Section 1.3). To test the 
hypothesis that Hectd2 substrates are targeted to the proteasome for basal degradation, 
inhibition of the proteasome with pharmacological inhibitors should result in the 
accumulation of the putative targets. If Hectd2 is shown to be a functional E3 ubiquitin 
ligase then residues of the HECT domain may be systematically mutated or its predicted 
cysteine active site and the effect of these mutations on catalytic activity and binding 
chemistry may be measured using enzyme assay or co-immunoprecipitation experiments. 
When a protein has been established as a Hectd2 substrate, peptide mapping by mass 
spectrometry can be employed to identify sites of post translational modification such as 
ubiquitination, which may confirm whether a given substrate is indeed ubiquitinated. This 
may also shed light on the site at which the protein is modified or ubiquitination chain 
topology, which might provide insight into the fate of a given protein as particular 
modifications direct specific processes161. 
 
7.5.2 Characterisation of the molecular pathway by which prion clearance is mediated 
 
Lessons can be learnt from the perspectives taken by research in autophagy in 
neurodegeneration in the wider context as this field is under-recognised in prion disease. 
It is anticipated that prion clearance is mediated by the autophagy-lysosomal pathway as 
aggregated prions are beyond the capacity of proteosomal degradation (Section 1.3). 
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Autophagic flux may be measured in cells in which Sh3glb1, Sept7 or Hectd2 gene 
expression has been manipulated. The candidates may be tagged and their distribution 
visualised to assess whether they colocalise with autophagosomes, which may indicate 
involvement in the autophagic process. These factors can be investigated in prion-infected 
cells treated with pharmacological inhibitors and inducers of autophagy to assess whether 
prions are cleared through the autophagy-lysosomal pathway and whether these 
candidates are effectors in this pathway.  
 
The role of Hectd2 could be investigated further by overexpressing this gene in the SCA. 
It is expected that this would lower PrPSc levels in cells. This could be investigated further 
by overexpressing Hect414, which would be expected to bind to its substrates but should 
not ubiquitinate them. This may result in an effect similar to that of knockdown of Sh3glb1 
or Sept7. Overexpression of Sept7 and Sh3glb1 may result in decreased PrPSc as the 
effectors of their downstream processes may clear PrPSc. However, if Sept7 and Sh3glb1 
are dependent on Hectd2 ubiquitination to activate their downstream processes, a 
reduction in prion infection may not be observed solely by their overexpression, if 
endogenous Hectd2 is not able to ubiqutinate the overexpressed protein effectively. 
Rather, if Hectd2 is overexpressed with either Sh3glb1 or Sept7, a reduction in prion 
infection would be expected.  
 
Extending on the SCA, it would be interesting to assess whether the autophagy response 
is correlated in terms of PrPSc signal. PK1/2 cells may be treated with activators or 
inhibitors of autophagy where candidate gene expression is manipulated. It would be 
particularly interesting to evaluate whether double knockdown of Sh3glb1 and Sept7 in 
the same cell line produces an additive effect where we might observe a cumulative 
increase in PrPSc signal or whether these candidates have opposing effects.  
 
Mitochondrial impairment has been implicated in prion pathology132 and recent evidence 
for Sh3glb1 and Stmn2 suggest their involvement in mitochondrial function309, 339.  
Further investigations could be undertaken to assess the role of mitochondria in the 
autophagy-lysosomal pathway in prion pathology. Chronically infected cells could be 
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measured for their ability to clear prions following treatment with a mitochondrial 
uncoupler such as carbonylcyanide m-chlorophenylhydrazone (CCCP), to determine 
whether dysfunctional mitochondrial metabolism correlates with prion clearance 
mechanisms. 
 
Sept7 and Sh3glb1 have shown to be promising candidates in the modulation of prion 
disease and thus a key step to extrapolating these findings is to generate mouse models 
for each of these genes in prion disease and search for an association with incubation time. 
Gene knockdown or overexpression in primary neuronal cultures could also be developed 
to search for whether Hectd2, Sept7 or Sh3glb1 confer neuroprotective roles. If these 
genes are identified as essential to neuronal function, this could provide support for the 
hypotheses outlined in this thesis in that perturbation of Hectd2, Sept7 and Sh3glb1 may 
deregulate normal function and may thus modulate the disease process. 
 
7.6 Concluding comments 
 
This has been the first demonstration of interactome mapping of a genetic modifier of 
prion disease that also influences susceptibility to human prion diseases. 20 novel binding 
partners of Hectd2 were identified of which 5 were verified as putative interactors. A cell 
based model of prion disease, the SCA, was used to define the phenotype of Hectd2 and 
each interactor from which Sh3glb1 and Sept7 were confirmed as modulators of cell 
susceptibility to prion infection. Interestingly, the SCA data for Hectd2 showed 
convincing evidence for a modulatory role in the same direction as Sh3glb1 and Sept7, 
suggesting that these genes may function in the same pathway. These analyses were 
extended to a mouse model, whereby an association of Hectd2 with incubation time was 
investigated from which it was found that Hectd2 modulates disease onset in a strain and 
sex- specific manner.  Together, these data provide support for Hectd2 and specific 
components of its interactome as genetic modifiers of prion disease and has shed light on 
molecular pathways that have not been previously implicated in prion disease. 
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Hectd2 is an HECT E3 ubiquitin ligase with no previously associated functional 
information assigned. Cytoskeletal regulation, autophagy and mitochondrial dysfunction 
are themes which have emerged from characterising Hectd2 and the pathways in which 
its substrates lie.  These themes are under-recognised in prion disease and it is expected 
that these findings will lead the way into scrutinising how deregulation of the 
cytoskeleton, autophagy or mitochondria may affect the pathology of prion disease. The 
significance of Hectd2, the first E3 ubiquitin ligase linked to human prion diseases, is thus 
apparent, although the precise role it plays is yet to be determined. However, the 
identification of these novel targets and the molecular networks in which they are placed 
may accelerate research in this field and draw us closer to a treatment for this fatal disease. 
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9 Appendices 
Appendix 1 Solution formulations 
1.1 Bacterial selection plates 
Media Antibiotic selection [concentration] 
LB agar/broth Kanamycin, [50 µg/ml], reconstituted in ddH2O 
LB agar/broth Ampicillin, [100 µg/ml], reconstituted in ddH2O 
 
1.2 Yeast selection plates 
Ready-to-go yeast media pouches were sourced from Clontech Takara BioEurope and 
prepared as follows: 500 ml of ddH2O was mixed with the pouch contents and autoclaved 
at 121°C for 15 minutes. Agar/broth media were cooled to 50°C prior to addition of 
supplements; agar was poured into plates and set at room temperature and both media 
types were stored at 4°C. 
YPDA plates are constituted from a mix of yeast extract, peptone and dextrose 
supplemented with adenine hemisulfate and SD, (minimal synthetically defined) medium 
is a blend of yeast nitrogen base, glucose and the indicated amino acid dropout 
supplement. Growth and selection of yeast were carried out using the media listed below. 
Agar/broth media  Selection supplement [final concentration] Strain 
YPDA Agar - Y2HGold/Y187 
YPDA Broth - Y2HGold/Y187 
SD/-Trp  - Y2HGold 
SD/-Leu - Y187 
SD/-Trp/-Leu - Y2HGold 
SD/-Trp/-Leu/X X-α-Gal [40 µg/ml] Y2HGold 
SD/-Trp/-Leu/X/A X-α-Gal [40 µg/ml], Aureobasidin A [125 ng/µl] Y2HGold 
SD/-Trp/-Leu/-Ade/-His - Y2HGold 
SD/-Trp/-Leu/-Ade/-His/X/A X-α-Gal [40 µg/ml], Aureobasidin A [125 ng/µl] Y2HGold 
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Yeast media selection supplements 
X-α-Gal (X) 20mg dissolved in 1ml N, N-dimethylformamide 
Aureobasidin A (AbA) 1mg dissolved in 2ml absolute ethanol 
 
1.3 Yeast transformation solutions 
Yeast transformation solutions 
Reagent Final concentration 
TE/Lithium Acetate 1.1 X  
PEG/Lithium Acetate  
50% PEG 3350 40%  v/v 
TE 1X 
1M Lithium Acetate 1X 
NaCl 0.9% w/v 
 
1.4 Yeast protein extraction solutions and buffers 
Protease inhibitor solution 
 Final concentration 
Pepstatin A  1 mg/ml 
Leupeptin  10.5 mM  
Benzamidine  200 mM  
Aprotinin  2.1 mg/ml  
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Cracking buffer stock solution 
 Final concentration 
Urea  8M 
SDS  5% w/v 
Tris.HCl  40mM 
EDTA  0.1 mM 
Bromophenol blue  0.4mg/ml 
 
 
Complete cracking buffer 
 To prepare 1.13ml 
Cracking buffer stock solution 1ml 
Β-mercaptoethanol 10 µl 
Protease inhibitor solution 70 µl 
PMSF 50 µl of 100X stock solution 
 
1.5 Mammalian cell lysis buffers 
1.5.1 Standard cell lysis buffer* 
Reagent Final concentration 
HEPES 25mM 
EGTA 1mM 
Glycerol 5% v/v 
MgCl2 1mM 
β-glycerophophate 20mM 
Triton x-100 0.5% v/v 
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1.5.2 RIPA buffer* 
Reagent Final concentration 
NaCl 150mM 
HEPES 10mM 
Triton x-100 1% v/v 
Sodium Dodecyl Sulphate 0.1% v/v 
Sodium deoxycholate 1% v/v 
*Buffers adjusted to pH 7.5 and protease inhibitors added as detailed in Section 2.2.9.2 
 
Appendix 2 Vectors 
Vector Source Vector map electronic reference 
pGBKT7 Clontech PT3248-5 
pGADT7-recAB Clontech PT3718-5 
pCRII-Blunt-TOPO Life Technologies Ltd K2820-20 
pCMV-MYC Clontech PT3282-5 
pCMV-HA Clontech PT3283-5 
pSUPER.retro.puro OligoEngine VEC-PRT-0002 
                     
       
Appendix 3 Sequences 
Nucleotide sequences of clones were obtained using the ABI PRISM 3700 DNA Analyzer 
platform and are presented below. Identities of each sequence were ascertained via a 
BLAST search using the NCBI mouse transcript database (Section2). Nucleotide 
positions in reference to the mRNA transcript are provided with the reference sequence 
accession numbers. Start and stop codons are marked in green or red, respectively, on the 
full length sequences obtained and if appropriate on the cDNA fragment of the same 
sequence. The cDNA sequences represent fragments of genes cloned into the pGADT7-
recAB plasmid, derived from the yeast two-hybrid screen. Their coverage of the full 
length counterpart is indicated in Table 3.5.1, Section 3. 
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Hectd2 | accession number: NM_172637.2 
5 atgagtgaggcggctcgggatctctcgcccggagcgccgccggcggtagccgcggccgccccggag 
gagaggaaggggaaagaaccggagcgcgagaagctgccgcccatcgtgacggccggcgcagccgcgggctt
ggacagaggatccaagggccagatttccaccttcagcagctttgtctcgactgtcacccagaagaaggaag
ctgctgagaacagaagctcgcctacccaccttgctctccctaacatcaggaatgtgagagacctaccacca
atttgtcttgatgttagacaaaaacagcgcatgtctgtggaagcgttaccatctgaagtgaaggtcccgcc
ccttccagaaccttctcttcctagccagcccaaaactgtaaaagactttgaggaagatttagaaaaagctg
aggccacagggaattggaagacagtacatgctttttatataacagcatttgattctttcacagaactaaac
actgcatttaagaaagatgccacggcctcatttaatactattgaggactctgggcttaatgccaatttggt
gaatgctgtgtttgatgccttacttaatactcctcaagatatccagaagtcagtattgaagggaatcatta
acagcttgttacaagaatggaaaggtccacgaacaaaagatgatcttagagcatattttatactgttacag
aatcctcaatttaatatcacatctacatatgtcatctatgctcatttgctacgacagatagctaccttagt
ggaagctgaccatcacttcctagttcactggcttaaaaaattatcccagaagaaattcaagcaactggtag
agagattgctgcaatttgtttctttacggctgtttccagcaaaacctgaagaattcccgcctctaacgaag
tgtacctggtggatcccatcagccggtaaagttctggctttgcttaacactgccaacaatttggttcaccc
tcccctcgttccttacactgatttctataattctaccctggatcacattgatctcatggaagagtatcaca
cgtggcagagctttgggaactctcacaggttttccttctgtcagtacccattcgttatttctatagctgca
aaaaaaatcattattcaaagagactcagaacaacagatgataagcatcgcaaggcaaagtctggtggataa
agtatctcgaagacaaagacctgatatgaatatgttatttctaaatatgaaagtaaggaggacacatctgg
ttagcgactcacttgatgagttaacccggaagagagctgacttgaagaagaagttgaaagttacatttgta
ggtgaagctggtttggatatgggcggcttgactaaagaatggttccttcttctaattcgccagattttcca
tccagattatggcatgtttacataccacaaggattcacactgccattggtttagcagctttaaatgtgata
actattctgaattccgattggttggaattctcatgggactagctgtttataacagcatcaccttggatatt
cgttttcctccctgctgttacaaaaaattactgagccctcctgtcgtaccaagtgatcagagtacaccagt
aggcatctgcagtgttaccattgacgacttgtgccaggttatgcctgaattggcccatggactaaaggaac
ttttatcatatgaaggcaacgttgaagaagatttctattcaacatttcaggtttttcaagaagaatttgga
gtaattaaatcctataacttaaaaccagggggtgataagattccagttaccaatcagaatagaagagagta
tgtacagctttatactgacttcctgttgaacaaatctatctataagcaatttgctgcattttactgtggat
ttcatagtgtgtgtgcttcaaatgccctaatgctgcttcgtccagaagaagtagaaatcctggtttgtggc
agtcctgaactggatatgcatgcactgcagaggagcacacagtacgacggctatgcgaagacagacctgac
catacgatacttttgggatgttgtgcttggatttccacttgaacttcagaaaaagctgttacactttacta
caggaagcgacagagtacctgttggagggatggctgatttgaattttaaaatttcaaagaatgaaacttct
actaactggttacctgtggcacacacttgtttcaatcaactctgccttcccccatacaagagcagaaaaga
tctgaaacagaaactgattattggaatttcaaattcagaaggttttggacttgaa 2326 
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Hect414 
5 atgagtgaggcggctcgggatctctcgcccggagcgccgccggcggtagccgcggccgccccggag 
gagaggaaggggaaagaaccggagcgcgagaagctgccgcccatcgtgacggccggcgcagccgcgggctt
ggacagaggatccaagggccagatttccaccttcagcagctttgtctcgactgtcacccagaagaaggaag
ctgctgagaacagaagctcgcctacccaccttgctctccctaacatcaggaatgtgagagacctaccacca
atttgtcttgatgttagacaaaaacagcgcatgtctgtggaagcgttaccatctgaagtgaaggtcccgcc
ccttccagaaccttctcttcctagccagcccaaaactgtaaaagactttgaggaagatttagaaaaagctg
aggccacagggaattggaagacagtacatgctttttatataacagcatttgattctttcacagaactaaac
actgcatttaagaaagatgccacggcctcatttaatactattgaggactctgggcttaatgccaatttggt
gaatgctgtgtttgatgccttacttaatactcctcaagatatccagaagtcagtattgaagggaatcatta
acagcttgttacaagaatggaaaggtccacgaacaaaagatgatcttagagcatattttatactgttacag
aatcctcaatttaatatcacatctacatatgtcatctatgctcatttgctacgacagatagctaccttagt
ggaagctgaccatcacttcctagttcactggcttaaaaaattatcccagaagaaattcaagcaactggtag
agagattgctgcaatttgtttctttacggctgtttccagcaaaacctgaagaattcccgcctctaacgaag
tgtacctggtggatcccatcagccggtaaagttctggctttgcttaacactgccaacaatttggttcaccc
tcccctcgttccttacactgatttctataattctaccctggatcacattgatctcatggaagagtatcaca
cgtggcagagctttgggaactctcacaggttttccttctgtcagtacccattcgttatttctatagctgca
aaaaaaatcattattcaaagagactcagaacaacagatgataagcatcgcaaggcaaagtctggtggataa
agtatctcgaagacaaagacctgatatgaatatgttattt 1246 
 
Sh3glb1 | full length |accession number: NM_019464.2 
271 atgaacatcatggatttcaacgtgaagaagctggcggccgacgcgggcaccttcctcagccggg 
ccgtgcagttcacagaagaaaagcttggccaggcagagaagacagaactggacgctcacctggaaaacctc
cttagcaaagctgaatgtaccaaaatatggacagaaaagataatgaagcagaccgaagtgctgttgcagcc
aaatccaaatgccaggatagaagaatttgtttatgagaaactggatagaaaagcaccaagtcgtataaaca
acccggaacttttgggacaatatatgattgatgcaggaactgagtttggcccagggacagcttatggaaat
gcccttattaaatgtggagaaacacagaagcgaattggaacagctgaccgagagctgattcaaacatcagc
cttaaatttcctcactcctttaagaaactttatagaaggggattacaaaacaatcgcaaaagaaaggaaac
tattacagaataagagactggatttggatgctgcaaaaacaagactaaaaaaggcaaaagctgcagaaact
aaaagttcatctgaacaggaattgagaataactcaaagtgaatttgatcgtcaggcagagattacccgact
cctgcttgagggaatcagcagtacacacgcccatcatctccgctgtctgaatgactttgtagaagcccaga
tgacttactatgcacagtgttaccagtatatgctagacctacagaagcaactgggaagttttccatccaat
tatctttctaacaacaatcagacctctgggacaccagtgccatatgctttgtcaaatgcaattggtccttc
tgcccaggcttcaacgggtagccttgtaatcacctgtccttctaacctcaatgaccttaaagaatccagca
acaacaggaaggctagggtcctctatgattatgatgctgcaaatagcactgaactgtcactcctggccgat
gaggtaatcactgtgttcagtgtcgttggaatggactccgactggctaatgggagagagaggaaatcaaaa
gggcaaggtgccaattacctacttagaacttctcaattaa 1368 
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Sh3glb1 | cDNA clone from library plasmid pGADT7-recAB 
349 gaagaaaagcttggccaggcagagaagacagaactggacgctcacctggaaaacctccttagca 
aagctgaatgtaccaaaatatggacagaaaagataatgaagcagaccgaagtgctgttgcagccaaatcca
aatgccaggatagaagaatttgtttatgagaaactggatagaaaagcaccaagtcgtataaacaacccgga
acttttgggacaatatatgattgatgcaggaactgagtttggcccagggacagcttatggaaatgccctta
ttaaatgtggagaaacacagaagcgaattggaacagctgaccgagagctgattcaaacatcagccttaaat
ttcctcactcctttaagaaactttatagaaggggattacaaaacaatcgcaaaagaaaggaaactattaca
gaataagagactggatttggatgctgcaaaaacaagactaaaaaaggcaaaagctgcagaaactaaaagtt
catctgaacaggaattgagaataactcaaagtgaatttgatcgtcaggcagagattacccgactcctgctt
gagggaatcagcagtacacacgcccatcatctccgctgtctgaatgactttgtagaagcccagatgactta
ctatgcacagtgttaccagtatatgctagacctacagaagcaactgggaagttttccatccaattatcttt
ctaacaacaatcagacctctgggacaccagtgccatatgctttgtcaaatgcaattggtccttctgcccag
gcttcaacgggtagccttgtaatcacctgtccttctaacctcaatgaccttaaagaatccagcaacaacag
gaaggctagggtcctctatgattatgatgctgcaaatagcactgaactgtcactcctggccgatgaggtaa
tcactgtgttcagtgtcgttggaatggactccgactggctaatgggagagagaggaaatcaaaagggcaag 
1335 
 
Stambp | full length | accession number: NM_024239.2 
109 atgtctgaccatggggatgtgagcctcccaccccaagaccgggtgaggattctgtcccaacttg 
ggagtgcagttgagttaaatgaagacattccaccccgtcgctactaccgctccggtgttgagatcatccgc
atggcgtccgtttactcggaagaaggcaacattgaacatgcctttatcctctacaacaagtacatcacgct
gtttattgaaaaacttccgaaacaccgagactacaaatcagctatcattcctgagaagaaagatgctgtca
agaaattaaagagcgtcgctttccctaaagcggaagagctgaagacagagctcttgagaagatacaccaaa
gaatatgagcagtataaagagcgaaagaaaaaggaagaagaggaacttgcccgaaatatcgccatccagca
agagttggaaaaagaaaaacagagggttgctcagcagaagcagaagcagctagagcaggagcaattccatg
cctttgaggagatgatccagaggcaggagctggaaaaagaacggctgaaaattgttcaagagttcgggaag
gtagaccctggcccctgcgggcctctgctccctgatctggaaaagccttgtgtagatgtggcccccagctc
accgttctcgcccacgcagactccagactgtaacacaggcatgaggccagctaagccacctgtggtggaca
ggtccctgaaacctggagcgttaagcgtcatagaaaatgttcccaccattgaaggcctgcgccacatcgtg
gtgccccgtaatctgtgctcagaatttctccagcttgccagtgccaataccgccaaaggcattgaaacctg
tggagtcctctgtggaaaactgatgagaaatgaattcacaatcacacatgttctcatccccagacaaaatg
gtgggcctgattattgccacacggagaatgaagaagaaattttctttatgcaggatgaccttggactcctc
actcttggctggatccatactcatccaacccaaacggcctttctgtccagtgtggatctccacactcactg
ctcctaccaaatgatgttaccagagtccatcgcaatcgtctgttccccaaagttccaggaaactggattct
ttaagctaactgactatggtcttcaagagatttcaacctgccggcagaaaggctttcacccccatggcaga
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gacccaccgctgttctgtgactgcagccatgtcactgtcaaggacagaattgtgacgatcacagaccttcg
ataa 1383 
 
Stambp | cDNA clone from library plasmid pGADT7-recAB 
460 tatgagcagtataaagagcgaaagaaaaaggaagaagaggaacttgcccgaaatatcgccatcc 
agcaagagttggaaaaagaaaaacagagggttgctcagcagaagcagaagcagctagagcaggagcaattc
catgcctttgaggagatgatccagaggcaggagctggaaaaagaacggctgaaaattgttcaagagttcgg
gaaggtagaccctggcccctgcgggcctctgctccctgatctggaaaagccttgtgtagatgtggccccca
gctcaccgttctcgcccacgcagactccagactgtaacacaggcatgaggccagctaagccacctgtggtg
gacaggtccctgaaacctggagcgttaagcgtcatagaaaatgttcccaccattgaaggcctgcgccacat
cgtggtgccccgtaatctgtgctcagaatttctccagcttgccagtgccaataccgccaaaggcattgaaa
cctgtggagtcctctgtggaaaactgatgagaaatgaattcacaatcacacatgttctcatccccagacaa
aatggtgggcctgattattgccacacggagaatgaagaagaaattttctttatgcaggatgaccttggact
cctcactcttggctggatccatactcatccaacccaaacggcctttctgtccagtgtggatctccacactc
actgctcctaccaaatgatgttaccagagtccatcgcaatcgtctgttccccaaagttccaggaaactgga
ttctttaagctaactgactatggtcttcaagagatttcaacctgccggcagaaaggctttcacccccatgg
cagagacccaccgctgttctgtgactgcagccatgtcactgtcaaggacagaattgtgacgatcacagacc
ttcgataaatctcaaatcatgaaccagggagatggatcactgggtaacagcacttgtcaccaagcccaaca
gcccaggctcagttcttgggacccacatggtagaaggagtgtaccgacattcccccaagttgtcctctaac
ctccacatgtgtgctgtggtatgtgtgttctcacgtgtgtgtgcacatacacacacacacgcatatcaatt
aatttaaaaagcgaataaatgtaaattataaaaagagtcctacccccctcttaagctgcatatcccgttca
gtttattgcccccatggagttgagtaagcttttaagacaggataggaaagggtcaacactaaggggagact
gttgttgttgttgttgttgttgttgttgttgtttttccttaatttgaaatcatcttattttttaagacaaa
tgtgaaaatgaccaaatcacaccaagcaactaactcaaaaattaggatgcaagagaaaatacttctctaga
tccaaacactggccttctgttcctcttgaaatttacctcccaacttgttcatctctgcctttggactaaat
aggggcatctgtgcaaaactgtagaagccattttgaaggatttggctttttattgtttgtggcattaataa
gggagcttaccattctggtgggatgtgcatgaggcgttcacagcccccatacatggatcttgtttaaagtg
tattatttaaaaggtcagggtgttattttcttctataataaaacagctcacttgtgttgtg 2146 
 
 
Stmn2 | full length | accession number: NM_025285.2 
86 atggctaaaacagcaatggcctacaaggaaaaaatgaaggagctgtctatgctgtcactgatctg 
ctcctgcttctacccggagccgcgcaacatcaacatctacacctacgacgacatggaggtgaagcagatca
acaagcgggcctctggccaggcttttgagctgatcttgaagccaccatctcccatctcagaagctccacga
actctagcttctccaaagaagaaagacctgtctctggaggagattcagaaaaagctggaggctgcagagga
gcgaagaaagtctcaagaggctcaggtgctgaagcagttggcagagaagagggagcacgagcgagaggtgc
tccagaaggcgctggaggagaacaacaacttcagcaagatggcggaggagaagctgatcctgaagatggaa
202 
 
cagattaaggaaaaccgtgaggctaatctagctgctatcattgaacgtctgcaggaaaaggagaggcatgc
tgcagaggttcgcaggaacaaggaactgcaggttgaactgtctggctga 625 
 
Pacsin2 | full length | accession number: NM_011862.3 
261 atgtctgtcacctacgatgactctgtgggagtggaagtgtccagcgacagcttctgggaggttggga 
actacaaacggactgtgaagcggattgacgatggccaccgcctgtgtggtgacctcatgaactgtctgcat
gagcgggcacgcatcgagaaggcgtatgcacagcagctcactgagtgggcccgacgctggaggcagctggt
agagaagggaccacagtatgggaccgtggagaaggcctggatagctgtcatgtctgaagcagagagggtga
gtgaactgcacctggaagtgaaggcatcactgatgaatgaagactttgagaagatcaagaactggcagaag
gaagcctttcacaagcagatgatgggaggcttcaaggagaccaaagaagcagaggatggctttcggaaggc
ccagaagccctgggccaagaagctgaaagaggtggaagcggcaaagaaggcgcaccacacagcgtgcaaag
aggagaagctggccatctcccgggaagccaacagcaaggcagatccatccctcaaccctgagcagctgaag
aaactgcaagacaagatagaaaaatgcaaacaggacgttctaaagaccaaggacaagtatgagaagtccct
gaaggagcttgatcagaccacaccccagtacatggagaacatggagcaggtgttcgagcagtgccagcagt
ttgaagagaagcgcctgcgcttcttccgggaggttctgctggaggttcagaagcacttggatctgtccaat
gtggctagctataaaaccatttaccgggagctggagcagagcatcaaagcagcagatgcggtagaggacct
gaggtggttccgggctaaccatgggccaggcatggctatgaactggccacagtttgaggagtggtctgcag
atctgaatcgaactctcagccggagagagaagaagaaggctgttgacggtgtcaccctaacagggatcaac
cagacaggtgaccagtctggacagaacaagcctggcagcaaccttagtgtcccgagcaaccccgcccagtc
cacgcagttacagtccagctacaaccccttcgaggacgaggacgacacgggcagcagcatcagtgagaagg
aggacattaaggccaaaaatgtcagcagctatgagaagactcagacttaccccactgactggtctgatgat
gagtctaacaaccctttctcctccacggatgccaacggggattcgaacccatttgatgaggacacgacctc
aggaacagaagtgcgagttcgggccctctatgactatgaggggcaggaacatgatgagctgagcttcaagg
ctggggatgaactgaccaagatagaggatgaagatgaacagggttggtgcaagggacgtttagacagcggc
caggttggcctatacccagccaactatgtcgaggctatccagtga 1721 
 
Pacsin2 | cDNA clone from library plasmid pGADT7-recAB 
597 aagaactggcagaaggaagcctttcacaagcagatgatgggaggcttcaaggagaccaaagaag 
cagaggatggctttcggaaggcccagaagccctgggccaagaagctgaaagaggtggaagcggcaaagaag
gcgcaccacacagcgtgcaaagaggagaagctggccatctcccgggaagccaacagcaaggcagatccatc
cctcaaccctgagcagctgaagaaactgcaagacaagatagaaaaatgcaaacaggacgttctaaagacca
aggacaagtatgagaagtccctgaaggagcttgatcagaccacaccccagtacatggagaacatggagcag
gtgttcgagcagtgccagcagtttgaagagaagcgcctgcgcttcttccgggaggttctgctggaggttca
gaagcacttggatctgtccaatgtggctagctataaaaccatttaccgggagctggagcagagcatcaaag
203 
 
cagcagatgcggtagaggacctgaggtggttccgggctaaccatgggccaggcatggctatgaactggcca
cagtttgag 1166 
 
Sept7 | full length | accession number: NM_001205367.1 
201 atgtcggtcagtgcgagatccgctgctgccgaggagaggagcgtcaactgcggcaccatggctc 
aaccgaagaaccttgagggctatgtgggctttgccaacctcccaaatcaagtgtacagaaaatccgtgaaa
agaggatttgaattcactcttatggtagtaggtgaatctggactgggaaagtcgacattaatcaactcatt
attcctcacagatttgtattctccagagtatccaggaccttctcatagaatcaaaaagactgtacaggtgg
agcaatccaaagttttaatcaaagaaggtggtgttcagttgctgctgacaatagttgatactccaggattt
ggagatgcagtggataatagtaattgctggcagcctgttatcgactacattgatagtaaatttgaagatta
cttaaatgcagaatctcgagtgaacagacgtcagatgcctgataacagggtgcagtgttgtttatacttca
ttgctccttcaggacatggacttaaaccattggacattgagtttatgaaacgtttgcatgaaaaagtgaat
atcatcccattaattgccaaagcagacacacttacaccagaggaatgccaacagtttaaaaagcagataat
gaaagaaattcaagaacataaaattaaaatatatgaatttccagaaacagatgatgaagaagagaataaac
tggttaagaagataaaggaccgtttacctcttgctgtggtaggtagtaatactatcattgaagttaatggc
aaaagagtcagaggaaggcagtatccttggggtgtggctgaagttgaaaatggtgaacattgtgatttcac
aattctaagaaatatgttgataagaacacatatgcaggacttgaaagatgttaccaataacgtacactatg
agaactacagaagcagaaagctagcagcagtgacttacaatggagtggataacaacaagaacaaagggcag
cttaccaagagccctctggcacagatggaagaagaaagaagggaacatgtagccaaaatgaagaagatgga
gatggagatggaacaggtgtttgagatgaaggtcaaagaaaaagttcaaaaactgaaggactctgaagcag
agctccagcggcgccatgagcaaatgaaaaagaatttagaagcacagcacaaagaattagaggaaaaacgt
cgtcagtttgaagaagaaaaggcaaactgggaagctcaacagcgtattttagagcaacagaactcttcaag
aaccttggaaaagaacaagaagaaaggcaagatcttttaa 1511 
 
Sept7 | cDNA clone from library plasmid pGADT7-recAB 
1167 aacaacaagaacaaagggcagcttaccaagagccctctggcacagatggaagaagaaagaagg 
gaacatgtagccaaaatgaagaagatggagatggagatggaacaggtgtttgagatgaaggtcaaagaaaa
agttcaaaaactgaaggactctgaagcagagctccagcggcgccatgagcaaatgaaaaagaatttagaag
cacagcacaaagaattagaggaaaaacgtcgtcagtttgaagaagaaaaggcaaactgggaagctcaacag
cgtattttagagcaacagaactcttcaagaaccttggaaaagaacaagaagaaaggcaagatcttttaaac
tctattgaccaccagttatgtattagttgccaatatgccagcttggacatcagtgtttgttggatccgttt
gaccaatttgcaccaattttatccataatgatggatttaacagcatgacaaaaattattttttgttgttct
cgaaggagattaagatgccttgaattgtctaggatattgtgtacttagaaattaacagctctaagtacctt
tctacattttttttcttttttttttaaattaaaagatgtcttcagtttaatgcaagaaaacattttactgt
tgtacaatcatgttctggtggtttgattgtttacagaatattctaaaataaaaggactctggaaggttttc
attgaggataaattgccataatatgatgcaaactatgcttctctatgataattataatacagaggttccat
tcgatgcagcctatacaataatgtatttagtctaacacagtggaccctattttttgacacttccattgttt
204 
 
aaaagtacacatggaaaaaacatatatgcttacagtgcacctagagctttttataacagccttttttgttt
gtttgtttgttttggattctttaaatatataaatatattattctcatttagtgcccctgtagccagaacct
cattactgcttcatttttgtaataacatttaatttagatattttccatatattggccctgctaaaatagaa
tatagcatctttcatatggtaggaaccaacgaggaaactttcctttaactccctttttacactttatggaa
agtagcaggaggagaaatgcatttgtagatcatttctaggcaaattgtgaagctaacgaccagcctgtttc
ttcctatactcagtcttgttttactagaaatgggaatcatggcctcttgaagagaaaaaagtcaccattct
gcatttagctgtatctatatattgcatacctgtatttttttgtttgtattgtaaaaaaaattcacataata
aacaatgttgtgat 2521 
 
Klhdc2 | cDNA clone from library plasmid pGADT7-recAB | NM_027117.3 
828 ttgggaacttttgaatttgatgaaacatctttttggaattcaagtcatccaagaggatggaatg 
atcatgtccatattttagacactgaaacatttgcctggagccagcccatcaccactggtaaggcaccttca
cctcgggctgcccatgcctgtgcaactgttggaaacaagggctttgtgtttggtggcagataccgggatgc
tagagatcttcactatcttaatctggatacgtgggagtggaatgaactaattccacaaggtgtgtgccctg
ttggcagatcctggcactcactgacaccagtctcttcagaccatctttttctctttggaggatttaccact
gaaaaacagccactaagtgatgcctggacttactgcatcagtaaaaatgaatggattcagtttaatcatcc
ttatgttgaaaaaccaagattatggcacacagcttgtgcgagtgatgaaggagaagtcattgtttttggtg
gttgtgctaacaatctgctggttcatcacagagctgcacacagtaatgaagtacttatattttcagttcaa
ccaaaatctcttgtacggctaagcttagaagcagtcatctgctttaaagagatgctagccaactcgtggag
ctgccttccaaaacacttacttcacagcgttaatcagaggtttggtagtaacaacacttctggatcataa 
1529 
 
 
Pbld1 | cDNA clone from library plasmid pGADT7-recAB | NM_026701.2 
2 atgaagctcccaatcttcatagcagatgcgttcactgcgacagctttccggggcaatcctgccgca 
gtctgcctcctggagcgcacattggaggaagacgcccatcagcaaattgcgagggagatgaacctctcaga
aacggctttcatcaggaaactgcagccgactgacagcttcacacaaagctctcgctttggactgagatggt
ttacgccagtgagtgaagtccccttgtgcggccacgccacactggcctctgcggctgtgctgtttcacaaa
atacagaacaggaacagcaccctgacctttgtcacaatgagcggggagctaaaggccagaagagcagaaga
tgggatagtcctggactttcctgtctacccaacctttccccaggacttccatgaagttgaagacttgataa
aggcagccataggtgacaccctggtccaggacatccggtactctacagataccagaaaactcctggtccgg
ctcagcgattcttatgacaggtcctttctagagagcctgaaggtgaacacagagcctctgcctgcaattga
gaagacagggaaggtgagaggcctcatcctcactgtcaaaggagagcctggggggcagacggccccgtatg
acttctactccagatacttcgcgccgtgggttggtattgctgaagacccggtgacagg 693 
 
 
 
205 
 
Cpe | cDNA clone from library plasmid pGADT7-recAB | NM_013494.3 
652 gaaccgtaacttcccagacctggacaggatcgtgtatgttaatgagaaagaaggcggtcctaac 
aatcacctgctgaagaatctgaagaaaattgtggaccaaaattcaaagcttgcccccgagaccaaggctgt
cattcactggatcatggacattccatttgtgctttctgccaatctgcacggaggagaccttgtggctaatt
acccatatgatgagacacggagcggtactgctcacgaatacagttcctgccctgatgacgcaattttccaa
agcttggctcgcgcgtactcttctttcaacccagtcatgtctgaccccaatcgacctccctgtcgcaagaa
tgacgatgacagcagctttgtagatggaacgaccaatggtggtgcatggtacagcgtccccggtggaatgc
aagacttcaattacctgagcagcaactgcttcgagatcactgtggagcttagctgtgagaagttcccaccg
gaagagactctcaaaagctactgggaagataacaaaaactccctcatcagctacctggagcagatacaccg
aggtgttaaagggtttgtccgtgaccttcagggtaacccgattgccaacgcaaccatctctgtggacggga
tagaccatgatgtcacctcggctaaggatggggattactggcgattgcttgctcctggaaactataaactt
acagcctccgctcctggctacctggcaatcacaaagaaagtggcagttccttttagccctgctgttggggt
ggactttgagcttgagtctttctctgaaaggaaggaggaggagaaggaagaattgatggagtggtggaaaa
tgatgtcagaaactttgaatttttaa 1522 
 
 
Crtac1 | cDNA clone from library plasmid pGADT7-recAB | NM_145123.4 
1662 ggaggtgacgtggccagatggcaagatggtgagccgaagtgtggccagcgaggagatgaactc 
ggtgttggagatcctctacccccaggatgaggacaaacttcagaacacagccccactagagtgcggccaag
gattctcccagcaggacaatggccattgcatggacaccaatgaatgcatccagttcccatttgtgtgccct
cgagacaaacccgtatgtgtcaacacctatggaagctacaggtgccggaccaataaaagatgcaatcgggg
ctatgaacccaatgaagacggcacagcctgtgtggctcaagtggcctttttaggtgggtactcatcggctg
cctttagactctctgagcctctctctcaggcctcgtatctttctctaggcctgggactttgccttcagtta
tatgcactttaa 2091 
 
 
Zbed4 | cDNA clone from library plasmid pGADT7-recAB | NM_181412.3 
3534 gtccctgaaggaagccatggcaagccgcctgtctgccacactccatgaccccaggtacatctt 
tgccacactgctggaccctcgctacaaagcttccctgttcacagaggaggaggcagagcagtacaggcaag
acttaatcagggagctagaaatactgaattctacctcagaggacactgccacctccaatggctgtgactca
gggtccccacttaaagacactggcacagaggagagcctgtggtcactcgcaccgataaagagagatcagag
agagaagctacctgaagacatggtgcttgcgtatttggaggaagaggtgctggaacacagctgtgacccac
tcacctactggaacctaaagcggtcatcgtggcctgggctgtctaccttagcagttcgatttctgggatgt
cccccaagtacagtcccctcagaaaagctgttcagcacacccatggatgctggcagctttggccagcccag
gctcatgatggagcattttgaaaagctcatctttttaaaagtgaatcttcctttaatatgctttcagtatt
ga 4095 
206 
 
Pcca | cDNA clone from library plasmid pGADT7-recAB | NM_144844.2 
1180 aagcaagaggatattcccatcagtggctgggcagttgaatgtcgggtttatgctgaggacccc 
tacaagtctttcggtttaccgtctattgggaggctgtcccagtaccaagagccgatacatctacctggtgt
ccgagttgacagtggcatccaaccaggaagtgacatcagcatctattatgatcctatgatttcaaagctag
tcacatatgggtctgacagagcagaagccctgaagaggatggaagacgcactggacaattatgtgatccgg
ggtgttacacacaacatcccattgctccgggaggtgataatcaacacacgttttgtgaaaggagacatcag
cactaagtttctctctgatgtgtatcctgatggcttcaaagggcacacgttaacactgagtgagagaaacc
agttattggccattgcatcatctgtatttgtggcatcccagctacgagctcagcgcttccaagaacattca
agagtaccagttattaggcctgatgtggctaagtgggagctctcggtaaagttacatgatgaagatcatac
tgtcgtggcatctaacaatgggccggcatttaccgtggaagttgatggctcgaaactaaatgtgaccagta
cgtggaacctggcgtcacccttattgtctgtcaacgttgatggcacgcagaggactgtgcagtgtctttct
cgggaagcaggtggaaacatgagcatccagtttcttggcacagtgtacaaagtgcacattttaaccaagct
tgctgcagagctgaacaaattcatgcttgaaaaagtgcccaaggacaccagcagcactctgtgctccccga
tgcctggagtggtggtggccgtttctgtcaagcctggagacatggtagcagaaggtcaggaaatctgtgtg
attgaagctatgaaaatgcagaacagtatgacagctgggaaaatgggcaaggtgaaattggtgcactgcaa
agctggagacacagttggtgaaggagacctgcttgtggagctggaatga 2214 
 
 
Catsperb | cDNA clone from library plasmid pGADT7-recAB| NM_173023.2 
2708 gccaaccataaagagcagctgcagttacctcaggactatgcaccacactcctggcaggcacat 
accacctgaagactggattagcggagttcacaaggacagtcagggtttcaatatgatcaaaactctgccga
taaactacagacctccatcccacatgggaatttctattccactcacagataatttttatcatgcagaccct
agcaaacccataccgagaaatcaatttcacaagtcaaaggaaactggcaaatacaaacagtgtgctaatgt
taccagtcgggcaatgtgcaactgctcagaacatcaaaagttttcccatgctgttgctttctcagattgca
aagaaaaggttcatcgtttcaagtttccagtcacacaatacccagttgttttggaaattttcaatgaaaga
gacaaaatctccgcagaacctccgtatttagttaccatgactgaagtgaatatgaggaaaaactggcaact
aaaacacaatgagccagaaaacgttaagaaaatgaagcattacttagagccactgcttaagactccagtgt
ataatcctttaggtctcaacctaaccatacagggctctgaactgtttcacttcaaggtgtctgtggttcct
ggagtcagcttttgtgagttaagtgaagaatttcagatttatgtcgacgaagtcccattgccttttccagg
acatgcactaatagctgttgcaacatctgtagtgctaggagtattaatttttatagcatttgtattccaac
tgcgtaacatccacccactgaaggcattgaagaaatctattaggggaaatcctggactcacctcaagtaca
actgttagctcataa 3449 
 
 
Vps13d | cDNA clone from library plasmid pGADT7-recAB | NM_001128198.1 
11698 cacctgatggtcacggctcagaggttcacagtacaaattgaggagaaactgctgctcaagct 
actaagtttctttggctacgatcaggcagaatcagaggtggaaaagtatgatgaaaacatccatgagaaaa
cagcagagcagggaggaactccaactcgatactactttgagaacctcaagatcagcatcccccagatcaag
207 
 
ctcagtgtgttcacctccaacaagctgccactggaccttaaggctctgaaaagcaccctaggattcccact
gattcggtttgaagatgctgtgatcaatctggatcccttcactcgggtgcatccctatgagaccaaggagt
tcatcatcaatgacatcctcaagcacttccaggaggaactccttagccaggcagctcggatcctaggatcg
gtagacttccttggcaatcccatgggccttttgaatgatgtatccgaaggggtcactggactgataaagta
tggaaatgtcgggggtctcataagaaatgttacccatggagtgtcaaattctgccgccaagtttgcaggga
cactatcagatggcctggggaagacgatggacaatcggcaccagtcagagcgagagtacatcagataccat
gctgccaccagtggagagcaccttgtggctggcattcatggattggctcatggtatcattggtggattgac
cagtgttataacatcaacagtggaaggtgtaaaaacagaaggaggagtcagtggattcatatctggccttg
gcaagggactcgttggcactgtgaccaagccagtggcaggtgccctggattttgcatcagaaacagctcag
gcagtgagagacacagccacactcagtggtcccaggacccaagcccagagggttcggaaaccacgttgctg
cactggtccccaggggctgcttcctcgatattctgagagccaagcagaaggacaggaacagctcttcaagc
taacggacaacatccaggacgagttcttcatagccgtggagaacattgatagctactgcgtgctcatctcc
tctaaagctgtgtactttctgaagagcggggactacgtagaccgagaggccattttcctcgaggtcaaata
tgatgacctctaccactgtcttgtctccaaagaccatgggaaggtgtatgtgcaagtaactaagaaagctg
caaattctagcagtggtgtgtccatcccaggtccatcccaccagaagccaatggtgcatgtgaaatctgag
gtccttgctgtcaagttatcacaagaaataaactatgcaaagagcctctactatgaacagcaacttatgtt
aagactcagtgagaatcaagagcagttggagctggactcctga 13080 
 
 
Pcnxl4 | cDNA clone from library plasmid pGADT7-recAB | NM_026327.3 
3350 aagcaagtttgggtccaatagaagactttaaagaactgaccaactgcctcagagagtacgaga 
gagactggtacattggcttagtgtctgaagagcagtggaagagagcaattctagaagaaaagccatgcttg
ttctgcctggggtatgagtctagtatgggcgtttacacctcgagggtgctgatgcttcaggagatgtcggt
gcacatcgggaagctgaacgctgaggccgttcgaggtcagtgggccaacctctcgtgggaactgctttatg
ccaccaacgatgatgaggaacggtacagcatccaggctcacccactgctgctgaggaacctcactgtacaa
gccgctgaccctcccttgggatacccaattttctcttcaaaacctctccctatacatctgtgttagttcat
tttgacatccaaatgcaggcacatcagaggaggctctaactgaaaagtaagagtgtgagtattgtaatttc
actagactttctctttgccccaagaatgcctgagagaaaaccatatggtctgcaaagctgtttgtcagccg
ttcaaatgactcagacaacaggtcctctgtgtctaacgtgggtaaaagtagttggccaatatttgtgctgt
atgagttctgattggttttggtagctagagatatttgtacacgattagatattttttttactgctttgtta
aatgtctgaaaagtggtttgtcttttaaaaagtcaacaggtatgtaattacatagttaaaaagacgttcat
atcagtgttttaaataataatgaatctttttgatgttaacataacatgtatatatatttatttgaaatgta
attaatttttagtattttcgaatgtactgttttagcatttaacatggtgtgggcagttccattcagtgtat
ccatgattcatatacttggcttggaaaccgaaaaaacttgaaataaaatctcaccagctaaa 4326 
 
 
 
208 
 
Cop9 | cDNA clone from library plasmid pGADT7-recAB | NM_012001.2 
211 tcaagcggctctcataaagatctggcgggcaaatatcgtcagattctggaaaaagccattcagt 
tatctgggacagaacaactagaagcattgaaagcttttgtggaagcgatggtgaatgagaatgtcagcctc
gtgatctcacggcaactgctaacagatttctgcacacacctccctaacctgccagacagcacagccaagga
ggtctaccatttcaccttggagaagatccagcctcgggtcatttcctttgaagagcaggttgcttccataa
gacagcatctggcatctatttatgagaaggaggaagactggagaaatgcagcccaagtgttggtggggatt
cctctggaaacaggacaaaaacagtacaacgtagattataagctggagacttacctgaagattgcaaggct
atacctggaggatgacgatcccgtccaggccgaggcttacataaaccgagcgtccttacttcagaacgaat
ccacaaatgaacagttacagatacactataaggtttgctatgcgcgtgtccttgattacagaaggaaattc
attgaggccgcccagaggtacaatgagctctcttacaagacaatagtccatgaaagtgagagactagaggc
cttaaagcatgcactgcactgcaccatcttagcatcggcaggacagcagcgctctcggatgctggctactc
tttttaaggatgaaaggtgccagcaactagctgcatatgggatcctagagaagatgtacctagacagaatc
atcagagggaaccagcttcaagaatttgctgctatgctgatgccacaccaaaaagcaacgacagctgatgg
ttccagcatcttggacagagctgttattgagcataatttgttgtcagcaagcaaattatataacaatatca
cctttgaagaacttggagctcttttagagatccctgcagctaaggcagaaaagatagcatctcagatgata
acggaaggacgcatgaatgggtttattgaccagatcgatggaatagttcattttgaaacacgagaagccct
gccaacatgggacaagcagatccagtcactttgtttccaagtaaacaacctcctggagaaaattagtcaga
cggccccggagtggacagcacaagccatggaagcgcagatggcccagtgagccctcagcgctgtgcgcact
gcatctttgccacttcgtgcagattgattcactgcccctcaaagcatttgcatcatgaccttagacatctc
agcctcctttgctggatcccacttgaagaagatgctagagcaagaagtgcatcgtttaaacataatagctc
ccgtgagatctgggtctgtgtattgaactaactcagacgctttgaaaacttgttctttaagtggaagtgaa
agacctgaagtttgggatttgtgatcactttgtagtcatgtaaaacttaagtgctttgtgcctctccacat
gtggttactctaataaacggagcggtgagccaaataaaggcagtacttggtttttaattaaaaaaaaaaaa
aaaaaa 1771 
 
 
Gvin1 | cDNA clone from library plasmid pGADT7-recAB | NM_001039160.2 
6634 tgttcagaaaaagagagtgaaaaaataaaaacttttttaaacataagcttaggtgacatcaag 
aatactatcctgtctgccattcataactccacaaaggtagctaaagctaaaggcagcactgcatctcactg
gctggatttgttctgtgaccacctagggagcaacctggtcttcccaaggaaagacctggtaagcatagagc
accaggagctaatggatactgagttcctcaaagaagccatgagcaaagctttggatcctgcaatgagggaa
gtagaagaggattgttcaagtaagcacatagatgaaattgttcctgacattgagaaaattctctctgaaca
tctctgtggctgttggaaacagtgtcctttttgtaaggcaatttgtacaaacaccattccccagcatgaag
gagaccacagtgtgccattccaccgtcctcaggctgtcagtggttggcattggcataaaacagaccagttc
cacattaatgtttgtactagtagtgtagcaagtaatatttccttcattttagatggcttccgggaattccc
actcaagaaatatcgagaagcaggaggtgattatgccacatggagcatcaccccagactcatctacccagc
catattggaaatggtttgtctgtcatttcagatcaaacctagaagagaattatggcaaaaaatttacaggg
aaaggtagtcttccagatttatggaccaaaatcacaaagcaagaagtcctgaatgacttaaaaaaataata
actgccacagacagaacactagatgggccacagaaattttacttcagccaagggagcctaatggagaacac
209 
 
catgcaggaggatctgcagtagacatttgagcttcctcgatatggcccactctattgggcaatttttctgc
agaccaatatgaagttaaactttcataaaataagactgtttagatgaattaatgattttatagaatttctg
agttgatttaaatagttttaggcactagggttaatgatagaaagtttaaggagatggcttaatttgttctg
ctaaatagatatgataaagttagaattaagagcagaatgtgacctttcccttgtaggataatgagagctac
ataggtttgaaaaggagtacagtgagctttcatgcattgcaagtatgtgattgtacttggaagaagaaaat
aggcttgggacaagttaatgctcaaaacattcattctaggttgggtctgagttcctggattttgtgatcta
gagacatagtcacaggttttggtgggcaccataaaaaggcaaggtaataaacaaggagtaaataattcgat
tattagtatagaatagagaatagatgattctccagtatagctgaacaagactacaaaaataagatgtaaga
gagattgttccttcgtaaatacagattgatcaccatctaagcatatggaaaacttgctactgtagacttgg
cttgcttaaacattgttaatcaataacaaaaaaattatagctttaggtttgctatggagaaaaagatgaga
gaacgttagatgagaaatgcttaggtatgagtttcaaaagagaaatacacaatcaatgctcctgttgtaat
ctcttgtgtgatgattttattgtcttattgaagaacatgtgttttgtgattgtttttagaaaacttgcaac
ttatggctatgaagtaatttttgtcaaacatagagaactttgtcttagatggtgttaaaaggctaagagaa
caataaagatgttagagctca 8421 
 
 
Stk16 | cDNA clone from library plasmid pGADT7-recAB | NM_011494.5 
617 aagaaaggtacactgtggaatgagatagaaaggctgaaggaccaaggcagcttcctgactgaag 
accagatcctgccgctgttgctgggtatcagcagaggccttgaggctattcatgccaaaggttatgcacac
agggacctgaagcccaccaatattttgcttggtgatgaggggcagccagttttaatggacttgggttctat
gaatcaagcatgcattcaagtggagggctctcgccaggcactagctcttcaggactgggcagctcagcggt
gcaccatctcctaccgggcacctgaacttttttctgtgcaaagccactgtgtcatcgatgagcggactgat
gtctggtccctaggctgtgtgctttatgccatgatgtttggggaaggcccttacgatatggtgttccagaa
gggtgacagtgtggcccttgctgtgcagaatgaactcagcatcccacaaagccccaggcattcttcagcat
tgcgacagctattgtcttctatgatgactgtggacccccagcagaggcctcacatccctgtcctcctcagt
cagttggaggcattgcagccaccagctcctggccagcacaccacccaaatctgatcaaatcagtggacata
ttgggaagatgaccttgaagtggctttcatccctcattggaactccttccattcttccaggatggctctca
cagctagtggcaaggatagtgggtccttgtatattctgccttcttaccccaatacctgggcaaggaaccta
ggg 1393 
 
 
Ppp2ca| cDNA clone from library plasmid pGADT7-recAB | NM_019411.4 
580 gagagcagacagatcacacaggtttatgggttctacgacgagtgtttaaggaaatacggaaatg 
caaatgtttggaaatacttcacagacctttttgactatcttcctctcactgccttggtggatgggcagatc
ttctgtctacacggtggtctgtcaccatccatagacacactggatcacatccgagcactcgatcgcctaca
ggaagttcctcatgagggtccaatgtgtgacttgctgtggtcagatccagatgaccgtggtggctggggga
tatctcctcggggagctggttatacctttggccaagatatttctgagacatttaatcatgccaatggcctc
210 
 
acgttggtgtccagagctcaccagctggtgatggagggatataactggtgccatgaccggaacgtagtaac
aattttcagtgctccaaactattgctatcgttgtggtaaccaagctgcaatcatggaacttgacgacactc
ttaagtattctttcttgcagtttgacccagcacctcgtagaggcgagccacatgtcactcgtcgtacccca
gactacttcctgtaatgaaaatgtaaacttgtacagtattgccatgaaccgtatattgacctaatggaaat
gggaagagcaacagtaactccaaagtgtcagaaaatagttaacattcaaaaacttgttttcacacggacca
aaagatgtgccatataaaatacaaagcctcttgtcatcaacagccgtgaccactttagaatgaaccagttc
attgcatgctgacgcgacattgttggtcaagaatccagtttctggcatagcgctatttgtagttacttttg
ctttcttgagagactgcagatataggattaaacattaacacccgtgagtccagttgacttcacttagctgt
agcttactcagcatgactgtagatgaggatagcaaacaatcattggagcttaatgaacatttttaaataag
taccaaggcctcccctcttgttgtgtttctttcagggataccattaatttaattgtatgatttgtctgcac
tcagtttctccccttctcaaatctcagccccgcgttgttctttgttactgtcagaaaacctggtgagttgt
tttgaacagaactgtttccctcctgtaagatgatgttactgcacaagtcaccgcagtgttttcataataaa
cttgagaactgagaaagtcaggtttgaattgtatcagtgggcacgactggtgctgtttattaacaagataa
atctattgatcaatttcagaatttgtagaatcccaggtaaagaaaaataaagatcaaggccactgtgtaac
ctctctggc 1930 
 
 
Rbm39 | cDNA clone from library plasmid pGADT7-recAB | NM_133242.2 
896 ggaaaggttcgagatgtgagaatgatttctgatagaaattcaagacgttccaaaggaattgcat 
atgtggaatttgttgatgtcagttcagtgcctctagcaattggattaactggccaacgagttttaggagtg
ccaatcatagttcaggcatcacaggcagaaaaaaacagagctgctgcaatggcaaacaatttacaaaaggg
aagtgctggacctatgaggctctatgtaggctcattacactttaacataactgaagacatgcttcggggga
tctttgaaccttttggaaggattgaaagtattcagctcatgatggatagtgaaactggccgatctaaggga
tatggatttattacattttctgactcagaatgtgccaaaaaggctttggaacaactgaatggatttgagtt
agctgggagaccaatgaaagttggtcacgttactgaacgaactgatgcttcgagtgctagttcatttttgg
acagtgacgaactagaaaggactggaattgacttgggaacaactggacgtcttcagttaatggcaagactt
gcggagggtaccggtttgcagattccacctgccgcacaacaagcattacaaatgagtggctctctggcatt
tggtgctgtggcagaattctcttttgttatagatttgcaaacacgactttcccaacagaccgaagcctcag
ctttagctgcagctgcgtctgttcaacctcttgcaacacagtgtttccaactttctaacatgtttaatcct
caaacagaagaagaagttggatgggatacagagattaaagatgatgtcattgaagaatgtaataaacatgg
aggagtcattcatatttatgttgataaaaattcagctcagggcaatgtgtatgtgaagtgcccatctattg
ctgcggctattgctgctgtcaatgcattgcatggcagatggtttgctggtaaaatgataacagcagcgtat
gtacctcttccaacttaccacaacctctttcctgattctatgacagcaacacaactactggttccaagtag
acgatgaaggaagatacagtcccttatgtatatagcttttttttctcttgagaattcatcttgagttatct
tttatttagataaaataaagaggcaagggtctactgtcatttgtatacaactcctgttaccttgaaaaata
aaaatgttaacaggaatgcagtgtgctcattatccctaactagcaaatcctactttatgcaaagctgttct
cttgttctgctgttttaaatgtccatgtagaaaatgacattaaggatctatagaatagctctaggggaaca
aatgtgctttctgtataaaggcagacaggtcacgttttaatgtttcagaaacctaactttttacacagcag
211 
 
ttacaattcacattcatgtatttggctcatggttcagcaaaggtttccagaatccacatttagtgtgtgaa
aagtctaagtggctgtatggctgcttggcatttgatcttgattatttggcaagaatgggatttcaaaataa
tatttctcgatggtaattttttcaattaatgtctctgtaaaagtttctttgtaaatactgtatgttttagt
gtgtcttgagattccaaacaaaatgatccctgcatttcctcaaggtggctgacgtaacagattgagtaagc
agtcttgggcaagagatgggaaatgcagaaaaaggttttgtctggttgcatataatctttgctctttttaa
gctctgtgagctctgaaatatatttttgggttacttcagtgtgtttgacaagacagcttgatatttctatc
aaacaaatgactttcatattgcaacaatctttgtaagaaccactcaaataaaattctctgaaaaaggccac
aa 2807 
 
 
Sh3yl1 | cDNA clone from library plasmid pGADT7-recAB | NM_013709.4 
895 gcctttgcaaagggtggaaacctgacccttggagggaattttactgtcgcagttgggcccctag 
gcaggaacctggaaggcaacgtgtccctgaggagctccgcagccgtcttcacatactgcaagtccaggggc
ctctttgctggtatctccctggaaggaagctgtctgattgagaggaaagaaaccaatcggaaattttactg
tcaggacattcgagcttacgacattttatttggagatgttccgcagcctgctcaagcagaagatctttatg
aaattcttaattccttcactgagaaatatgaaactgaagggcagcgcatcaatttgaagaaagtagcccgg
gagcagaggaaggccaaagaattacctccaaaaccatcttcaaggccccagccagcccacccacctgtaca
gctgaatgctggctcccagggtaatagaaatgaatataagctatatcctgagctttctagctatcatgaga
aaactggcaatttgaatcaaccaatagaagtgacagcattatactctttcgaaggacaacagccaggagac
ttgaattttcaagcaggagacagaatcatagttatatcaaagaccgactcaaattttgattggtgggaagg
aaaacttcgaggtcaaactggaattttcccagccaactatgtaactatgaattaaagttcatgctattttg
ttactt 1603 
 
 
Mfsd6 | cDNA clone from library plasmid pGADT7-recAB | NM_133829.2 
4105 ggagacaggatcagctgtacagtgaaggcctctgtgtgaccgttctgcctgcccctgcctcgg 
gagaaacattctacacctggatgcctagcttcactacaaaacacagcttggaatgatgggaacaattaagc
tgatggttacttttgcacttgaatggtactgcactgtcaacccccaaggctcattttaagtgacctttaaa
atcagatgtatttattatgctcgtgcaattacagaaatgaagtgggagacaggctgagccccacctatgaa
tgtacagtatgtggattgtgaaagtgactgtagggaatcagagcgttgtatcttgtgtttacaattctggt
tgatttctttgaaaagctgctggtttgggaaatgcacagtgggtgtattgaaataaaaggtaaataccatt
tttaaatatttcgtaaatgaaaaacacgtgaccaaacaagagaacatcctctgctctgtaatgaatgacac
caaattcaatatgccttcgttacaaaatgtttactgtgagcgtcgatccaacagtgcagtaatttctagcc
ttttgagctgacaccttcacgagtttgtggactttgtgactttttcttcctgttcttacagtgccatatgt
cacttgaaaaatattaaagtgaattccaattaaa 4770 
 
Strn3 | cDNA clone from library plasmid pGADT7-recAB | NM_052973.2 
212 
 
1868 gatgcaaccattcagtggtggaatatgcctagtcctaatgtggatccctatgatacatatgag 
tcaaacgttctagctggcactttagttgctcatacagatgcagtctggggtcttgcctatagtggcataaa
aaaccaattactctcttgctcagcagatggcactattaggttatggaacccacaagaaaagctgccatgtg
tttgcacttacaatggagacaaggaacatggaatacctacatcagttgattttataggctgtgatccagcc
catatggttacgtctttcaacactggtagtgcggtaatttatgatttagaaacatcacagtcattagtgat
gctttcctcacaggtagattctggtttacaatctagtaatcacattaacagagtagtaagtcaccctacac
ttcctgttacaataactgctcatgaagacagacacatcaagttttttgacaataaaacgggtaaaatgatc
cattctatggtagctcatttggatgctgttacaagtttagcagtagatcccaatggaatctatttgatgtc
tggaagccatgactgttccattagactatggaatttggacagtaagacatgtgtacaagaaataacagctc
ataggaagaaattggatgagtcaatttatgatgttgctttccatccatcaaaggcatatatcgccagtgca
ggagctgatgctcttgccaaagtatttgtgtgaaccaacatagactcgcatcttagaaaaaaaagatttac
ttggtcagaaagggggtctgcatcactgccatcatgaaggttcctgacatgacactacatgtgatctgcct
ggtgattggggcaggcagaaattgggaatcacatcctaatgtcaggtttattagtttaagtgtaattaact
gtattttgtgggacagaaagaaaaaggactccagtatctgtgccctatactggatatgaactgagcggttt
ttgtttttgttttttaaggtgtttaagccaatgtggagtctgctcttagggggaaggactttttgttggac
tctgtgtgctgccttagggttaggaatgtggtgctctggtggggaagcaagctccaagagtagctttgttc
atctcttagtgatcttatgttcatcagtgaatgccacagattcccttttaaagttattttgctttaaaaaa
aaaaaaagaaaaa 3079 
 
 
LOC100046859 | cDNA clone from library plasmid pGADT7-recAB | XM_003084438.1 
1857 gaagataatttgaaacaggctcagtcgtggattagaggcatcaaggttggaagttccacaaat 
accctgaatgccctgaaaattgcttttgctgatgaagaaacacaagtaatctaccttctgacagatgggag
accggaccagccaccagaaatggtgatggaccacgtcaaactctttcagaacatccccatctgtgccatct
ccttcagttacaacgatgaggttgcgaacgagttcttgaaggagcttgctgccttgaccggaggcgagttc
cgagcttataactttggctgcaaggatcccattcaggatactcaggatgaagatctgaaccttttgcttca
ggaaatggagcagggtcacagcgacctggagaagatgcaggagctctacatggagtccttagtcgttgact
ggtggtacaacgcagacaaggacacggatagcaaacaccaaaaggaaatcttgtccatggtttcaactcca
gaagagcgtgcaaactcccaacccgacgccgattcactggcttcttcacccccaaatgtgtctacaggatc
atggaagtttttggaggaaaagacacagaaaaagaaaatcctccatgcagaatcaaccaaaacgagcctcc
tcagaagccacatctccaacttcaagagcagcagcaacaaagacagctccaactccagctccaggagccac
acctcagctctcagcaacagag 2580 
 
 
 
 
Htra2 | cDNA clone from library plasmid pGADT7-recAB | NM_019752.3 
213 
 
1161 gggagtttctgcatcgcggggaaaagaaaaattcctggtttggaaccagtgggtcccagcgcc 
gctacattggagtgatgatgctgaccctgactcccagcatccttattgaactacagctccgtgagccaagc
ttccctgatgttcagcatggtgtcctcattcataaagttatcctgggctcccccgcacacagggctggtct
gcggcctggtgatgtgatcttggccattggggagaaattggcacaaaatgctgaagatgtttatgaagctg
ttcgaacccaatcacagctggcagtgcggatccggcgcggatcagagacactgaccttatatgtgaccccc
gaggtcacagaatgaatgactggaccggcaagagtgtgaagctcttgccctgatctcctccttgctttcct
agcctaggttctgagtgcatgtgggtagaggaggagtcagtgaacctgcggagggcaagtccctctaaccg
ctgcatcagtcctgggctccgaagaacacattttatataaaataaaattatacctagcaacatgtta
cagtcaaaaaaaaaaaaaaaa 1737 
 
Ces1d | cDNA clone from library plasmid pGADT7-recAB | NM_053200.2 
1112 gtcccctacatagtgggcatcaacaagcaagagtttggctggatcattccaacgcttatgggc 
tatccactcgctgaaggcaaactggaccagaagacagccaattctctcttgtggaagtcctacccaacact
taaaatctctgagaatatgattccagtggtcgctgagaagtatttaggagggacagatgacctcaccaaaa
agaaagacctgttccaggacttgatggctgatgtggtatttggtgtcccatcagtgattgtgtctcgaagt
cacagagatgctggagcctccacctatatgtatgagtttgagtatcgcccaagctttgtatcggccatgag
acccaaggcagtaataggagaccatggtgatgagatcttctcagtatttggatctccatttttaaaagatg
gtgcctcagaagaggagaccaacctcagcaagatggtgatgaaattctgggccaactttgctcggaatggg
aaccccaatggtggagggctgccccactggccagaatatgaccagaaggaagggtatctgaagattggtgc
ctcaactcaggcagcccagaggctgaaggacaaagaagtgagtttttgggctgagctcagggccaaggagt
cagcccagaggccatcccacagggaacatgttgagctctgatcaggagggtcagctgtgcttaagaacctg
gagtcaaaggagtattattccacagaagatttttgtagaaaaataacacttatctttgaagctataacatt
atatggtattttatacaaatgcattaaaaaggaaatatttatctccttcaacttgtaaaaataaaataatg
ttttgaaaatc 1966 
 
 
Mlst8 | cDNA clone from library plasmid pGADT7-recAB | NM_001252464.1 
186 acagtgcagcatcaggactctcaggtaaatgcattggagattactccggaccgaagcatgatt 
gctgctgcaggttaccaacatatccgcatgtatgatctcaactccaataaccccaaccccatcatcagtta
tgacggagtcagtaagaacattgcatcagtgggctttcacgaggatggtcgctggatgtatacaggtggcg
aggactgcacagctcgcatctgggacctcaggtcccggaacttgcagtgtcagcgtatcttccaggtgaac
gcacccattaattgcgtgtgtctgcatcccaaccaggcagaactcattgtgggtgatcagagcggtgctat
ccacatctgggacctgaagacagaccacaatgagcagctgattcccgagcctgagtcttccatcacgtctg
ctcacatcgacccagatgctagctacatggcagccgtcaatagtgccggaaactgctatgtctggaacctg
acagggggcattggtgacgatgtgactcagctcatccctaagaccaagatcccagcccatacacgctatgc
cctgcaatgccgcttcagccctgattccacgcttcttgccacctgttcagctgaccagacatgtaaaatct
ggaggacatccaacttctccctgatgacagagcttagcatcaagagtagtaaccctggagagtcatcccgt
ggctggatgtggggctgtgccttctcaggggattcccagtacattgtcacagcttcttctgacaacctagc
214 
 
ccggctctggtgtgtagagactggagaaatcaagagagagtatggtggccatcagaaagctgtcgtctgct
tggccttcaatgacagtgtgctgggttagacttggcccttgaggctgcattgggcaatcaggactgcctgg
tatagtgacgccaagaggatgtatctgaacaatacccgggtccaagtgagactctcaggttagcatgtcag
gccagttggacctgaccggactatgcaggcccctcctggccaacctagactttttggctactctacgctgg
gactctttccatgcccagtttgttgtcagaaagctcactcactaagccagactggactgggagtctttgct
cctttagagagactagacctagaggacttgggactgttgaggaggtcagaggttaatgcctgtattccagg
tatgttaccccgacttgcttcagaaattaccattatggccaggcaatctgggtttattaatccctactgtc
agctgccttccataggtactggtgacctggccagcttactgacctgtggggacaggactggcctatggaac
caaaggccaggagggcttgggtagggggtcttagtctgggaggtaataaaagcagacagacacaca 
1592 
 
 
Atp6v1h | cDNA clone from library plasmid pGADT7-recAB | NM_133826.4 
846 ggttttcaacttcaataccaaatgattttttcaatatggctcctggcattcagtcctcaaatg 
tgtgagcaccttcgtcgctataatatcattcctgttctatcagacatccttcaagaatctgtcaaagagaa
agtaacaagaatcattcttgcagcattccggaatttcttagaaaaatcaacggaaagagaaactcgccaag
agtatgctctggctatgattcaatgcaaagtactgaaacagttggagaatttggagcagcagaagtatgat
gatgaagatatcagtgaagacatcaaatttcttttggaaaaacttggtgagagtgtccaggaccttagctc
atttgatgaatacagttcagaacttaaatctggaagattggaatggagccctgtacacaagtctgagaaat
tttggagagaaaatgccgtgaggttgaatgagaagaactatgaactcttgaaaatcttgacaaaacttctg
gaggtatcagatgatccacaagtcttagctgttgctgctcacgatgttggagaatatgtccggcattatcc
ccggggaaaacgggttattgagcagcttggtggaaagcagttggtgatgaaccacatgcaccatgaagacc
agcaggttcgctacaatgctcttctggccgtgcagaagctcatggtgcacaactgggaatatcttggtaaa
caactacagtcagagcagcctcagactgctgctgctcggagctgagctgacctgttcagcctttctgcact
tcccatggaccagtggagtgagaacctcagtctttagggttaaaagcaaatagtttttaatttaatgatta
cttcttttctgttgtatagcttttccctatggtaattcctgggagaataaaagtgtttgcttgttaaattg
tataaaattagatactgcctgtattagagaaatattactgttacttatattctttatgatttttgtattta
ttgtcctctgaaaatgaatataattaaaggattctcactccaaacatgttcttaaattttgcttattccta
ttgtggactttgaataaacatcatttatttcaaataaaaattgggagaagtgttcccaggtgatgatgaga
ag 1974 
 
